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4PL 4-parameter logistic, 84 
A 
ACE angiotensin-converting enzyme, 14 
ACE2 angiotensin-converting enzyme 2, 14 
ADP adenosine diphosphate, 18 
ADQI Acute Dialysis Quality Initiative, 20 
AKD acute kidney disease, 27 
AKI acute kidney injury, 15 
AKIN Acute Kidney Injury Network, 16 
AKS acute kidney stress, 39 
Ang II angiotensin II, 9 
aPC activated protein C, 32 
ARF acute renal failure, 15 
AT1 type-1 Ang II, 14 
AT2 type-2 Ang II, 14 
ATP adenosine triphosphate, 18 
AUC-ROC area under the receiver-operating 
characteristics curve, 63 
B 
BMI body mass index, 126 
C 
C creatine, 18 
CAZy Carbohydrate-Active Enzymes database, 46 
CCL2 C-C motif chemokine 2, 32 
CDK cyclin-dependent kinase, 36 
CDKI CDK inhibitor, 36 
CHI3L1 chitinase 3-like protein 1, 40 
CHI3L3 chitinase 3-like protein 3, 57 
CHIA acidic mammalian chitinase, 57 
CI confidence interval, 24 
CK creatine kinase, 18 
CKD chronic kidney disease, 21 
CKD-EPI Chronic Kidney Disease Epidemiology 
Collaboration, 96 
CL central laboratory, 163 
CLP chitinase-like protein, 46 
CO carbon monoxide, 43 
CPB cardiopulmonary bypass, 118 
cPC circulating protein C, 32 
Cr creatinine, 9 
CSA-AKI cardiac surgery-associated AKI, 117 
CV coefficient of variation, 97 
D 
d day, 9 
Da Dalton, 41 
DAMP damage/danger-associated molecular pattern, 
30 
DM diabetes mellitus, 126 
DMT-1 divalent metal transporter 1, 42 
E 
ECC extracorporeal circulation, 118 
eGFR estimated GFR, 96 
ELISA enzyme-linked immunosorbent assay, 66 
EMA European Medicines Agency, 23 
EPCR endothelial protein C receptor, 32 
ESRD end-stage renal disease, 26 
EuroSCORE European system for cardiac operative 
risk evaluation, 126 
F 
FDA U.S. Food and Drug Administration, 23 
Fe2+ ferrous iron, 42 
Fe3+ ferric iron, 42 
FLVCR feline leukaemia virus subgroup C receptor, 43 
Fp-1 ferroportin-1, 42 
G 
G1 first gap phase, 36 
G2 second gap phase, 36 
GFR glomerular filtration rate, 9 
GPX4 glutathione peroxidase 4, 38 
H 
h hour, 16 
HCP1 haem carrier protein 1, 43 
HI high-income, 24 
HO-1 haem oxygenase-1, 34 
HPX haemopexin, 43 
I 
ICU intensive care unit, 20 
IGFBP7 insulin-like growth factor-binding protein 7, 
64 
IL-13Rα2 IL-13 receptor α2, 49 
IL-1β interleukin-1β, 30 
iNOS inducible NO▪ synthase, 31 
IQR interquartile range, 84 
IRI ischemia-reperfusion injury, 36 
IRIS International Renal Interest Society, 28 
K 
KDIGO Kidney Disease | Improving Global 
Outcomes, 16 
L 
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LOD limit of detection, 87 
LOQ limit of quantification, 87 
LOS length of stay, 20 
LPS lipopolysaccharide, 38 
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 M 
M mitosis, 36 
MAS1 proto-oncogene Mas, 14 
min minute, 9 
MMP matrix metalloproteinase, 31 
mo month, 20 
N 
NADPH nicotinamide adenine dinucleotide 
phosphate, 31 
NF-κB nuclear factor-κB, 30 
NGAL neutrophil gelatinase-associated lipocalin, 40 
NGALR NGAL receptor, 42 
NLRP3 nucleotide-binding domain and leucine-rich 
repeat family pyrin domain containing 3, 50 
NO▪ nitric oxide, 31 
O 
O2▪– superoxide anion, 31 
OD optical density, 84 
OR odds ratio, 25 
P 
PAMP pathogen-associated molecular pattern, 30 
PAR-1 protease-activated receptor-1, 33 
PC phosphorylcreatine, 18 
PETIA particle-enhanced turbidimetric immunoassay, 
67 
PMDA Japanese Pharmaceuticals and Medical 
Devices Agency, 23 
POCT point-of-care testing, 163 
PRR pattern recognition receptor, 30 
PSTC Predictive Safety Testing Consortium, 23 
R 
RAS renin-angiotensin system, 12 
RB retinoblastoma, 36 
RCD regulated cell death, 34 
RFR-G renal functional reserve of the glomerular 
function, 132 
RIPK3 receptor-interacting protein kinase 3, 38 
RISK Risk, Injury, Failure, Loss, and End-stage renal 
disease, 15 
ROS reactive oxygen species, 33 
RPF renal plasma flow, 9 
RRT renal replacement therapy, 24 
S 
S DNA synthesis phase, 36 
SCHI3L1 serum CHI3L1, 75 
SCr serum Cr, 15 
SD standard deviation, 99 
SIRS systemic inflammatory response syndrome, 159 
SOFA Sepsis-related Organ Failure Assessment, 96 
STROBE strengthening the reporting of observational 
studies in epidemiology, 65 
T 
Tf transferrin, 42 
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U 
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I. The kidneys 
I.A. Renal morphology and function 
n humans the kidneys are crucial for maintaining the extracellular 
environment in equilibrium. They excrete some of the waste products of 
metabolism (e.g., creatinine (Cr)), specifically adjust the urinary excretion 
of water and electrolytes to match net intake and endogenous production, and participate in the 
regulation of acid-base balance. The basic unit of the kidney is the nephron (Figure 1), with each 
kidney in humans containing ±1.0-1.3 million nephrons. The formation of an ultrafiltrate of 
plasma across the glomerulus (Figure 2), termed glomerular filtration, is the initial step in the 
excretory function of the nephron. The kidney secretes hormones as well. In this way it 
participates in the regulation of systemic and renal haemodynamics, red blood cell production 
and bone metabolism. Finally, it performs such miscellaneous functions as gluconeogenesis when 
fasting and catabolism of peptide hormones [1]. 
I.B. Regulation of glomerular filtration rate and renal plasma flow 
The blood flow to the kidneys (0.95-1.25 l/minute (min)) averages 20 % of the cardiac output. 
In terms of flow per 100 g weight, this is 8 times greater than coronary blood flow. The rate of 
glomerular filtration (GFR) averages 95-125 ml/min (135-180 l/day (d)) in a normal adult [2]. 
Over a wide range of renal arterial pressures the GFR and renal plasma flow (RPF) remain 
roughly constant. This phenomenon has been termed autoregulation. Initially, it is primarily 
mediated by the stretch receptors in the afferent arterioles (myogenic response) and 
tubuloglomerular (TG) feedback (Table 1). When the renal arterial pressure is substantially 
reduced, angiotensin II (Ang II) dependence is most prominent (Figure 3). 
I 
 Figure 1 | Section of a human kidney with anatomic relationships of the component parts 
of the nephron (adapted from [1]; created with Motifolio) 
The thick ascending limb has a cortical segment that returns to the region of the parent 
glomerulus. In this area the specialized tubular cells of the macula densa are located. Together 
with the renin-secreting juxtaglomerular cells of the afferent arteriole, the macula densa 
composes the juxtaglomerular apparatus. 
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Figure 2 | Anatomy of the glomerulus (based on [3, 4]; created with Motifolio) 
Abbreviations: AA afferent arteriole, BS Bowman’s space, EA efferent arteriole, EC endothelial 
cell, FP foot process of podocyte, G glycocalyx, GBM glomerular basement membrane, GC 
glomerular capillary, SD slit diaphragm, TP tubular pole, VP vascular pole 
 
Autoregulation can be overridden by neurohumoral vasoconstriction in hypovolemic states, in an 
attempt to maximize cerebral and coronary perfusion. An important role in modifying the 
vasoconstrictive Ang II and norepinephrine effects is played by renal vasodilator prostaglandins. 
They attenuate the degree of arteriolar constriction and prevent excessive renal ischemia [2]. 
TG feedback refers to the alterations in GFR induced by changes in tubular flow rate (especially 
when renal arterial pressure is increased). In the cortical segment of the thick ascending limb, 
which returns to the region of the parent glomerulus, the specialized tubular cells of the macula 
densa are located (Figures 1 and 2). These cells sense changes in the delivery and subsequent 
reabsorption of chloride (Table 1).  
AA EA
VPBS
TP
GC
GC G
EC
GBM
SD
FP
G BS
Thick ascending limb 
with macula densa cells
 Table 1 | Myogenic response and tubuloglomerular feedback (based on [2]) 
Stimulus ↑ Renal arterial pressure 
 
Response Myogenic response Tubuloglomerular feedback 
 ↑ Degree of stretch in stretch receptors in the wall 
of the afferent arteriole 
↑ GFR 
 ↑ Cell entry of calcium in vascular smooth muscle ↑ Macula densa chloride delivery and subsequent 
reabsorption 
  ↑ Cell entry of calcium in vascular smooth muscle 
   
Effect Constriction of the afferent arteriole Constriction of the afferent arteriole 
 ↓ GFR ↑ Renal vascular 
resistance 
↓ GFR ↑ Renal vascular 
resistance 
  ↓ RPF  ↓ RPF 
Conversely, as renal arterial pressure decreases, all directions of change are reversed and the afferent arteriole is 
dilated. 
Abbreviations: GFR glomerular filtration rate, RPF renal plasma flow 
 
Besides the stretch receptors in the afferent arteriole and the sympathetic nerves ending in the 
renin-secreting juxtaglomerular cells, the composition of tubular fluid reaching the macula densa 
contributes to the regulation of renin1 secretion as well. The ‘renal’ or ‘systemic’ renin-angiotensin 
system (RAS) importantly affects the GFR (Figure 3) [1, 2]. 
Although both afferent and efferent arterioles are constricted by Ang II, the efferent arteriole has 
a smaller basal diameter, resulting in a greater increase in efferent resistance. The net result on the 
regulation of GFR is variable in different conditions, as Ang II also sensitizes the afferent 
arteriole to the constricting signal of TG feedback and constricts the glomerular mesangium (i.e., 
specialized smooth muscle cells) as well [2]. 
                                                     
1 uniprot/P00797 
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Figure 3 | The ‘renal’ or ‘systemic’ renin-angiotensin system with the classic 
angiotensin-converting enzyme/angiotensin II/type-1 angiotensin II receptor axis (based 
on [2]; created with Motifolio) 
Abbreviations: AT1 type-1 angiotensin II receptor 
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 The effects of Ang II are mediated by the type-1 Ang II2 (AT1) receptor, which is present in 
practically all tissues. Besides vasoconstriction, many inflammatory and fibrotic effects of Ang II 
are also a consequence of AT1 receptor activation. However, Ang II can also activate the type-2 
Ang II3 (AT2) receptor, which is upregulated in many cases of injury (e.g., to the kidney, heart 
and brain). The AT2 receptor is part of the protective arm of the RAS, i.e. when activated it has 
anti-inflammatory and anti-fibrotic effects (Figure 4). In addition, the non-classic angiotensin-
converting enzyme 24 (ACE2)/Ang 1-7/proto-oncogene Mas5 (MAS1) axis has been reported to 
function as a counterbalance to the classic angiotensin-converting enzyme6 (ACE)/Ang II/AT1 
axis (Figure 4) [5]. 
Figure 4 | The non-classic angiotensin-converting enzyme 2/angiotensin 1-7/proto-
oncogene Mas receptor axis (based on [5]; created with Motifolio) 
The type-2 angiotensin II receptor and the non-classic ACE2/Angiotensin 1-7/proto-oncogene 
Mas axis are part of the protective arm of the RAS. 
Abbreviations: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme 2, 
RAS renin-angiotensin system  
                                                     
2 uniprot/P30556 
3 uniprot/P50052 
4 uniprot/Q9BYF1 
5 uniprot/P04201 
6 uniprot/P12821 
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II. Acute kidney injury 
II.A. Current definitions of acute kidney injury 
Acute kidney injury (AKI) is an abrupt loss of kidney function that includes, but is not limited to, 
acute renal failure (ARF). It is a broad clinical syndrome encompassing various aetiologies 
(Table 2) and was described for the first time more than 200 years (y) ago [6]. However, AKI 
did not have a consensus definition until a decade ago with the birth of the ‘Risk, Injury, Failure, 
Loss, and End-stage renal disease’ (RISK) system [7]. 
Table 2 | Potential aetiologies of acute kidney injury [8] 
Rhabdomyolysis-induced pigment nephropathy 
Acute tubular necrosis 
 Ischemic 
 Direct injury 
Acute interstitial nephritis 
Glomerular injury 
Thrombotic micro-angiopathy 
Malignant hypertension 
Vascular injury 
 Vasculitis 
 Renal infarct 
Obstructive nephropathy 
Acute kidney injury represent a very heterogeneous syndrome, with often a multifactorial aetiology including several 
injurious hits in time. 
 
Before 2004 AKI was still termed ARF. A logical approach to renal ‘failure’ is to start by defining 
what it is that the kidney does. However, many of its functions either require complex 
neurohumoral interactions involving also other organs (e.g., RAS) or are shared with other organs 
(e.g., acid-base balance with the lung). In fact, there are only two functions that are unique to the 
kidney, i.e. the production of urine and the excretion of nitrogenous (Cr and urea) waste products 
[9]. The lack of a precise definition of ARF resulted in more than 30 definitions in the medical 
literature [7], which caused wide variation in the reported incidence and clinical outcomes of 
ARF. Most definitions had common elements, including the use of serum Cr (SCr) and, often, 
urine output (UO). In 2004, the RIFLE system opened a new era for the definition of AKI [7]. 
Revised definitions for the diagnosis and staging of AKI followed, with in 2007 the Acute Kidney 
 Injury Network (AKIN) system [10], and in 2012 the Kidney Disease | Improving Global 
Outcomes (KDIGO) system [11]. KDIGO defines AKI in adults as either increase in SCr by ≥ 
0.3 mg/dl within 48 hours (h) or increase in SCr to ≥ 1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 d, or UO of < 0.5 ml/kg/h for 6 consecutive h. 
Then, AKI is staged for severity according to defined criteria (Figure 5). Evaluation of these 
systems in many studies has enabled a better understanding of the epidemiology of AKI and has 
shown a clear association between the severity of AKI and poor outcomes. 
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Figure 5 | Kidney Disease | Improving Global Outcomes definition and staging of acute 
kidney injury in adults (adapted from [11]) 
aFor staging purposes, patients should be staged according to the criterion or criteria that give(s) 
them the highest stage 
Abbreviations: AKI acute kidney injury, d day, h hour, KDIGO Kidney Disease | Improving 
Global Outcomes, RRT renal replacement therapy, SCr serum creatinine, UO urine output 
 
  
Diagnosis of AKI by KDIGO
Staginga of AKI by KDIGO
UOSCr
SCr increase to ≥ 1.5 times baseline, which 
is known or presumed to have occurred 
within the prior 7 d
Patient must fulfil at least 1 of 3 criteria 
UO < 0.5 ml/kg/h for ≥ 6 consecutive h
SCr increase by ≥ 0.3 mg/dl within 48 h
Stage 3 SCr UO
Increase to ≥ 3 times baseline
Increase to ≥ 4 mg/dl
Initiation of RRT
< 0.3 ml/kg/h for ≥ 24 consecutive h
Anuria for ≥ 12 consecutive h
Stage 2 SCr UO
Increase to ≥ 2 times baseline < 0.5 ml/kg/h for ≥ 12 consecutive h
Stage 1 SCr UO
Increase to ≥ 1.5 times baseline < 0.5 ml/kg/h for ≥ 6 consecutive h
Increase by ≥ 0.3 mg/dl
 II.A.1. Imperfections in current definitions of acute kidney injury 
Current definitions of AKI define acute changes in kidney function using SCr and UO as criteria. 
These two proxies of the GFR are not perfect in terms of sensitivity and specificity, and clinicians 
should be alert for making a faulty diagnosis. 
II.A.1.i. Background: creatine metabolism and the creatine kinase 
energy shuttle 
The creatine kinase (CK) / phosphorylcreatine (PC) / creatine (C) system participates in energy 
metabolism. In tissues devoid of CK and PC, like liver, it is assumed that high-energy phosphate 
transport between sites of adenosine triphosphate (ATP) production (mitochondria) and ATP 
consumption (cytosol) relies on diffusion of ATP and adenosine diphosphate (ADP) alone. This 
is, however, clearly inadequate for CK-containing tissues, like skeletal or cardiac muscle, brain, 
retina and spermatozoa, with high and fluctuating energy demands. The daily demand for C is 
met either by intestinal absorption of dietary C or by de novo C biosynthesis (Figure 6). In 
mammals the main route of C biosynthesis involves formation of guanidinoacetate in the kidney, 
its transport through the blood, and its methylation to C in the liver. Up to 94% of C is found in 
muscular tissues (Box 1), where C has to be taken up from the blood against a large 
concentration gradient by the saturable sodium- and chloride-dependent C transporter 17 (Figure 
6). The muscular C and PC are non-enzymatically and irreversibly converted at an almost steady 
rate (±1.7 % of total C and PC per day) to Cr, which diffuses out of the cells and is excreted by 
the kidneys into the urine (Figure 6) [12]. 
                                                     
7 uniprot/P48029 
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Figure 6 | Major routes of creatine metabolism and the creatine kinase energy shuttle in 
the mammalian body (based on [12, 13]; created with Motifolio) 
Abbreviations: AdoHcy S-adenosyl-L-homocysteine, AdoMet S-adenosyl-L-methionine, ADP 
adenosine diphosphate, AGAT L-arginine:glycine amidinotransferase, ATP adenosine 
triphosphate, C creatine, CK creatine kinase, Cl- chloride, Cr creatinine, GAA guanidinoacetic 
acid (guanidinoacetate), GAMT S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase, 
Gly glycine, L-Arg L-arginine, M-CK cytosolic muscle-type CK isoenzyme, Mi-CK mitochondrial 
CK isoenzyme, Na+ sodium, PC phosphorylcreatine 
 
Box 1 | The creatine metabolism in the human body (based on [12]; created with Motifolio) 
Abbreviations: C creatine, Cr creatinine, PC phosphorylcreatine 
 
Dietary C
AdoMet + GAA
GAMT
AdoHcy + C
PC
Oxidative phosphorylation
PCC
C
L-Arg + Gly
AGAT
L-Ornithine + GAA
Na+- and Cl--dependent
C transporter 1
Cr
Urinary Cr excretion
ADPATP
ADPATP
M-CK
Mi-CK
Contraction
The total amount of C and PC 
in the ♂ human body is
±120 g
94 % of total C and PC
(113 g) is found in muscular 
tissues
The muscular C and PC are 
converted to Cr at an almost 
steady rate of
 
±1.7 % of total C and PC per 
day
2.0 g of muscular C and PC 
is converted to Cr per day
1.5 g of Cr is excreted by the 
kidneys per day, but
0.5 g of Cr is not excreted by the 
kidneys each day
When the plasma volume is 
2.75 l, the concentration of 
SCr is 0.8 mg/dl
 II.A.1.ii. Imperfections of serum creatinine and urine output 
The validity of SCr as proxy of the GFR critically depends on the assumptions that Cr is 
produced at a steady rate, is physiologically inert and is excreted solely by glomerular filtration in 
the kidney [12]. However, these assumptions are not by default valid in each patient. 
Age, gender, ethnicity and dietary protein intake all affect muscle mass and, therefore, Cr 
production. After the age of 30 y, adults lose 3-8 % of their muscle mass per decade [14]. 
Further, lean tissue loss is largely inevitable during prolonged bed rest. Inactivity-induced loss of 
muscle mass is most rapid during the initial d or weeks (w) of inactivity and predominantly 
affects the lower body musculature [14]. A loss of 0.4 kg of lean leg mass was reported in healthy 
young adults following 28 d of bed rest [15]. In healthy older adults a loss of 0.95 kg of lean leg 
mass was reported following just 10 d of bed rest [16]. Importantly, an increased stress response 
(e.g., hypercortisolemia) may also contribute to muscle loss during periods of impaired physical 
activity. Compared with eucortisolemic controls, pharmacologically-induced hypercortisolemia in 
healthy young adults resulted in a 3-fold greater loss of lean leg mass following 28 d of bed rest 
[15]. Consequently, a false-low SCr concentration due to muscle wasting and fluid overload is 
common in critically ill patients with a long intensive care unit (ICU) length of stay (LOS). In 
addition, many patients will present without a reliable baseline SCr on record. KDIGO suggests 
that in patients without haemodilution secondary to massive fluid resuscitation, the lowest SCr 
obtained during a hospitalization should be used to diagnose and stage AKI [11]. Assuming that 
the illness and LOS were not too long, this SCr would then usually be equal to or greater than the 
baseline [11]. Alternatively, the international and interdisciplinary organization Acute Dialysis 
Quality Initiative (ADQI) recommends that a reliable baseline SCr concentration may be 
obtained within a 3-month (mo) period preceding the current event in patients who are in stable 
condition [17, 18]. 
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Although extrarenal Cr clearance may be negligible in healthy individuals, which led to the 
postulate that Cr is physiologically inert, it may become highly relevant in chronic kidney disease 
(CKD) patients. Most likely, Cr is excreted into the gut where it is converted by bacterial 
creatininase to C. In turn, C is retaken up into the blood [12]. This enteric cycling may limit Cr 
toxicity, as there are two oxidative Cr degradation pathways as well. One leads to the formation 
of methylguanidine and the other to methylurea, which are both uremic toxins [12]. In CKD 
patients, an increasing proportion of Cr is excreted by tubular secretion rather than glomerular 
filtration as well [12]. These factors may result in overestimation of the GFR. 
Importantly, accurate estimation of GFR from the serum level of an endogenous filtration 
marker, like Cr, requires a steady state. After an acute GFR decline, generation of Cr is 
unchanged, but filtration is reduced, resulting in retention of Cr (a rising positive balance) and a 
rising plasma level (non-steady state). Although GFR remains reduced, the rise in plasma level 
leads to an increase in filtered load until filtration equals generation (new steady state). In the 
non-steady state, the direction of change in SCr indicates the direction of change in GFR, and the 
rate of change in SCr provides some indication of the magnitude of change in GFR [19]. 
Meanwhile, UO is an imperfect proxy of the GFR as well, obviously because it is affected by 
diuretic use [20, 21]. In addition, when patients are fluid-loaded, a varying amount of plasma 
water may be removed by glomerular filtration, increasing UO [22, 23]. Another issue is that even 
in catheterized patients, urine volume measurements may be inaccurate. For example, a decreased 
urine volume may be caused by physical obstruction either internally (e.g., urinary catheter debris) 
or externally (e.g., urinary catheter kinking) to the urinary catheter. Also, for the nurses it may be 
difficult to provide exactly timed 1-h registrations of urine volume, complicating accurate 
measurement of UO [22, 23].  
 II.A.2. Rationale for the urgent need for novel biomarkers that are not 
proxies of the GFR 
Because there is no single proven intervention for AKI, clinicians may be hesitant to change the 
‘status quo’ concerning the diagnosis of AKI. Nevertheless, single center studies have shown that 
more early recognition of AKI combined with some simple preventive or supportive measures 
may lower the progression of less severe to severe AKI. The first study providing an 
intervention-based clinical rationale for using more sensitive definitions of AKI was the ‘early 
renal service involvement (EARLI)’ pilot study [24], showing that a 1-time nephrology 
consultation within 18 h of the onset of mild AKI decreased the incidence of subsequent more 
severe AKI from 12.9 % in the control group to 3.3 % in the intervention group (P = 0.020). 
Later on, the first study evaluating the impact of an electronic real-time AKI sniffer on the 
timeliness and number of preventive or supportive measures for AKI, and on the development 
of AKI in the ICU [25], showed that in the alert group more patients with RIFLE class ‘Risk’ had 
an improved RIFLE class within 8 h (65.9 %) than in the pre- (61.0 %) and post-alert (63.1 %) 
control groups. However, this benefit could not be demonstrated in patients with RIFLE class 
‘Injury’ or ‘Failure’, and no beneficial effect on outcome parameters could be found. In 2017 
Meersch et al. showed that the use of an AKI care bundle (i.e., intervention therapy; Table 3) vs. 
a standard care bundle (i.e., control therapy; Table 3) targeted at a cohort of adult cardiac surgery 
patients at high risk for AKI – as identified by a novel biomarker that is not a proxy of the GFR 
– could reduce the occurrence and severity of AKI [26]. A pilot study that used the same 
biomarker for risk stratification in adult ICU patients after major elective non-cardiac surgery 
could demonstrate a reduced occurrence and severity of AKI in the intervention group (AKI care 
bundle) compared to the control group (standard care bundle) in a subgroup (based on 
biomarker concentration) analysis [27]. Despite the limitations of these studies – e.g., single-
center setting, limited number of patients studied – they give us a strong suggestion that there is 
an association between early management of AKI and beneficial patient and kidney outcomes, 
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and so provide convincing rationale for using more sensitive definitions of AKI. Moreover, it is 
likely that the current diagnostic criteria are still not sensitive enough. In this context, following 
drug toxicity studies and analysis of biomarker performance by the Predictive Safety Testing 
Consortium's (PSTC) Nephrotoxicity Working Group, the first formal qualification of renal 
safety biomarkers that are not proxies of the GFR for regulatory decision making (2008-2010) 
marks a milestone in the application of biomarkers to drug development [28]. PSTC brings 
together pharmaceutical companies and academic institutions to share and validate innovative 
safety testing methods. The consortium’s mission is to identify new and improved safety testing 
methods and submit them for formal regulatory qualification by the U.S. Food and Drug 
Administration (FDA), the European Medicines Agency (EMA) and the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA). 
Table 3 | The ‘Kidney Disease | Improving Global Outcomes care bundle’ to reduce the 
risk of acute kidney injury among adult patients who have undergone cardiac surgery 
(based on [26, 29]) 
Surgery 48 h 72 h 
Avoidance of nephrotoxic agents 
 
Withholding of ACE inhibitors and 
ARBs 
 
  
Close monitoring of SCr and UO 
 
Avoidance of hyperglycaemia 
 
Consider alternatives to radio-contrast agents 
 
Optimization of volume status and haemodynamic parameters 
 
Volume status and haemodynamics were optimized using stroke volume variation, cardiac output and MAP. 
Patients in the control group received standard of care: MAP was kept > 65 mmHg and CVP between 8 and 10 
mmHg. 
Abbreviations: ACE angiotensin-converting enzyme, ARB type-1 angiotensin II receptor blocker, CVP central 
venous pressure, MAP mean arterial pressure, SCr serum creatinine, UO urine output 
  
 II.B. The incidence of acute kidney injury is high and still increasing 
The incidence of AKI has increased over the years [30, 31]. Do these changes reflect actual 
increases in disease incidence, or rather changes in consensus definition, in alerting (e.g., real-time 
electronic alerting), in coding, or in use of renal replacement therapy (RRT)? In their 
retrospective multicentre study conducted in Canada, Wald et al. observed a near-quadrupling in 
the incidence of RRT-requiring AKI among critically ill adults over 15 y (Figure 7) [32]. This 
study nicely illustrates that increases in AKI are indeed occurring, which can be attributed to 
population aging, severe comorbidities, and increased use of modifiable risk factors (e.g., 
nephrotoxic agents) [31]. 
Figure 7 | Increasing incidence of RRT-requiring 
AKI among critically ill adults from 1996 to 2010 
(based on [32]; created with GraphPad Prism) 
P for trend is shown. Incidence is expressed as a 
percentage. 
 
 
 
 
 
 
Most available data for AKI epidemiology come from high-income (HI) and upper-middle-
income (UMI) countries. In a recent meta-analysis of studies primarily conducted in hospital 
settings, among the 147 studies (n = 3,212,925) that adopted a KDIGO-equivalent SCr-based 
AKI definition, the pooled incidence rate of AKI was 21.0 % in adults (95 % confidence interval 
(CI): 18.7-23.6 %) [33, 34]. 97.3 % of the studies were from HI (84.4 %) and UMI countries. 
The AKI incidence in the ICU is extremely high, i.e. up to 67.2 % in adults [35]. Consistent with 
this, the multinational cross-sectional AKI-EPI study (n = 1,802) found a similar AKI incidence 
of 57.3 % for adult ICU patients [36]. 74.9 % of the patients were from HI countries, 16.2 % 
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from UMI and 8.9 % from lower-middle-income (LMI) countries. No significant difference in 
the occurrence of AKI was found between patients from HI, UMI and LMI countries (P = 
0.264). 
As 85 % of the world’s population resides in low-income (LI) and LMI countries, the 
multinational cross-sectional International Society of Nephrology 0by25 Global Snapshot study 
enrolled 4,018 adult (91.2 %) and paediatric AKI patients (31.4 % from HI, 39.9 % from UMI, 
23.8 % from LMI and 4.9 % from LI countries) from both hospital and non-hospital settings 
[37]. 58.2 % of these AKI patients had community-acquired AKI. A significant difference in the 
occurrence of community-acquired AKI was found between LI+LMI countries (77.1 %) and 
both HI (50.2 %) and UMI (50.8 %) countries. Further, AKI was significantly more severe at 
diagnosis in patients from LI+LMI countries (57.8 % stage 3) compared with patients from both 
HI (46.7 % stage 3) and UMI (41.0 % stage 3) countries. In the younger AKI patients from 
LI+LMI countries, animal envenomation, infections, dehydration and complicated pregnancy 
were the most important drivers of AKI. By contrast, cardiac failure, surgery and nephrotoxic 
agents predominantly drove AKI in the older comorbid patients from both HI and UMI 
countries. 
II.C. Patients show poor outcomes after acute kidney injury 
II.C.1. High mortality 
In the above-mentioned meta-analysis by Susantitaphong et al. [33, 34], among the 106 studies 
that used a KDIGO-equivalent SCr-based AKI definition and assessed mortality, the pooled 
mortality rate was 23.3 % for adults with AKI (95 % CI: 21.3-25.5 %). In the AKI-EPI study 
increasing AKI severity in ICU patients was associated with hospital mortality (median hospital 
LOS = 14 d) when adjusted for other variables: odds ratio (OR) of stage 1 = 1.679 (95 % CI: 
0.890-3.169), OR of stage 2 = 2.945 (95 % CI: 1.382-6.276), and OR of stage 3 = 6.884 (95 % CI: 
3.876-12.228) [36]. No significant difference in the hospital mortality rate was found between 
 AKI patients from HI, UMI and LMI countries (P = 0.457; hospital mortality rate within AKI 
patients of all countries = 26.9 %) [36]. The 0by25 Global Snapshot study reported that in 
patients with community-acquired AKI, the mortality rate at 7 d was significantly higher in 
LI+LMI countries compared with both HI and UMI countries [37]. The mortality rate at 7 d 
within all AKI patients was 11.0 % [37]. 
Retrospective data from 32,045 adult ICU patients, of which 74.5 % developed AKI, showed that 
risk for both short- (hospital) and long-term (1 y) outcomes (age-adjusted survival and freedom 
from RRT) was highest for patients that had any stage of AKI defined by both SCr and UO 
criteria [38]. Duration of AKI was also a significant predictor of long-term outcomes irrespective 
of severity [38]. Importantly, Rimes-Stigare et al. demonstrated that even severe de novo AKI 
(i.e., AKI that is not superimposed on CKD) was independently associated with increased long-
term risk for death [39]. Further, Uchino et al. showed that even transient AKI, defined as SCr 
reduced to ‘no AKI’ range within 72 h of the onset, was an independent predictor of hospital 
mortality (OR = 2.264; 95 % CI: 1.856-2.762) [40]. Yet, the majority of these patients with 
transient azotaemia were classified as RIFLE stage Risk (74.1 %). 
II.C.2. Association with chronic kidney disease and cardiovascular disease 
Patients who survive an episode of AKI are at risk for progression to CKD, as well as for major 
adverse cardiovascular events [41, 42]. Importantly, Rimes-Stigare et al. demonstrated that even 
severe de novo AKI was independently associated with increased long-term risk for not only 
death, but also CKD and end-stage renal disease (ESRD)[39]. Further, Horne et al. 
demonstrated that even less severe AKI can have significant long-term effects on renal function 
and proteinuria [43]. In the recent review by Vanholder et al., the authors state that “the 
treatment of CKD and of ESRD imposes substantial societal costs” [44]. They emphasise that 
“costs for CKD are not limited to RRT, but also include non-renal healthcare costs, costs not 
related to healthcare, and costs for patients with CKD who are not yet receiving RRT.” In 2001 
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Van Biesen et al. calculated the annual expenditure per ESRD patient in Belgium by modality of 
RRT (Table 4) [45]. Renal transplantation imposes the lowest societal cost while offering the 
highest quality of life [44]. Conversely, in-hospital haemodialysis imposes the highest cost and 
provides the lowest quality of life [44]. Importantly, in the UK the yearly expense (during 2009 
and 2010) to the National Health Service for patients with CKD not requiring RRT almost 
matched that for ESRD patients treated with RRT [46]. 
Table 4 | Annual expenditure per end-stage renal disease patient in Belgium by modality 
of renal replacement therapy (2001) (based on [45]) 
Modality of RRT Cost in euro 
Haemodialysis 71,790 
Peritoneal dialysis 45,000 
Renal transplantation Surgery 
24,356 
First post-operative year 
12,810 
Abbreviations: RRT renal replacement therapy 
 
Recovery from AKI has recently been investigated by ADQI [47], as there was still a lack of a 
consensus definition. ADQI states that “persistent AKI is characterized by the continuance of 
AKI by SCr or UO criteria (as defined by KDIGO) beyond 48 h from AKI onset. Complete 
reversal of AKI by KDIGO criteria within 48 h of AKI onset characterizes rapid reversal of 
AKI. Although the optimal duration of sustained AKI reversal is unknown, a minimum of 48 h is 
necessary to separate two distinct AKI episodes. Persistent AKI frequently becomes acute kidney 
disease (AKD), defined as a condition wherein KDIGO criteria for AKI stage ≥ 1 persist ≥ 7 d 
after an exposure. AKD that persists beyond 90 d is considered to be CKD.” 
II.D. Acute kidney injury in veterinary medicine of companion animals 
In humans, the KDIGO system was developed to stratify the extent and duration of AKI. 
Unfortunately, KDIGO-like criteria are not as consistently applicable in dogs and cats because 
AKI in pets most commonly develops outside the hospital setting. Consequently, the abruptness 
of the disease and the magnitude of changes in SCr and UO are rarely known or quantitated. A 
canine and feline AKI grading (Table 5A) and subgrading scheme (Table 5B) was developed by 
 Cowgill and accepted by the International Renal Interest Society (IRIS), provisionally in 2012 
and finally in 2013 (revised in 2016) [48]. IRIS was created in 1998 to advance the scientific 
understanding of kidney diseases in dogs and cats. It defines five AKI grades based on SCr. Each 
grade is further subdivided on the basis of UO (either oligo-/anuric or non-oliguric) and 
requirement for RRT. This scheme provides an instrument for the more early recognition and 
assessment of outcomes of AKI in dogs and cats. 
Table 5A | International Renal Interest Society grading criteria for acute kidney injury in 
dogs and cats (based on [48]) 
AKI 
grade 
SCr 
(mg/dl) 
Clinical description 
I ≤ 1.6 Non-azotaemic AKI documented by 
  Historical 
evidence 
Clinical evidence Laboratory evidence Imaging 
evidence 
   Including measured oliguria (< 
1 ml/kg/h) or anuria over 6 h 
Including progressive non-
azotaemic increase in SCr of 
≥ 0.3 mg/dl within 48 h 
 
   Including volume 
responsivenessa 
Including volume 
responsivenessb 
 
II > 1.6 Mild AKI documented by 
  Historical 
evidence 
Clinical evidence Laboratory evidence Imaging 
evidence 
   Including measured oliguria (< 
1 ml/kg/h) or anuria over 6 h 
Including progressive 
azotaemic increase in SCr of 
≥ 0.3 mg/dl within 48 h 
 
   Including volume 
responsivenessa 
Including volume 
responsivenessb 
 
III 
 
IV 
 
V 
> 2.5 
 
> 5.0 
 
> 10.0 
Documented moderate to severe AKI 
aDefined as an increase in UO to ≥ 1 ml/kg/h over 6 h 
bDefined as a decrease in SCr to baseline over 48 h 
Abbreviations: AKI acute kidney injury, SCr serum creatinine, UO urine output 
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Table 5B | International Renal Interest Society subgrading of acute kidney injury (based 
on [48]) 
AKI 
grade 
SCr 
(mg/dl) 
Subgrade    
I ≤ 1.6 Non-oliguric (NO) Non-oliguric (NO) 
with RRT need 
Oligo-/anuric (O) Oligo-/anuric (O) 
with RRT need 
II > 1.6  
 
   
III > 2.5  
 
   
IV > 5.0  
 
   
V > 10.0  
 
   
Abbreviations: AKI acute kidney injury, SCr serum creatinine 
 
The most common aetiologies of AKI in dogs and cats are listed in Table 6. Unfortunately, a 
definitive underlying aetiology for development of AKI is often not found. 
Table 6 | Common aetiologies of acute kidney injury in dogs and cats (based on [49]) 
Dogs Dogs and cats Cats 
Leptospirosis (2.0 %) Pyelonephritis (2.0 %) Ureteral obstruction** 
Grape or raisin toxicity Nephrotoxic drugs (e.g., NSAIDs) 
(9.1 %) 
Lily toxicitya 
Acute pancreatitis* (9.1 %) Ethylene glycol (12.1 %) Renal lymphoma** (1.0 %) 
Lyme nephritis Severe blood pressure alterations 
(low or high) (24.2 %) 
 
aLilies (plants) considered potentially nephrotoxic to cats are Easter lily, Stargazer lily, Japanese Show lily, Tiger lily, 
Asiatic lily, Leopard lily, Trumpet lily, Panther lily, White lily, Yellow lily, Day lily and Calla lily [50]. 
*Indicates that the disorder can occur in both dogs and cats, but occurs much more commonly in dogs 
**Indicates that the disorder can occur in both dogs and cats, but occurs much more commonly in cats 
The percentage of AKI dogs that were identified with the disorder is given (retrospective study in 99 AKI dogs; 
[51]). Additionally, 18.2 % of the AKI dogs were identified with multiple disorders, while in 22.2 % no disorder was 
identified. 
 
Harison at al. investigated the incidence of hospital-acquired AKI in dogs and cats (i.e., patients 
with an initial SCr of > 1.6 mg/dl were excluded). This retrospective study (n = 400 for dogs, n 
= 128 for cats) reported an AKI incidence of 15 % in dogs and 21 % in cats based on an acute 
(non-)azotaemic increase in SCr of ≥ 0.3 mg/dl within 48 h [52].  
 III. Increased understanding of the pathophysiology of acute kidney injury 
As logical approach to other biological parameters for AKI than SCr and UO, the following 
paragraphs summarize the latest understanding of the pathophysiology of AKI. The cellular 
mechanisms behind AKI are reviewed, including cellular activation, hibernation and suicide. 
III.A. Cellular mechanisms 
III.A.1. Cellular activation of different cell types 
III.A.1.i. Macrophages 
A variety of pathogen-associated molecular patterns (PAMP) (i.e., proteins, sugars, lipids or 
nucleic acids unique to pathogens) and damage/danger-associated molecular patterns (DAMP) 
(i.e., molecules like heat-shock proteins and ATP that come mainly from distressed or dead host 
cells) activate the innate immune response by binding to pattern recognition receptors (PRR) on 
macrophages (Figure 8) [53]. Activated macrophages secrete tumour necrosis factor-α (TNF-α) 
and interleukin-1β (IL-1β), which – after binding to their receptors – lead to cellular activation 
[54]. 
While IL-1β precursor is produced by, inter alia, macrophages in response to a nuclear factor-κB 
(NF-κB) (transcription factor) activating stimulus (e.g., PAMP/DAMP binding to PRR, TNF-α 
and IL-1 itself), the IL-1α precursor is constitutively present in, inter alia, endothelial cells and 
renal tubular cells [55]. Unlike the IL-1β precursor, the IL-1α precursor is fully active and 
functions as an “alarmin” released upon regulated necrosis [55]. 
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Figure 8 | Major effector cells of both the innate and the adaptive immune system 
contribute to the establishment of acute kidney injury (based on [56]; created with Motifolio) 
The left panel shows a normal kidney, while the right panel shows a kidney with AKI. Dendritic 
cells act as messengers between the innate and adaptive immune systems. Note that adhesion 
molecules mediate lymphocyte capturing and rolling. 
Abbreviations: AKI acute kidney injury, DAMP damage/danger-associated molecular pattern, 
PAMP pathogen-associated molecular pattern, TLR Toll-like receptor (a type of pattern 
recognition receptor) 
 
Although innate responses do have some specificity in recognizing pathogens, their effector 
molecules kill non-specifically. Activated macrophages produce superoxide anion (O2▪–) from 
preformed nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzymes, nitric 
oxide (NO▪) gas from arginine by means of inducible NO▪ synthase (iNOS) and various matrix 
metalloproteinases (MMP) [53]. Therefore, whenever innate immunity kills, it also causes 
collateral damage to normal tissues (e.g., MMPs degrade extracellular matrix components like 
collagen [53]). Within the kidney, the glomerular basement membrane, the specialized cell-to-cell 
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 junctions of the podocytes, called slit diaphragms, and the endothelial and podocyte glycocalyx 
are harmed, resulting in vascular leakage and interstitial oedema (Figure 2) [57]. This increased 
permeability allows haemo-concentration, which in turn increases the endothelial-leukocyte 
interactions [54]. The outcome is amplification of the pro-inflammatory signal, leading to further 
dysfunction of the endothelial permeability barrier [54]. 
III.A.1.ii. Kidney endothelial cells 
Endothelial cells release a variety of pro-inflammatory mediators (i.e., cytokines and chemokines) 
upon TNF-α or IL-1 stimulation. The chemokine IL-8 plays a key role in neutrophil chemotaxis 
and degranulation, whereas C-C motif chemokine 2 (CCL2) (alternative name: monocyte 
chemoattractant protein 1 or MCP-1) is involved in attracting monocytes (Figure 8) [54]. Fusion 
of Weibel-Palade bodies (storage granules of endothelial cells), containing P-selectins8, with the 
cell membrane and synthesis of E-selectins9 are mediated by TNF-α or IL-1 as well [54]. These 
adhesion molecules mediate lymphocyte capturing and rolling by binding to the lymphocyte 
adhesion receptor L-selectin10 (Figure 8) [58]. Activated endothelial cells also activate 
coagulation, which is central to microcirculatory dysfunction [54]. Activation of the endothelial 
NF-κB pathway reduces thrombomodulin11 and endothelial protein C receptor12 (EPCR) 
transcription and increases their shedding from the endothelial surface [59]. Such activation 
impairs the activated protein C (aPC) anti-coagulant and anti-inflammatory mechanisms. Under 
physiological conditions, EPCR binds circulating protein C13 (cPC), synthesized in the liver, and 
presents it to the thrombin14-thrombomodulin complex, generating aPC (Figure 9). Besides 
                                                     
8 uniprot/P16109 
9 uniprot/P16581 
10 uniprot/P14151 
11 uniprot/P07204 
12 uniprot/Q9UNN8 
13 uniprot/P04070 
14 uniprot/P00734 
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interrupting the coagulation cascade by cleavage of factors Va15 and VIIIa16, aPC also activates 
anti-inflammatory properties by coupling of the aPC-EPCR complex to protease-activated 
receptor-117 (PAR-1) [59]. 
Figure 9 | Anticoagulant mechanisms of the protein C system (based on [60]; created with 
Motifolio) 
Protein S acts as a cofactor of activated protein C and the complex inhibits factors VIIIa and Va. 
Protein C is activated by the EPCR bound to the complex thrombin (factor IIa)-
thrombomodulin. Solid lines denote activation and broken lines inhibition. 
Abbreviations: Ca2+ calcium, EPCR endothelial protein C receptor 
 
III.A.1.iii. Kidney tubular epithelial cells 
An organized interaction between PAMPs/DAMPs and the tubular epithelial cell occurs in the 
S1 segment of the proximal tubule. The findings of Kalackeche et al. suggest that activation of 
surveillance receptors, or PRRs, increases reactive oxygen species (ROS) through the oxidation 
of NADPH by NADPH oxidase enzymes [61]. As essential second messengers, ROS are 
required for the release of pro-inflammatory cytokines (e.g., TNF-α) to effect an appropriate 
innate immune response [62]. The S1 segment would thus act as the ‘sensor’ of PAMPs and 
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 DAMPs in the filtrate and, as such, auto-protect itself (i.e., upregulation of cytoprotective 
molecules with antioxidant properties, like haem oxygenase-118 (HO-1)), while simultaneously 
signalling to neighbouring segments (i.e., paracrine fashion through secretion of TNF-α), 
resulting in an organized oxidative outburst in these epithelial cells of the adjacent proximal 
tubular segments (S2 and S3) (Figure 10) [61]. Further, it is hypothesized that this oxidative 
outburst is the trigger for S2 and S3 proximal tubular epithelial cellular hibernation (cf. section 
III.A.2. “Cellular hibernation of kidney tubular epithelial cells”), which is an adaptive response [61]. 
III.A.2. Cellular hibernation of kidney tubular epithelial cells 
Gomez et al. hypothesize that the kidney tubular epithelial cells of specifically the S2 and S3 
segments of the proximal tubule, coordinate a response to the oxidative outburst directed by S1 
proximal tubular epithelial cells [63]. This adaptive response, i.e. reprioritization of energy-
consumption, autophagy and cell-cycle arrest, would avoid triggering regulated cell death (RCD) 
(cf. section III.A.3. “Cellular suicide of kidney tubular epithelial cells”) [63]. 
As part of the cellular response to threatening circumstances, a highly conserved mechanism 
across species is that ATP-consuming processes have a hierarchy of response dependent on the 
level of energy (i.e., ATP) charge or supply, avoiding energy expenditure in non-essential 
pathways, and allowing the cell to prioritize energy-consumption in essential processes [64]. 
During AKI both relocation of the sodium-potassium ATPase pump19 [65], and downregulation 
of the megalin receptor20 reduce cellular energy demands [66], thereby causing an important 
reduction in oxygen consumption. 
                                                     
18 uniprot/P09601 
19 uniprot/P05023 and uniprot/P50993 and uniprot/P13637 and uniprot/Q13733 
20 uniprot/P98164 
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Figure 10 | The S1 segment as the ‘sensor’ of pathogen-associated molecular patterns 
and damage/danger-associated molecular patterns in the filtrate (based on [63]; created 
with Motifolio) 
Simultaneously, the S1 segment signals to neighbouring segments (i.e., paracrine fashion through 
secretion of TNF-α), resulting in an organized oxidative outburst in these epithelial cells of the 
adjacent proximal tubular segments (S2 and S3). 
Abbreviations: DAMP damage/danger-associated molecular pattern, PAMP pathogen-
associated molecular pattern, TLR Toll-like receptor (a type of pattern recognition receptor), 
TNF-α tumour necrosis factor-α 
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 The evolutionarily conserved multi-step process of autophagy was traditionally viewed as a non-
selective sequestration of the cytoplasmic contents in autophagosomes and its degradation by 
lysosomes [67]. Selective autophagy has, however, been reported (e.g., for the elimination of 
damaged mitochondria, termed mitophagy) [67]. Per milligram of tissue, only the heart exceeds 
the kidney's abundance of mitochondria [68]. Not surprisingly, mitophagy was increased in 
kidney tubular epithelial cells in vivo in ischemia-reperfusion injury (IRI) models of AKI [69, 70]. 
Four distinct phases compose the eukaryotic cell-cycle: the first gap phase (G1), the DNA 
synthesis phase (S), the second gap phase (G2), and finally mitosis (M) (Figure 11) [71]. 
Quiescent cells in the G0 phase have dropped out of the cell-cycle [71]. In a model of cecal 
ligation and puncture-induced sepsis, Yang et al. showed that G1/S cell-cycle arrest was 
associated with AKI, and that recovery from AKI paralleled cell-cycle progression [72]. During 
cellular insults this G1/S cell-cycle arrest reduces oxygen consumption and prevents mitosis in 
damaged cells, thereby protecting the kidney from extended injuries. Cell-cycle arrest appears to 
protect cells from mitotic catastrophe, an event in which a cell becomes arrested in mitosis if 
chromosomal defects or problems affecting the mitotic machinery are sensed during the M phase 
[73]. Mitotic catastrophe can be defined as an oncosuppressive mechanism that precedes and is 
distinct from, yet operates through, either RCD or senescence [73]. 
The activities of complexes of cyclins and cyclin-dependent kinases (CDK), which phosphorylate 
retinoblastoma (RB) family ‘pocket proteins’, drive progression through the cell-cycle (Figure 
11) [71]. The ability of RB to sequester members of the E2F transcription-factor family, which 
allow for the expression of a transcriptional programme that enables progression through S-
phase and mitosis, is inhibited by this phosphorylation [71]. Two classes of CDK inhibitors 
(CDKI), which have differing mechanisms of action, modulate the activities of cyclin-CDK 
complexes (Figure 11). The INK4 CDKI family (p15, p16, p18 and p19) inhibits CDK activity 
through direct interaction with and sequestration of the CDK concerned [71]. However, the 
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‘CIP/KIP’ CDKI family (p21, p27 and p57) binds to cyclin-CDK complexes. At high levels, p21 
and p27 function as cyclin-E-CDK2 inhibitors, while at lower levels they promote the assembly 
of cyclin-D-CDK4 and cyclin-D-CDK6 complexes [71]. Both these complexes also function as a 
sink for p21 and p27, thereby relieving cyclin-E-CDK2 complexes from the p21/p27-mediated 
inhibition (Figure 11). The regulatory pathways involved in the G1/S checkpoint are thus 
multiple, complex and interdependent [74]. Whether a cell will progress through the G1 phase of 
the cell-cycle is therefore determined by the relative levels of cyclins, CDKs and CDKIs [71]. 
Both cyclin-D- and cyclin-E-associated CDKs are believed to be required for G1-phase 
progression. 
Figure 11 | Modulation of the 
eukaryotic cell-cycle (based on [71]; 
created with Motifolio) 
Movement through the cell cycle is 
driven by the activities of complexes of 
cyclins and CDKs, which phosphorylate 
RB-family ‘pocket proteins’, thereby 
blocking their growth-inhibitory 
functions and permitting cell-cycle 
progression. Cyclin-D-CDK4 and cyclin-
D-CDK6 complexes are active when 
associated with p21 or p27 CDKIs, but 
only cyclin-E-CDK2 complexes that are 
free of CDKIs are active in vivo. 
Right box: Cyclin-D-CDK4 and cyclin-
D-CDK6 complexes also function as a 
sink for p21 and p27, thereby relieving 
cyclin-E-CDK2 complexes from the 
p21/p27-mediated inhibition. 
Left box: The NephroCheck® Test is an in vitro diagnostic device that quantitatively measures 
TIMP-2 and IGFBP7 proteins in human urine. In response to renal stress or damage, TIMP-2 
and IGFBP7 are expressed in the kidney tubular epithelial cells of the proximal tubule. TIMP-2 
stimulates p27 expression, while IGFBP7 increases the expression of p21. These effects are 
conducted in an autocrine and paracrine manner via TIMP-2 and IGFBP7 receptors. 
Abbreviations: CDK cyclin-dependent kinase, CDKI CDK inhibitor, G1 first gap phase, G2 
second gap phase, IGFBP7 insulin-like growth factor-binding protein 7, M mitosis, RB 
retinoblastoma, S DNA synthesis phase, TIMP-2 tissue inhibitor of metalloproteinases-2 
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 III.A.3. Cellular suicide of kidney tubular epithelial cells 
Non-apoptotic RCD pathways have gained special attention particularly due to their role in 
inflammation. The concept of immunogenic RCD suggests an auto-amplification loop: the 
release of DAMPs upon regulated necrosis (receptor-interacting protein kinase 321 (RIPK3) 
dependent or independent [73, 75, 76]) and ferroptosis amplifies the pro-inflammatory signal 
[75]. A unique feature of pyroptosis, a RCD pathway originally thought to occur exclusively in 
macrophages [75], is the maturation of the pro-inflammatory cytokines IL-1β and IL-18 during 
the RCD process, which depends on cleavage mediated by non-apoptotic caspase-122 [73]. 
Therefore, pyroptosis represents maximal immunogenicity [75]. 
The mode of RCD of kidney tubular epithelial cells in AKI has been a matter of intense debate. 
In IRI models, the protection from AKI reported for RIPK3-knockout mice likely involves 
vascular effects. Linkermann et al. showed that RIPK3-knockout mice exhibited statistically 
significant increases in the diameter of peritubular capillaries compared with wildtype mice, 
suggesting non-cell death functions for RIPK3 [77]. Further, they found that ferroptosis, a RCD 
pathway driven by loss of activity of the lipid repair enzyme glutathione peroxidase 423 (GPX4) 
and subsequent accumulation of lipid-based ROS (particularly lipid hydroperoxides) [78], 
mediated RCD of kidney tubular epithelial cells upon IRI [77]. Because RIPK3-knockout mice 
have been demonstrated to be resistant to AKI in sepsis models, the authors investigated first-
generation ferrostatin (termed ferrostatin-1) – a ferroptosis inhibitor whose activity depends on 
the primary aromatic amine, which specifically inhibits accumulation of ROS from lipid oxidation 
[79] – in a model of lipopolysaccharides (LPS) (Escherichia coli O111:B4 LPS) induced shock, but 
no difference compared with vehicle-treated mice was evident [77].  
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III.B. Novel ‘acute kidney stress’ biomarkers 
III.B.1. Acute kidney stress 
Only recently Katz and Ronco proposed to describe the pre-phase that leads to AKI as ‘acute 
kidney stress’ (AKS) [80]. Whether AKS is a condition of increased susceptibility to exposures 
that lead to AKI (i.e., renal stress) or a condition of very early injury (i.e., renal damage), is 
debatable (Figure 12). Regardless, biomarkers – or “measurable and quantifiable biological 
parameters” [81] – that respond to AKS open new horizons in regard to the early detection – or 
‘prediction’ – of emerging AKI. These renal stress or damage biomarkers serve as surrogate 
measurements, estimating renal cell perfusion, function or metabolism [80]. 
Figure 12 | Potential utilization of biomarkers for acute kidney injury (based on [82]; 
created with Motifolio) 
A window of opportunity in which renal stress or damage has been initiated, but has not 
progressed to renal functional change, may be identified by assessment of AKS biomarkers. 
Abbreviations: ARF acute renal failure, GFR glomerular filtration rate, KDIGO Kidney Disease 
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 In response to the urgent need for biomarkers that predict human AKI and ideally localize renal 
stress or damage to a specific nephron site, several promising urinary ‘renal stress or damage 
biomarker candidates’ have recently emerged (Table 7) [83]. These include, inter alia, neutrophil 
gelatinase-associated lipocalin (NGAL) (Table 7). This dissertation will focus on NGAL and the 
in 2012 by our group discovered novel candidate chitinase 3-like protein 1 (CHI3L1) [84], which 
may appear and be measured in the urine of humans. 
Table 7 | Nephron segment-specific urinary biomarkers of kidney injury (based on [83]) 
Glomerulus  Proximal tubules  Loop of Henle  Distal tubules  Collecting 
duct 
Total protein  Kim-1  Osteopontin  Osteopontin  Calbindin D28 
Cystatin C (urinary)  Clusterin  NHE-3  Clusterin   
β2-microglobulin  NGAL    GST-μ/π   
α1-microglobulin  GST-α    NGAL   
Albumin  β2-microglobulin    H-FABP   
  α1-microglobulin    Calbindin D28   
  NAG       
  Osteopontin       
  Cystatin C (urinary)       
  Netrin-1       
  RBP       
  IL-18       
  HGF       
  Cyr61       
  NHE-3       
  Exosomal fetuin-A       
  L-FABP       
  Albumin       
Abbreviations: Cyr cysteine-rich protein, GST glutathione S-transferase, H-FABP heart-type fatty acid-binding 
protein, HGF hepatocyte growth factor, IL-18 interleukin-18, Kim-1 kidney injury molecule-1, L-FABP liver-type 
fatty acid-binding protein, NAG N-acetyl-β-glucosaminidase, NGAL neutrophil gelatinase-associated lipocalin, 
NHE-3 sodium/hydrogen exchanger isoform 3, RBP retinol-binding protein 
 
III.B.2. Neutrophil gelatinase-associated lipocalin 
III.B.2.i. The lipocalin-family of proteins 
Human NGAL24 (also known as siderocalin, lipocalin-2 and human neutrophil lipocalin) is a 
member of the lipocalin-family of proteins [85]. The name ‘lipocalin’ reflects their ability to 
complex lipophilic molecules inside a cup-shaped protein fold [85]. The ligand pocket of NGAL 
can accommodate a spectrum of catecholic and phenolic iron chelators, but also iron-complexed 
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L-norepinephrine [85]. In keeping with the size range of lipocalins, the 178 amino acid 
deglycosylated human NGAL protein has a calculated molecular mass of 20,542 Dalton (Da) 
[86]. While N-glycosylation occurs at asparagine at position 65, cysteine at position 87 is 
responsible for dimerization [86]. A 3D protein structure model of human NGAL is shown in 
Figure 13. 
Figure 13 | 3D protein structure model of human 
neutrophil gelatinase-associated lipocalin (adapted from 
the Research Collaboratory for Structural Bioinformatics 
Protein Data Bank; viewer: JSmol; structure: 1NGL [87]; style: 
cartoon; display mode: secondary structure) 
The direction of the protein chain can be identified by arrows 
at the ends of β-sheets. 
 
 
 
As suggested by its name, human NGAL is released from neutrophils as a disulphide-linked 
heterodimer with MMP-925 (also known as gelatinase B) [88]. However, it can be released from 
the secondary granules of neutrophils in two other forms as well: i.e., a monomer and a 
disulphide-linked homodimer [88]. Moreover, it is also markedly induced in injured epithelial 
cells, including the thick ascending limb and collecting duct cells of the kidney [89]. This suggests 
a potential involvement of NGAL in enhancing the epithelial phenotype – a documented effect 
of NGAL – both during kidney development and following AKI [90]. Finally, NGAL is 
markedly induced in a number of human cancers, where it promotes cancer progression through 
MMP-9 binding, thereby preventing MMP-9 degradation [91].  
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 III.B.2.ii. Kidney iron transport: role of neutrophil gelatinase-
associated lipocalin 
The hepatic hormone hepcidin regulates iron metabolism systemically through its interaction 
with the iron exporter ferroportin-126 (Fp-1) on the basolateral membrane of enterocytes and the 
plasma membrane of macrophages [92]. Hepcidin binds to Fp-1, leading to Fp-1 endocytosis and 
degradation. Intracellular levels of iron are controlled by iron regulatory proteins that post-
transcriptionally regulate the translation of iron metabolism proteins, including transferrin 
receptor protein 127 (TfR1) (promotion of translation when small iron pool), divalent metal 
transporter 128 (DMT-1) (promotion of translation when small iron pool), ferritin29 (inhibition of 
translation when small iron pool) and Fp-1 (inhibition of translation when small iron pool) [92]. 
Kidney iron transport is illustrated in Figure 14 [92]. The reader is encouraged to study this 
Figure together with the following paragraphs. 
Circulating iron exists in the form of ferric iron (Fe3+), either free or bound to, inter alia, 
transferrin30 (Tf), lactoferrin31 (LTf) and NGAL. Through the membrane proteins DMT-1, 
TfR1, cubilin32, megalin and NGAL receptor33 (NGALR), Fe3+ is imported into the kidney 
tubular epithelial cell, where it locates in the endosome. There, Fe3+ is reduced to ferrous iron 
(Fe2+) by the metalloreductase STEAP334 with ferrireductase activity. Finally, Fe2+ is released 
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from the endosome into a labile iron pool in the cytoplasm through DMT-1. Excess iron is 
stored in the form of Fe2+ in ferritin, an iron storage protein complex [92]. 
Circulating iron bound to haem-(carrier proteins) exists in the form of Fe2+. Through the 
membrane proteins haem carrier protein 135 (HCP1), cubilin and megalin, haem-(carrier 
proteins) are imported into the cell. Inducible HO-1 catalyses the first and rate-limiting step in 
the degradation of haem, yielding biliverdin, carbon monoxide (CO) and Fe2+. HO-1 can also 
upregulate the expression of ferritin. This coupled response thus degrades haem, generates 
antioxidants (i.e., bile pigments) and chelates iron. Finally, hephaestin36 oxidizes Fe2+ to Fe3+, 
while Fp-1 mediates Fe3+ export. Iron can also be exported into the interstitial fluid and 
circulation bound to haem through feline leukaemia virus subgroup C receptor37 (FLVCR). This 
also requires the extracellular presence of a suitable haem-binding protein (preferably 
haemopexin38 (HPX)) [92]. As potential producers of HPX and the haemoglobin-binding 
protein haptoglobin39, and expressers of the HPX receptor LRP̻140 and the haemoglobin-
haptoglobin complex receptor CD16341, kidney macrophages help regulate renal iron metabolism 
through LRP-1- and CD163-mediated clearance in macrophages [92]. Likewise, renal tubular cells 
can secrete hepcidin and NGAL, which can possibly detoxify iron [92].
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 III.B.3. Chitinase 3-like protein 1 
III.B.3.i. The number-18 glycoside hydrolase-family of proteins 
Glycoside hydrolases – also referred to as glycosidases and sometimes also as glycosyl hydrolases 
– are “enzymes that catalyse the hydrolysis of the glycosidic linkage of glycosides” [93]. The 
Carbohydrate-Active Enzymes database (CAZy) further classifies glycoside hydrolases in families 
based on amino acid sequence similarities [93]. The number-18 glycoside hydrolase-family is 
special in that it comprises catalytically inactive proteins such as chitinase-like proteins (CLP) in 
addition to catalytically active proteins such as chitinases [93]. These CLPs function as lectins 
because they can bind, but not hydrolyse, the glycan chitin, and therefore represent the ‘chi-
lectin’ subfamily [94, 95]. 
Chitin is a linear homo-β-(1,4)-polymer made up of repeating units of β-N-acetyl-D-glucosamine 
[96]. Being the structural component in the coating of many living species including the cell wall 
of fungi, the cuticle of nematodes and the cysts of protozoan parasites, chitin is the second most 
abundant polysaccharide in nature after cellulose [96, 97]. In mammals, despite the absence of 
endogenous chitin, a number of chitinases and CLPs have been identified [97]. The 362 amino 
acid deglycosylated human CHI3L142 protein (also known as 39 kDa synovial protein, cartilage 
glycoprotein 39 and YKL-40 based on its three N-terminal amino acids (i.e., tyrosine Y, lysine K 
and leucine L)) has a calculated molecular mass of 40,476 Da [98, 99]. N-glycosylation occurs at 
asparagine at position 60 [100]. A 3D protein structure model of human CHI3L1 is shown in 
Figure 15.  
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Figure 15 | 3D protein structure model of human 
chitinase 3-like protein 1 (adapted from the Research 
Collaboratory for Structural Bioinformatics Protein Data 
Bank; viewer: JSmol; structure: 1NWR [101]; style: cartoon; display 
mode: secondary structure) 
The direction of the protein chain can be identified by arrows 
at the ends of β-sheets. 
 
 
 
Although originally discovered as a secretion product of human synovial cells and osteoblasts 
[102, 103], it has become clear that a variety of cells including macrophages, neutrophils and 
kidney tubular epithelial cells can secrete CHI3L1 [104]. Regarding its function, it has become 
evident that CHI3L1 is enhanced in differentiated and polarized macrophages. Therefore, it has 
pleiotropic effects in inflammation [96]. Concentrations of either circulating or tissue CHI3L1 
have been associated with a variety of inflammatory, remodelling, and neoplastic disorders, and 
with various primary and metastatic cancers [97]. 
III.B.3.ii. Background: galectin-glycan interactions, lipid rafts and 
signal transduction 
Endogenous glycan-binding proteins or lectins “can specifically decode saccharide structures and 
glycosidic linkages and convey this structural information into functional cellular responses 
[105].” Some of these lectins effectively function as PRRs to initiate host innate immune 
responses [106]. One family of lectins is the galectin family, which is special in that it comprises 
soluble instead of transmembrane proteins (Figure 16) [107]. Most galectins are either bivalent 
or multivalent with regard to their carbohydrate-binding activities, enabling the formation of a 
spatial array of multivalent galectins and multivalent glycans – often termed the galectin-glycan 
lattice – on the cell surface (Figure 16) [107]. 
 Figure 16 | Galectin-
glycan interactions: 
structural features 
(based on [107]; created 
with Motifolio) 
Galectins can be 
subdivided into three 
groups: prototype 
galectins, which contain 
one CRD and can form 
homodimers; tandem 
repeat-type galectins, 
which contain two 
distinct CRDs in 
tandem and are 
inherently bivalent; and 
the chimera-type 
galectin 3, which 
contains a CRD connected to a non-lectin region. Distinct types of galectin-glycan lattices could 
be formed between multivalent galectins and multivalent glycans. 
Abbreviations: CRD carbohydrate recognition domain 
 
Initiation of signal transduction involves complex protein-protein interactions between inter alia 
extracellular ligands, transmembrane receptors and kinases, but lipid micro-environments on the 
same cell surface – also known as lipid rafts – take part in this process too (Figure 17) [108]. 
More specifically, galectin-glycan lattices could initiate signalling through one or more of such 
lipid rafts, in which the galectin-glycan lattice serves either as receptor-oligomerizing agent 
(Figure 17, Model 1) or as raft-clustering agent (Figure 17, Model 2) [105, 108]. 
Structure and classification
Prototype Tandem repeat-type Chimera type galectin 3
Galectin-glycan lattices
Bivalent ligand Trivalent ligand Tetravalent ligand
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Figure 17 | Models 
of possible initiation 
of signal 
transduction 
through one or more 
lipid rafts (based on 
[108]; created with 
Motifolio) 
Receptors could 
behave in at least 
three different ways in 
rafts. First, receptors 
associated at steady 
state with lipid rafts 
could be oligomerized 
and activated through 
either multivalent 
antibody (e.g., Fc 
receptor activated by 
IgE) or multivalent 
ligand (e.g., TCR 
activated by peptide 
presented on MHC 
protein) binding (A, 
a). Second, individual 
receptors with weak 
raft affinity could 
oligomerize upon either multivalent antibody or multivalent ligand binding, and this would lead 
to an increased residency time in rafts and receptor activation (A, b). Third, activated receptors 
could recruit crosslinking proteins (e.g., activated TCR recruits LAT) that bind to proteins in 
other rafts, and this would result in raft coalescence (B). Clustering could occur either 
extracellularly, within the membrane, or in the cytosol. 
Abbreviations: Ig immunoglobulin, LAT linker for activation of T cells, MHC major 
histocompatibility complex, TCR T-cell antigen receptor 
 
Surprisingly, only in 2013 He et al. investigated the possibility that the ‘chi-lectin’ subfamily 
member CHI3L1 mediates its biological effects through receptor binding, and identified at first 
IL-13 receptor α243 (IL-13Rα2) as its binding partner [109]. They hypothesised that CHI3L1(chi-
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lectin) and IL-13Rα2 (transmembrane protein) are part of a ‘chi-lectin-glycan’ lattice on the cell 
surface, including other lectins and glycoproteins [109]. 
III.B.3.iii. Inflammation signalling cascades: role of chitinase 3-like
protein 1
Biological effects of CHI3L1 that are mediated through IL-13Rα2 binding include inhibition of 
apoptotic RCD in kidney tubular epithelial cells [109, 110], and inhibition of pyroptosis and IL-
1β production in macrophages through inhibition of ‘nucleotide-binding domain and leucine-rich 
repeat family pyrin domain containing 3’44 (NLRP3) inflammasome activation [109, 111]. It is 
possible that the ‘chi-lectin-glycan’ lattice composed of inter alia CHI3L1 and IL-13Rα2 initiates 
signalling in inflammation signalling cascades through one or more lipid rafts. These 
inflammation signalling cascades may include the RAS-ERK and PI3K-mTOR pathway (Figure 
18 and Table 8). Indeed, He et al. demonstrated that the intracellular domain of IL-13Rα2 is not 
required for RAS-ERK and AKT activation [109]. Consequently, the authors postulated that IL-
13Rα2 partners with another as of yet unidentified receptor to transduce CHI3L1 responses. This 
view is supported by previous studies showing that IL-13Rα2 co-immunoprecipitates with IL-
4Rα45 as component of the heterodimeric IL-13R that also includes IL-13Rα146 [112, 113] 
(Figure 18 and Table 8). Initiation of either RAS-ERK or PI3K-mTOR signalling leads to 
inhibition of apoptotic RCD. 
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Figure 18 | The ‘chi-lectin-glycan’ lattice composed of inter alia CHI3L1 and IL-13Rα2 
may initiate signalling in kidney tubular epithelial cells’ inflammation signalling 
cascades through one or more lipid rafts (based on [114, 115]; created with Motifolio) 
The upper panel shows the RAS-ERK pathway, while the lower panel shows the PI3K-mTOR 
pathway. The signal transducing partner of the ‘chi-lectin-glycan’ lattice could be the 
heterodimeric IL-13R that includes IL-4Rα and IL-13Rα1. Initiation of either RAS-ERK or 
PI3K-mTOR signalling leads to inhibition of apoptotic RCD in kidney tubular epithelial cells. 
Table 8 complements with detailed data lacking here for clarity purposes. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, IL-13Rα2 interleukin-13 receptor α2, RCD 
regulated cell death 
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 Likewise, it is possible that this ‘chi-lectin-glycan’ lattice hampers signalling in inflammation 
signalling cascades through one or more lipid rafts. These inflammation signalling cascades may 
include the TLR4-MYD88 pathway (Figure 19 and Table 9) as TLR4-MYD88 signalling is a 
prototypical priming event of NLRP3 inflammasome activation [116]. Hampering of TLR4-
MYD88 signalling leads to inhibition of pyroptosis and IL-1β production in macrophages 
through inhibition of NLRP3 inflammasome activation. 
Figure 19 | The ‘chi-lectin-glycan’ lattice composed of inter alia CHI3L1 and IL-13Rα2 
may hamper signalling in macrophages’ inflammation signalling cascades through one 
or more lipid rafts (based on [116, 117]; created with Motifolio) 
The TLR4-MYD88 pathway is shown. The signal transducing partner of the ‘chi-lectin-glycan’ 
lattice could be TLR4. Hampering of TLR4-MYD88 signalling leads to inhibition of pyroptosis 
and IL-1β production in macrophages through inhibition of NLRP3 inflammasome activation. 
Table 9 complements with detailed data lacking here for clarity purposes. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, IL-13Rα2 interleukin-13 receptor α2, TLR4 
Toll-like receptor 4 
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Table 8 | The RAS-ERK and the PI3K-mTOR pathways (based on [114, 115]) 
Type of signalling protein in RAS-
ERK pathway 
 Name of signalling protein in RAS-ERK pathway 
Receptor  Interleukin (IL)-13 receptor (R), which is comprised of IL-4Rα and IL-
13Rα1 
Tyrosine kinase  Janus tyrosine kinases (JAKs), i.e. JAK1 and Tyk2 
Adaptor protein  Insulin receptor substrates (IRSs), i.e. IRS-1 and IRS-2, which are 
recruited to a specific tyrosine residue of IL-4Rα 
Adaptor protein  GRB2 
Guanine nucleotide exchange factor 
(GEF) 
 SOS 
Guanosine triphosphate 
phosphohydrolase (GTPase) 
 Members of the RAS oncoprotein branch of the Ras family of proteins 
GTPase-regulated kinase (MAPKKK)  Raf 
Intermediate kinase (MAPKK)  MEK 1/2 
Effector kinase (MAPK)  ERK 1/2 
   
Type of signalling protein in PI3K-
mTOR pathway 
 Name of signalling protein in PI3K-mTOR pathway 
Receptor  Interleukin (IL)-13 receptor (R), which is comprised of IL-4Rα and IL-
13Rα1 
Tyrosine kinase  Janus tyrosine kinases (JAKs), i.e. JAK1 and Tyk2 
Adaptor protein  Insulin receptor substrates (IRSs), i.e. IRS-1 and IRS-2, which are 
recruited to a specific tyrosine residue of IL-4Rα 
Kinase  Phosphatidylinositol 3-kinase (PI3K) 
Lipid messenger  Phosphatidylinositol 3,4,5 tri-phosphate (PIP3) 
Kinase  AKT and PDK1, which recognize PIP3 and translocate to the 
membrane; mTOR in the second protein complex 
GTPase activating protein (GAP)  TSC2 
Guanosine triphosphate 
phosphohydrolase (GTPase) 
 RHEB 
Kinase  mTOR in the first protein complex 
GTPases have the intrinsic ability to catalyse the conversion of GTP (guanine triphosphate) to GDP (guanine 
diphosphate). GTPases are generally active when bound to GTP and inactive when bound to GDP. GEFs activate 
GTPases by inducing GTPases to release their bound GDP and thereby facilitating GTP binding. GAPs inactivate 
GTPases by inducing the GTPases to hydrolyse their bound GTP to GDP and become inactive. 
PI3K can be activated upon phosphorylation by JAK1. PDK1 and mTOR in the second protein complex can be 
activated upon phosphorylation by PI3K. 
 
Table 9 | The TLR4-MYD88 pathway (based on [116, 117]) 
Type of signalling protein in TLR4-MYD88 pathway  Name of signalling protein in TLR4-MYD88 
pathway 
Receptor and co-receptor  Toll-like receptor 4 (TLR4) and MD2 
Adaptor protein  TIR domain-containing adaptor protein (TIRAP) 
Adaptor protein  MYD88 
Kinase (autophosphorylation?)  Interleukin (IL)-1 receptor-associated kinases 
(IRAKs) 
Intermediate protein: ubiquitin ligase Æ K63-linked 
autoubiquitylation, which serves as signalling platform 
 TRAF6 
Regulatory component of kinase  Nuclear factor (NF)̻κB essential modifier 
(NEMO) 
Kinase  Inhibitor of NF-κB kinase (IKK) 
In most cells NF-κB exists in the cytoplasm as an inactive (heterodimeric) complex bound to inhibitor of NF-κB. 
Most agents that activate NF-κB do so through a common pathway based on phosphorylation-induced, proteasome-
mediated degradation of inhibitor of NF-κB. 
IKKβ is phosphorylated by an as of yet unidentified upstream kinase. 
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cute kidney injury represents an increasing global concern [118]. In 
response to the urgent need for biomarkers that predict human AKI 
and ideally localize renal stress or damage to a specific nephron site, 
our group discovered chitinase 3-like protein 3 (CHI3L3) as a novel candidate biomarker for 
sepsis-induced AKI by urinary proteomics [84, 119-121]. Validation with western blot analysis 
confirmed the presence of CHI3L3 in urine of septic mice with AKI, and its absence in urine of 
septic mice without AKI. In view of translational research [97], two other members of the 
number-18 glycoside hydrolase-family [93], i.e. CHI3L1 and acidic mammalian chitinase (CHIA), 
showed similar results. Subsequently, we found that CHI3L1 measured in urine was more 
discriminative for the presence of AKI in human septic patients than CHIA [84], resulting in the 
filing of a patent application on this invention (the international patent application has been 
published as WO2012/136548). 
The invention concerned relates to a method for evaluating renal status in a human subject, 
comprising: performing an assay method configured to detect CHI3L1 in a urine sample 
obtained from the subject to provide an assay result, i.e. a measured concentration of urinary 
CHI3L1 (UCHI3L1); and correlating the assay result to the renal status of the subject. This 
dissertation focuses on one preferred embodiment of this invention, i.e. a method wherein the 
correlation step comprises assigning a diagnosis of the occurrence or non-occurrence of AKI to 
the subject based on the assay result. 
For diagnostic AKI biomarker investigations, prospective cohort studies are optimal. Typically, a 
cardiac surgery cohort is chosen because these patients are homogeneous in terms of aetiology of 
AKI, and because the concentration-time-course of the novel biomarker after stress or damage to 
the kidneys can be easily monitored in these patients, as the timing of renal stress or damage is 
exactly known. AKI occurs in over half of general ICU patients [36], and sepsis patients (a 
condition that according to Reinhart et al. should be recognized as a global health priority too 
A 
 [122]) are at particular risk for AKI [123], so the choice for additional clinical validation of 
UCHI3L1 in a heterogeneous ICU cohort is also evident. 
Therefore, the SCIENTIFIC AIM of this dissertation was to provide CLINICAL VALIDATION OF 
THE BIOMARKER UCHI3L1 AS EARLY DIAGNOSTIC OR ‘PREDICTIVE’ TOOL FOR EMERGING AKI 
IN SPECIFIC ADULT ICU SETTINGS, comprising: CORRELATING a measured concentration of 
CHI3L1 IN URINE TO KDIGO-BASED DIAGNOSIS of the occurrence or non-occurrence of AKI; 
AND COMPARING THIS PREDICTIVE ABILITY with that of a measured concentration of SCr, a 
measured urine flow rate and a measured concentration of NGAL in urine, which is a well-
known biomarker of acute tubular damage.  
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I. Abstract 
ackground: AKI occurs frequently and adversely affects patient 
and kidney outcomes, especially when its severity increases from 
stage 1 to stages 2 or 3. Early interventions may counteract such 
deterioration, but this requires early detection. Our aim was to evaluate whether the novel renal 
damage biomarker UCHI3L1 can detect AKI stage ≥ 2 more early than SCr and UO, using the 
respective KDIGO criteria for definition and classification of AKI, and compare this to urinary 
NGAL (UNGAL). 
Methods: This was a translational single-center, prospective cohort study at the 22-bed surgical 
and 14-bed medical ICUs of Ghent University Hospital. We enrolled 181 severely ill adult 
patients who did not yet have AKI stage ≥ 2 based on the KDIGO criteria at time of enrolment. 
The concentration of Cr (serum, urine) and CHI3L1 (serum, urine) was measured at least daily, 
and UO hourly, in the period from enrolment till ICU discharge with a maximum of 7 ICU-days. 
The concentration of UNGAL was measured at enrolment. The primary endpoint was the 
development of AKI stage ≥ 2 within 12 h after enrolment. 
Results: After enrolment, 21 (12 %) patients developed AKI stage ≥ 2 within the next 7 d, with 
6 (3 %) of them reaching this condition within the first 12 h. The enrolment concentration of 
UCHI3L1 predicted the occurrence of AKI stage ≥ 2 within the next 12 h with a good area 
under the receiver-operating characteristics curve (AUC-ROC) of 0.792 (95 % CI: 0.726-0.849). 
This performance was similar to that of UNGAL (AUC-ROC = 0.748; 95 % CI: 0.678-0.810). 
Also, the samples collected in the 24-h time frame preceding diagnosis of the 1st episode of AKI 
stage ≥ 2 had a 2.0 times higher (95 % CI: 1.3-3.1) estimated marginal mean of UCHI3L1 than 
controls. We further found that increasing UCHI3L1 concentrations were associated with 
increasing AKI severity. 
Conclusions: In this pilot study we found that UCHI3L1 was a good biomarker for prediction 
of AKI stage ≥ 2 in adult ICU patients. 
B 
 II. Background 
AKI occurs in approximately half of adult critically ill patients [35, 36, 38, 124-129]. Besides its 
recognized adverse effect on individual patient outcomes, both in the short- and long-term [35, 
36, 38, 125-130], AKI causes an important socioeconomic burden ensuing from its relationship 
with the development of CKD [41], and ESRD requiring RRT [131]. 
Current diagnostic and staging criteria for AKI were defined by the KDIGO AKI work group 
and require monitoring of two surrogate GFR markers, i.e. SCr and UO, and of the intervention 
RRT [11]. As renal stress and damage to the kidneys precede the observed decline in GFR [63], 
diagnostic AKI biomarker research in the last decade has focused on detection of these early 
signals [121, 132, 133]. Studies have shown that urinary biomarkers like NGAL [134-138], and 
recently the panel tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth 
factor-binding protein 7 (IGFBP7) [136, 139, 140], can detect AKI in critically ill patients earlier 
than SCr or UO, even when using the most sensitive KDIGO criteria. In addition, these 
biomarkers may also allow detection of other outcomes such as progression of AKI, use of RRT, 
development of CKD, and long-term mortality [141, 142]. The complexity of the AKI syndrome 
and the interest in detecting other outcomes highly warrants evaluation of yet further candidate 
renal stress or damage biomarkers aiming to find either complementary or – less realistically – 
truly superior ones. 
Recently, our group discovered CHI3L3 as a novel candidate biomarker for sepsis-induced AKI, 
by urinary proteomics [84, 119, 120]. Validation with western blot analysis confirmed the 
presence of CHI3L3 in urine of septic mice with AKI, and its absence in urine of septic mice 
without AKI. In view of translational research [97], two other members of the number-18 
glycoside hydrolase-family [93], i.e. CHI3L1 and CHIA, showed similar results. Subsequently, we 
found that CHI3L1 measured in urine was more discriminative for the presence of AKI in 
human septic patients than CHIA [84]. 
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The number-18 glycoside hydrolase-family is special in that it comprises catalytically inactive 
proteins such as CLPs (e.g., CHI3L1) in addition to catalytically active proteins such as chitinases 
[93]. These CLPs function as lectins because they can bind, but not hydrolyse, the glycan chitin, 
and therefore represent the chi-lectin subfamily [94, 95]. 
The objective of this study was first to evaluate the diagnostic performance of the urinary 
biomarker CHI3L1 for early detection of AKI stage ≥ 2 in adult critically ill patients, and then to 
compare this performance to that of NGAL, which was chosen as the reference urinary 
biomarker. 
III. Methods (see also section VII. “Supplemental Material to Methods”) 
We followed recommendations for strengthening the reporting of observational studies in 
epidemiology (STROBE) (Supplemental Table S1) [143]. We will refer to AKI that was diagnosed 
and classified by KDIGO as AKISCr/UO, while AKISCr will imply that the KDIGO UO criteria 
were discarded (Supplemental Table S2). 
STUDY POPULATION 
As a pilot study, we conducted a prospective cohort study at the 22-bed surgical and 14-bed 
medical ICUs of Ghent University Hospital from September 2012 till August 2014. The inclusion 
and exclusion criteria are shown in Table 1. 
Table 1 | Inclusion and exclusion criteria of the study 
Inclusion criteria Exclusion criteria 
Age ≥ 18 y AKISCr/UO stage ≥ 2 at time of enrolmenta 
Presence of both arterial and urinary catheter CKD KDOQI stage 5 (GFR < 15 ml/min/1.73 m2 or 
RRT) [144] 
Expected ICU stay ≥ 48 h  
Respiratory SOFA score ≥ 2 (PaO2/FiO2 < 300) or 
cardiovascular SOFA score ≥ 1 (MAP < 70 mmHg or 
on vasopressor(s) for at least 1 h) 
 
Written informed consent  
aBased on the KDIGO criteria for AKI 
Abbreviations: AKI acute kidney injury, CKD chronic kidney disease, FiO2 fraction of inspired oxygen, GFR 
glomerular filtration rate, ICU intensive care unit, KDIGO Kidney Disease | Improving Global Outcomes, 
KDOQI Kidney Disease Outcomes Quality Initiative, MAP mean arterial pressure, PaO2 partial pressure of 
oxygen in arterial blood, RRT renal replacement therapy, SCr serum creatinine, SOFA Sepsis-related Organ 
Failure Assessment, UO urine output 
 ETHICS, CONSENT AND PERMISSIONS 
This study was approved by the Ethical Committee of Ghent University Hospital (Belgian 
registration number of the study: B670201213147), and conducted in accordance with the 
declaration of Helsinki and in compliance with the Good Clinical Practice Guidelines. All 
patients or their legally authorized representatives provided written informed consent. 
SAMPLE COLLECTION, SAMPLE HANDLING, AND DATA COLLECTION 
Blood and urine were collected at enrolment. The large majority of patients, i.e. 89 %, was 
enrolled on either the first (28 %) or second (61 %) ICU day, while the minority, i.e. 11 %, was 
enrolled on either the third (9 %) or fourth (2 %) ICU day. Each subject was sampled a second 
time on the day of enrolment (d1) at 6 pm if the first collection was before noon. The 
subsequent sampling times were at 6 am and 6 pm on d2-4, and at 6 am on d5-7 (Supplemental 
Table S3A). This is similar to the methodology used in the hallmark study by Kashani et al. [136]. 
If the patient was discharged from the ICU before d7, the sampling stopped. 
These paired blood and urine samples were collected by standard methods and centrifuged by 
standard protocols. Serum and urine supernatants were stored at -80°C and thawed at room 
temperature immediately prior to analysis. Clinical data needed to complete the individual clinical 
research files were extracted from the hospital records by study coordinators. Clinical data and 
samples were anonymized. J. De Loor had access to the anonymized SCr and serum C-reactive 
protein data in order to determine the appropriate sample dilution for CHI3L1 measurement by 
enzyme-linked immunosorbent assay (ELISA) (Supplemental Table S3B). All other technicians 
were blinded to clinical data. 
BIOMARKER MEASUREMENTS 
Cr and UNGAL analyses were performed externally. Cr concentrations were measured with a 
kinetic rate-blanked Jaffé assay (commercial reagents, Roche Diagnostics, Basel, Switzerland) on a 
Cobas c502, while UNGAL concentrations were measured with a particle-enhanced turbidimetric 
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immunoassay (PETIA) (ST001-3CA, BioPorto, Hellerup, Denmark) on a Modular P. The 
concentration of CHI3L1 was determined in-house with a sandwich ELISA (DC3L10, R&D 
Systems, Minneapolis, MN, USA). 
Both UCHI3L1 and UNGAL concentrations were statistically analysed as such and after 
correction for urine dilution by using the ratio to urinary creatinine (UCr). The relative change in 
SCr measured at enrolment was defined as the ratio of the enrolment SCr to reference SCr. The 
UO after enrolment, defined as the mean UO in the first valid 6-h period after enrolment, was 
determined as the mean of the 6 UO values that were calculated each h in the first valid 6-h 
period after enrolment. 
PRIMARY ENDPOINT 
The primary endpoint of the study was the development of AKISCr/UO stage ≥ 2 within 12 h after 
enrolment. Reference SCr was defined as the lowest SCr value within the last 3 mo prior to 
enrolment. The details for calculation of UO are outlined in the Supplemental Material to Methods. 
SECONDARY ENDPOINTS 
Secondary endpoints of the study were: AKISCr/UO stage ≥ 2 within 24 h and 7 d after enrolment; 
AKISCr stage ≥ 2 within 12 h, 24 h and 7 d after enrolment. 
UCHI3L1 RESPONSE TO AKI 
We compared samples that were collected in the 24 h preceding diagnosis of the first episode of 
AKISCr/UO stage ≥ 2 to those that were not followed by a first episode of AKISCr/UO stage ≥ 2 
within the next 24 h. For this analysis, we excluded all samples collected in the period starting 
from diagnosis of the first episode of AKISCr/UO stage ≥ 2 till the end of the study. 
For all 21 patients who developed AKISCr/UO stage ≥ 2 (reference time 0 h) within 7 d after 
enrolment, we documented the UCHI3L1 concentrations corresponding with the time points 24 
h before, 12 h before, 12 h after, and 24 h after diagnosis of the first episode of AKISCr/UO stage ≥ 
 2. This allowed us to investigate the distribution of UCHI3L1 over time in patients with 
AKISCr/UO stage ≥ 2. 
We also studied the distribution of UCHI3L1 in samples corresponding with different stages of 
severity of AKISCr/UO. If the total study period of 7 days was completed, 11 serum and 11 urine 
samples were available per ICU patient. All available UCHI3L1 concentrations were classified 
according to their AKISCr/UO stage at that moment. As such, UCHI3L1 concentrations were 
divided into four groups: no AKISCr/UO at the time of sampling, and AKISCr/UO stages 1, 2, or 3 at 
the time of sampling. 
STATISTICAL ANALYSIS 
The primary analysis was based on comparison of the AUC-ROCs of UCHI3L1 with those of 
UNGAL for predicting the defined endpoints, which was performed in MedCalc 15.2.1 
(MedCalc Software, Oostende, Belgium). We also calculated Spearman’s coefficients of rank 
correlation with this program. In SPSS 22 (IBM, Armonk, NY, USA) we performed (1) mixed 
model analysis with log10(UCHI3L1) as the outcome variable; diagnosis of the first episode of 
AKISCr/UO stage ≥ 2 within 24 h after sampling as the predictor variable; and patient as the 
random factor; (2) Fisher’s exact or the chi-square test – the 95 % CI of a proportion was 
calculated with the Wilson procedure without correction for continuity [145, 146] – and the 
Mann-Whitney U test; (3) the Wilcoxon matched-pair signed-rank test; and (4) related-samples 
Friedman’s two-way analysis of variance by ranks. Box and whisker plots were generated in 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). For all analyses, two-sided P 
values < 0.05 were considered statistically significant. 
In the Supplemental Material to Methods, including Supplemental Tables S3C-F, we provide all details 
and also describe how the urinary biomarkers were introduced into the statistical programs. 
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IV. Results (see also section VIII. “Supplemental Material to Results”) 
PATIENT CHARACTERISTICS AND EVENT RATES 
The patient flow diagram is presented in Figure 1. 
Figure 1 | Flow diagram of patient selection 
AKI was defined and classified based on the KDIGO criteria. 
Abbreviations: AKI acute kidney injury, ICU intensive care unit, KDIGO Kidney Disease | 
Improving Global Outcomes, RRT renal replacement therapy 
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 Of the 190 enrolled patients in our study cohort, 9 already fulfilled the SCr criteria for AKI stage 
2 at enrolment and were therefore excluded. In this analysis cohort (n = 181), 21 patients (12 %) 
developed AKISCr/UO stage ≥ 2 within 7 d after enrolment. Within 24 h AKISCr/UO stage ≥ 2 was 
met by 9 patients (5 %) and within 12 h by 6 patients (3 %). In Table 2 the demographic 
information for these patients, either meeting or missing the primary endpoint, is depicted. 
Baseline characteristics were similar between both groups with the exception of an older age and 
a higher proportion of elective surgery in patients who developed AKISCr/UO stage ≥ 2 within 12 h 
after enrolment. 
Table 2 | Demographic information for patients of the analysis cohort 
 Total AKISCr/UO stage ≥ 
2a 
No AKISCr/UO 
stage ≥ 2a 
P value 
Number of patients 181 (100 %) 6 (3.3 %) 
[1.5-7.0 %] 
175 (96.7 %) 
[93.0-98.5 %] 
NA 
Baseline characteristics 
Male sex 114 (63.0 %) 
[55.7-69.7 %] 
4 (66.7 %) 
[30.0-90.3 %] 
110 (62.9 %) 
[55.5-69.7 %] 
1.000 
Age (y)b 60.0 (51.0-70.0) 70.5 (65.8-78.0) 59.0 (50.0-70.0) 0.040 
White race 181 (100 %) 
[97.9-100 %] 
6 (100 %) 
[61.0-100 %] 
175 (100 %) 
[97.9-100 %] 
NA 
BMI 24 (22-28) 25 (23-28) 24 (22-28) 0.594 
Reference renal function 
SCr (mg/dl) 0.66 (0.52-0.79) 0.64 (0.55-0.69) 0.66 (0.51-0.79) 0.660 
eGFRCKD-EPI 
(ml/min/1.73 m2) 
102 (89-118) 98 (92-102) 103 (89-118) 0.392 
Diabetes mellitus    0.787 
Type I 2 (1.1 %) 
[0.3-3.9 %] 
0 (0.0 %) 
[0.0-39.0 %] 
2 (1.1 %) 
[0.3-4.1 %] 
 
Type II 11 (6.1 %) 
[3.4-10.6 %] 
0 (0.0 %) 
[0.0-39.0 %] 
11 (6.3 %) 
[3.5-10.9 %] 
 
Heart failure    1.000 
NYHA class I 179 (98.9 %) 
[96.1-99.7 %] 
6 (100 %) 
[61.0-100 %] 
173 (98.9 %) 
[95.9-99.7 %] 
 
NYHA class II 2 (1.1 %) 
[0.3-3.9 %] 
0 (0.0 %) 
[0.0-39.0 %] 
2 (1.1 %) 
[0.3-4.1 %] 
 
NYHA class III 0 (0.0 %) 
[0.0-2.1 %] 
0 (0.0 %) 
[0.0-39.0 %] 
0 (0.0 %) 
[0.0-2.1 %] 
 
NYHA class IV 0 (0.0 %) 
[0.0-2.1 %] 
0 (0.0 %) 
[0.0-39.0 %] 
0 (0.0 %) 
[0.0-2.1 %] 
 
Myocardial 
infarction or cardiac 
arrestc 
17 (9.4 %) 
[5.9-14.5 %] 
0 (0.0 %) 
[0.0-39.0 %] 
17 (9.7 %) 
[6.2-15.0 %] 
1.000 
Malignancyc 17 (9.4 %) 
[5.9-14.5 %] 
1 (16.7 %) 
[3.0-56.4 %] 
16 (9.1 %) 
[5.7-14.3 %] 
0.451 
ICU admission 
Referred from    0.063 
Other hospital 42 (23.2 %) 
[17.7-29.9 %] 
0 (0.0 %) 
[0.0-39.0 %] 
42 (24.0 %) 
[18.3-30.8 %] 
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 Total AKISCr/UO stage ≥ 
2a 
No AKISCr/UO 
stage ≥ 2a 
P value 
Emergency room 75 (41.4 %) 
[34.5-48.7 %] 
1 (16.7 %) 
[3.0-56.4 %] 
74 (42.3 %) 
[35.2-49.7 %] 
 
Operating room 21 (11.6 %) 
[7.7-17.1 %] 
1 (16.7 %) 
[3.0-56.4 %] 
20 (11.4 %) 
[35.8-50.3 %] 
 
Floor 43 (23.8 %) 
[18.1-30.5 %] 
4 (66.7 %) 
[30.0-90.3 %] 
39 (22.3 %) 
[16.8-29.0 %] 
 
Reason    0.038 
Medical 108 (59.7 %) 
[52.4-66.5 %] 
3 (50.0 %) 
[18.8-81.2 %] 
105 (60.0 %) 
[52.6-67.0 %] 
 
Elective surgery 13 (7.2 %) 
[4.2-11.9 %] 
2 (33.3 %) 
[9.7-70.0 %] 
11 (6.3 %) 
[3.5-10.9 %] 
 
Urgent surgery 60 (33.1 %) 
[26.7-40.3 %] 
1 (16.7 %) 
[3.0-56.4 %] 
59 (33.7 %) 
[27.1-41.0 %] 
 
First day of study 
SOFA score 
(points) 
9 (7-11) 11 (8-16) 9 (7-11) 0.189 
Mechanical 
ventilation 
122 (67.4 %) 
[60.3-73.8 %] 
5 (83.3 %) 
[43.6-97.0 %] 
117 (66.9 %) 
[59.6-73.4 %] 
0.665 
Vasopressors 117 (64.6 %) 
[57.4-71.2 %] 
4 (66.7 %) 
[30.0-90.3 %] 
113 (64.6 %) 
[57.2-71.3 %] 
1.000 
Infection 153 (84.5 %) 
[78.6-89.1 %] 
6 (100 %) 
[61.0-100 %] 
147 (84.0 %) 
[77.8-88.7 %] 
0.592 
Infection ++d 122 (67.4 %) 
[60.3-73.8 %] 
6 (100 %) 
[61.0-100 %] 
116 (66.3 %) 
[59.0-72.9 %] 
0.179 
Nephrotoxic drugs (before or at the first study day) 
ACE inhibitors 25 (13.8 %) 
[9.5-19.6 %] 
1 (16.7 %) 
[3.0-56.4 %] 
24 (13.7 %) 
[9.4-19.6 %] 
0.596 
ARBs 5 (2.8 %) 
[1.2-6.3 %] 
0 (0.0 %) 
[0.0-39.0 %] 
5 (2.9 %) 
[1.2-6.5 %] 
1.000 
Iodinated contrast 
media 
81 (44.8 %) 
[37.7-52.0 %] 
2 (33.3 %) 
[9.7-70.0 %] 
79 (45.1 %) 
[38.0-52.5 %] 
0.693 
Aminoglycosides 6 (3.3 %) 
[1.5-7.0 %] 
0 (0.0 %) 
[0.0-39.0 %] 
6 (3.4 %) 
[1.6-7.3 %] 
1.000 
Vancomycin 15 (8.3 %) 
[5.1-13.2 %] 
0 (0.0 %) 
[0.0-39.0 %] 
15 (8.6 %) 
[5.3-13.7 %] 
1.000 
Diuretics 45 (24.9 %) 
[19.1-31.6 %] 
3 (50.0 %) 
[18.8-81.2 %] 
42 (24.0 %) 
[18.3-30.8 %] 
0.164 
Tacrolimus 2 (1.1 %) 
[0.3-3.9 %] 
1 (16.7 %) 
[3.0-56.4 %] 
1 (0.6 %) 
[0.1-3.2 %] 
0.065 
Cyclosporine 1 (0.6 %) 
[0.1-3.1 %] 
0 (0.0 %) 
[0.0-39.0 %] 
1 (0.6 %) 
[0.1-3.2 %] 
1.000 
NSAIDs (chronic) 10 (5.5 %) 
[3.0-9.9 %] 
1 (16.7 %) 
[3.0-56.4 %] 
9 (5.1 %) 
[2.7-9.5 %] 
0.292 
Corticosteroids 
(chronic) 
24 (13.3 %) 
[9.1-19.0 %] 
1 (16.7 %) 
[3.0-56.4 %] 
23 (13.1 %) 
[8.9-18.9 %] 
0.580 
Data represent number (proportion) [95 % CI of proportion] for categorical variables and median (IQR) for 
continuous variables. 
aWithin 12 h after enrolment (primary endpoint); based on the KDIGO criteria for AKI 
bDetermined at the 1st day of the study 
cAt time of hospital or ICU admission 
dSuspected bacterial infection, either leading to arterial hypotension or organ dysfunction, or leading to shock 
(Supplemental Table S4) 
Abbreviations: ACE angiotensin converting enzyme, AKI acute kidney injury, ARB angiotensin-II receptor 
blocker, BMI body mass index, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology 
Collaboration, eGFR estimated glomerular filtration rate, ICU intensive care unit, IQR interquartile range, 
KDIGO Kidney Disease | Improving Global Outcomes, NSAID nonsteroidal anti-inflammatory drug, NYHA 
New York Heart Association, SCr serum creatinine, SOFA Sepsis-related Organ Failure Assessment, UO urine 
output 
 In Table 3 the distribution of patients over different SCr and UO AKI stages that were 
maximally reached within 12 h, 24 h and 7 d after enrolment is shown. 
Table 3 | Distribution of patients over different stages of severity of acute kidney injury 
maximally reached within indicated observation periods 
Time 
window 
Maximum 
AKI stage 
UO 0a UO 1a UO 2a UO 3a Total in row 
12 h SCr 0a 140 (77 %) 11 (6 %) 2 (1 %) 0 (0 %) 153 (85 %) 
24 h 122 (67 %) 19 (10 %) 4 (2 %) 0 (0 %) 145 (80 %) 
7 days 95 (52 %) 23 (13 %) 2 (1 %) 0 (0 %) 120 (66 %) 
12 h SCr 1a 21 (12 %) 3 (2 %) 0 (0 %) 0 (0 %) 24 (13 %) 
24 h 27 (15 %) 4 (2 %) 0 (0 %) 0 (0 %) 31 (17 %) 
7 days 35 (19 %) 7 (4 %) 3 (2 %) 0 (0 %) 45 (25 %) 
12 h SCr 2a 1 (1 %) 1 (1 %) 0 (0 %) 0 (0 %) 2 (1 %) 
24 h 0 (0 %) 2 (1 %) 0 (0 %) 0 (0 %) 2 (1 %) 
7 days 4 (2 %) 4 (2 %) 3 (2 %) 0 (0 %) 11 (6 %) 
12 h SCr 3a 1 (1 %) 1 (1 %) 0 (0 %) 0 (0 %) 2 (1 %) 
24 h 2 (1 %) 1 (1 %) 0 (0 %) 0 (0 %) 3 (2 %) 
7 days 4 (2 %) 1 (1 %) 0 (0 %) 0 (0 %) 5 (3 %) 
12 h Total in 
column 
163 (90 %) 16 (9 %) 2 (1 %) 0 (0 %) 181 (100 %) 
24 h 151 (83 %) 26 (14 %) 4 (2 %) 0 (0 %) 181 (100 %) 
7 days 138 (76 %) 35 (19 %) 8 (4 %) 0 (0 %) 181 (100 %) 
Data represent number (proportion). 
Patients with different severity stages of AKISCr/UO maximally reached within indicated observation periods are 
marked with differently coloured kidneys: 
 represents AKI stage 1,  represents AKI stage 2 and  represents AKI stage 3. 
aSCr 0 represents no AKI based on the KDIGOSCr criteria. Likewise, UO 0 represents no AKI based on the 
KDIGOUO criteria. SCr 1/2/3 represents AKI stage 1/2/3 based on the KDIGOSCr criteria. Likewise, UO 1/2/3 
represents AKI stage 1/2/3 based on the KDIGOUO criteria. 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum 
creatinine, UO urine output 
 
BIOMARKERS’ DIAGNOSTIC PERFORMANCES 
The biomarkers UCHI3L1 and UNGAL, both measured at enrolment, were good predictors of 
the development of AKISCr/UO stage ≥ 2 within the next 12 h, with an AUC-ROC of 0.792 (95 % 
CI: 0.726-0.849) for UCHI3L1 and 0.748 (95 % CI: 0.678-0.810) for UNGAL (P = 0.587) 
(Figure 2). When UO criteria were discarded, these AUC-ROCs improved to 0.877 (95 % CI: 
0.820-0.921) for UCHI3L1 and 0.865 (95 % CI: 0.807-0.911) for UNGAL (P = 0.661). Extending 
our prediction window to 24 h slightly decreased the AUC-ROC for both biomarkers for 
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predicting AKISCr/UO stage ≥ 2, while the AUC-ROC for predicting AKISCr stage ≥ 2 remained 
similar (Figure 2). In the 7-d prediction window both biomarkers became poor predictors of 
AKI stage ≥ 2, irrespective of the definition used. To obtain two explicit clinical phenotypes, the 
AUC-ROC analyses were repeated excluding AKI stage 1 (comparing AKI stage ≥ 2 with no 
AKI). These showed essentially unchanged results for UCHI3L1 and UNGAL, both measured at 
enrolment (Supplemental Table S5). 
Figure 2 | Areas under receiver-operating characteristics curves of UCHI3L1 and 
UNGAL at enrolment for prediction of the six different endpoints 
The P value for the difference in AUC-ROC between both biomarkers for predicting AKI stage 
≥ 2 based on the KDIGO criteria (AKISCr/UO) within 12 h after enrolment was 0.587. In the 24-h 
prediction window the P value was 0.823, and in the 7-d prediction window it was 0.522. 
Likewise, the P value for the difference in AUC-ROC between both biomarkers for predicting 
AKISCr stage ≥ 2 within 12 h after enrolment was 0.661. In the 24-h prediction window the P 
value was 0.495, and in the 7-d prediction window it was 0.099. 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating 
characteristics curve, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum 
creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-
associated lipocalin, UO urine output 
 
Correction of the urinary biomarker concentrations for urine dilution by calculating the ratio to 
UCr, decreased the AUC-ROC for both biomarkers when diagnosing AKI stage ≥ 2 based on 
SCr or UO, while there was no difference observed when diagnosing AKI stage ≥ 2 based on 
SCr alone (Table 4). 
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 Table 4 | Comparison of areas under receiver-operating characteristics curves 
  AKISCr/UO stage ≥ 2a AKISCr stage ≥ 2b 
Biomarker 
measurement 
Time 
window 
AUC-
ROC 
95 % CI P valuec AUC-
ROC 
95 % CI P valuec 
N = 181 
Enrolment 
UCHI3L1 
12 h 0.792 0.726-
0.849 
 0.877 0.820-
0.921 
 
24 h 0.716 0.644-
0.780 
 0.901 0.848-
0.940 
 
Comparison with 
Enrolment 
UCr-corrected 
UCHI3L1 
12 h 0.674 0.601-
0.742 
0.038 0.832 0.769-
0.883 
0.359 
24 h 0.587 0.511-
0.659 
0.005 0.861 0.802-
0.908 
0.308 
Enrolment 
SCHI3L1 
12 h 0.645 0.570-
0.714 
0.071 0.784 0.717-
0.842 
0.300 
24 h 0.548 0.472-
0.622 
0.022 0.830 0.767-
0.881 
0.324 
Enrolment 
SCr 
12 h 0.624 0.549-
0.695 
0.113 0.732 0.662-
0.795 
0.363 
24 h 0.639 0.565-
0.709 
0.406 0.766 0.697-
0.826 
0.278 
Enrolment 
SCr to 
reference SCr 
ratio 
12 h 0.690 0.618-
0.757 
0.274 0.806 0.741-
0.861 
0.614 
24 h 0.695 0.622-
0.761 
0.784 0.847 0.786-
0.896 
0.622 
Enrolment 
UNGAL 
12 h 0.748 0.678-
0.810 
 0.865 0.807-
0.911 
 
24 h 0.702 0.630-
0.768 
 0.886 0.830-
0.928 
 
Comparison with 
Enrolment 
UCr-corrected 
UNGAL 
12 h 0.622 0.547-
0.693 
0.007 0.795 0.729-
0.851 
0.123 
24 h 0.570 0.495-
0.644 
0.001 0.826 0.763-
0.878 
0.109 
N = 180d 
Enrolment 
UCHI3L1 
12 h 0.791 0.724-
0.848 
 0.876 0.819-
0.921 
 
24 h 0.715 0.643-
0.779 
 0.901 0.847-
0.940 
 
Comparison with 
UO after 
enrolmente 
12 h 0.833 0.771-
0.885 
0.728 0.759 0.690-
0.820 
0.034 
24 h 0.808 0.743-
0.863 
0.438 0.795 0.728-
0.851 
0.022 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
cThe P value is shown for the difference in AUC-ROC. We always compared with the AUC-ROC of the urinary 
biomarker (UCHI3L1or UNGAL) marked in colour. 
dUO after enrolment could not be calculated in 1 patient. 
eDefined as the mean UO in the first valid 6-h period after enrolment (in ml/kg/h) 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 serum chitinase 3-like 
protein 1, SCr serum creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UCr urinary creatinine, UNGAL 
urinary neutrophil gelatinase-associated lipocalin, UO urine output 
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In contrast to UCHI3L1, serum CHI3L1 (SCHI3L1) measured at enrolment was a poor 
predictor of AKISCr/UO stage ≥ 2 within the next 12 h, with an AUC-ROC of 0.645 (95 % CI: 
0.570-0.714). In the 24-h prediction window SCHI3L1 did not predict AKISCr/UO stage ≥ 2. 
Again, when diagnosing based on SCr alone, the AUC-ROC for SCHI3L1 improved, i.e. AUC-
ROC of 0.784 (95 % CI: 0.717-0.842) in the 12-h and AUC-ROC of 0.830 (95 % CI: 0.767-0.881) 
in the 24-h prediction window (Table 4). 
We additionally studied the discriminatory ability of the individual KDIGO parameters, i.e. 
(relative change in) SCr measured at enrolment and UO after enrolment (Table 4). The AUC-
ROC was similar for UCHI3L1, SCr and UO. However, UCHI3L1 performed better than UO 
when diagnosing AKI stage ≥ 2 based on SCr alone (P = 0.034 in the 12-h prediction window; P 
= 0.022 in the 24-h prediction window). In addition, compared to SCr, there was a clear trend 
towards a better AUC-ROC for UCHI3L1, especially when diagnosing AKI stage ≥ 2 based on 
SCr or UO within 12 h after enrolment. 
Combining both urinary biomarkers as the two-biomarker panel [UCHI3L1]•[UNGAL] did not 
improve the diagnostic performance of each of these single biomarkers for predicting either the 
12-h or 24-h endpoints (Table 5). A positive relationship between these markers was observed, 
with a Spearman’s coefficient of rank correlation of 0.615 (95 % CI: 0.515-0.698) (Supplemental 
Table S6). 
With the Youden index a cutoff for UNGAL of 139 ng/ml was identified corresponding to the 
reference cutoff for this variable (> 150 ng/ml [135]) (Supplemental Table S7).  
 Table 5 | Comparison of areas under receiver-operating characteristics curves between 
the two-biomarker panel [UCHI3L1]•[UNGAL] and each of these single biomarkers 
  AKISCr/UO stage ≥ 2a AKISCr stage ≥ 2b 
Time 
window 
AUC-
ROC 
95 % CI P value AUC-
ROC 
95 % CI P value 
Enrolment 
[UCHI3L1]•[UNGAL] 
12 h 0.784 0.717-
0.841 
0.764c 0.874 0.817-
0.919 
0.879c 
  0.522d   0.544d 
24 h 0.721 0.650-
0.785 
0.856c 0.899 0.845-
0.939 
0.877c 
  0.622d   0.311d 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
cDifference in AUC-ROC between the two-biomarker panel and UCHI3L1, both measured at enrolment 
dDifference in AUC-ROC between the two-biomarker panel and UNGAL, both measured at enrolment 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum creatinine, UCHI3L1 
urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated lipocalin, UO urine output 
 
UCHI3L1 RESPONSE TO AKI 
Additions to the published paper are marked in italic font. 
Samples collected in the 24 h preceding diagnosis of the first episode of AKISCr/UO stage ≥ 2 had 
a 2.0 times higher (95 % CI: 1.3-3.1) estimated marginal mean of UCHI3L1 than those not 
followed by a first episode of AKISCr/UO stage ≥ 2 within the next 24 h. The general time-
concentration profile of UCHI3L1 showed a trend for increasing concentrations from 24 h 
before, towards diagnosis of the first episode of AKISCr/UO stage ≥ 2 (reference time 0 h) (Figure 
3). After reference time 0 h, median UCHI3L1 concentrations showed a decreasing trend. 
Samples corresponding with AKISCr/UO stage 1 at time of collection had higher UCHI3L1 
concentrations than those corresponding with no AKISCr/UO at time of collection (P < 0.001) 
(Figure 4 and Table 6). Stage 1 and stage 2 samples had similar UCHI3L1 concentrations (P = 
0.514). Stage 3 samples again had higher UCHI3L1 concentrations than stage 2 samples (P < 
0.001). The individual concentration-time-course of UCHI3L1 with the KDIGO stage-time-course are visually 
presented in Figure 5 for two AKI patients.  
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Figure 3 | Distribution of UCHI3L1 over 
time in patients who developed AKI stage 
≥ 2 based on the KDIGO criteria 
(AKISCr/UO) within 7 d after enrolment (n = 
21) 
The reference time 0 h represents time of 
diagnosis of the first episode of AKISCr/UO 
stage ≥ 2. At time -24 h, a UCHI3L1 
concentration was available for 14 of the 21 
patients. Likewise, 13 values were available at 
time -12 h, 19 at reference time 0 h, 14 at time 
12 h, and 12 at time 24 h 
Abbreviations: AKI acute kidney injury, 
KDIGO Kidney Disease | Improving Global 
Outcomes, SCr serum creatinine, UCHI3L1 
urinary chitinase 3-like protein 1, UO urine 
output 
 
 
 
Figure 4 | Distribution of UCHI3L1 in 
samples corresponding with different 
stages of severity of AKI based on the 
KDIGO criteria (AKISCr/UO) 
Abbreviations: AKI acute kidney injury, 
KDIGO Kidney Disease | Improving Global 
Outcomes, SCr serum creatinine, UCHI3L1 
urinary chitinase 3-like protein 1, UO urine 
output 
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 Table 6 | Quartiles of UCHI3L1 in samples corresponding with different stages of 
severity of AKI based on the KDIGO criteria (AKISCr/UO) 
 No AKISCr/UOa AKISCr/UO stage 1a AKISCr/UO stage 2a AKISCr/UO stage 3a 
Q1 of UCHI3L1 0.9 1.5 1.7 13.8 
Q2 of UCHI3L1 2.0 4.7 4.5 40.0 
Q3 of UCHI3L1 4.8 11.0 24.0 1413.3 
aBased on the KDIGO criteria for AKI 
Concentration of UCHI3L1 in ng/ml 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum 
creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UO urine output 
 
Figure 5 | Individual concentration-time-course of UCHI3L1 with the KDIGO stage-
time-course for two AKI patients 
The concentration of UCHI3L1 at different time points is represented by bullets in patient A 
(dashed line) and by triangles in patient B (full line). The colour of both symbols reflects the 
AKISCr/UO stage of these two patients at each time point: green represents no AKI, yellow 
represents AKI stage 1, orange represents AKI stage 2, and black represents AKI stage 3. For 
both patients, the vertical line at 0.0 d represents the time of first diagnosis of AKISCr/UO stage ≥ 
2. Patient A had a low UCHI3L1 at 3.5 d after first diagnosis of AKISCr/UO stage ≥ 2, while 
KDIGO still indicated AKISCr/UO stage 3 at that time. Patient B had a second UCHI3L1 peak at 
2.5 d after first diagnosis of AKISCr/UO stage ≥ 2, while KDIGO still indicated no AKISCr/UO at 
that time. 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global 
Outcomes, SCr serum creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UO urine output 
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V. Discussion 
We found that UCHI3L1 was a good biomarker for early detection of AKI stage ≥ 2 in adult 
critically ill patients admitted to an ICU, with a performance similar to that of UNGAL. 
These findings may have important clinical and socioeconomic impact. Increasing severity of 
AKI is associated with increased risk of worse patient and kidney outcomes [35, 36, 38, 125-130]. 
Importantly, observational and also intervention studies showed that early AKI management can 
counteract AKI deterioration, and is associated with lower mortality and less RRT dependence at 
discharge [24, 25, 147-152]. Consequently, even earlier identification of AKI using a biomarker 
may have a much stronger effect on these outcomes. 
Both UCHI3L1 and UNGAL better predicted AKI stage ≥ 2 that was defined based on SCr 
alone versus based on SCr or UO. These two urinary proteins are biomarkers of renal stress or 
damage [89, 110], while SCr and UO are GFR surrogates. However, UO is much more sensitive 
to decline in GFR, and therefore is probably associated with less renal stress or damage than SCr, 
which is supported by studies reporting that UO-based AKI classes are associated with a lower 
ICU/hospital mortality than SCr-based ones [38, 153, 154]. This may explain the better AUC-
ROCs when considering SCr alone for diagnosis. The findings by Macedo et al. [155], who 
reported similar ICU mortality for exclusively UO+ AKI patients (8.8 %) and (non)oliguric SCr+ 
AKI patients (10.4 %), appear contradictory to previous findings [38, 153, 154]. However, 
severity of AKI was greater in exclusively UO+ patients: > 60 % of these patients were stage 2, 
while > 70 % of the (non)oliguric SCr+ patients were stage 1 [155]. We also observed a partial 
overlap in UCHI3L1 between AKISCr/UO stage 1 and stage 2 samples, indicating heterogeneity of 
AKI severity within KDIGO classes, which can be partly explained by the different impact of 
meeting the defined criteria for either UO alone, or SCr alone, or both SCr and UO [38]. This 
could also clarify the decreased performance of UCHI3L1 and UNGAL at enrolment for 
prediction of AKISCr/UO stage ≥ 2 within the next 24 h. The majority of the extra AKISCr/UO stage 
≥ 2 patients in the 24 h observation period fulfilled UO criteria only. These patients, therefore, 
 probably had less renal stress or damage, and consequently a low biomarker signal. Another 
explanation could be that the hit leading to AKI is following the biomarker measurement. This 
may more likely occur when the observation period is longer [136]. 
The observation that the AUC-ROC for the individual KDIGO parameters, i.e. SCr and UO, 
were similar to those of UCHI3L1 for detection of AKI stage ≥ 2, warrants discussion. First, 
when comparing the AUC-ROC for UO and UCHI3L1, we must take into account that although 
the measurement of UO started at enrolment, it was only completed 6 h later than the time at 
which UCHI3L1 was measured. Second, renal stress or damage may not always be reflected by 
decline in GFR; vice versa, a decline in GFR may not always reflect renal stress or damage. This 
may lead to underestimation of the diagnostic performance of UCHI3L1 in our study. 
We found a trend for increased UCHI3L1 concentrations in the 24 h preceding AKI, and for 
decreased concentrations afterwards. However, it should be emphasized that after meeting 
AKISCr/UO stage ≥ 2, the individual courses of AKISCr/UO differed widely between patients: some 
patients remained in the same severity stage, some deteriorated and others ameliorated (data not 
shown). The number of patients observed in this pilot study also precludes firm conclusions. 
This is the first translational study demonstrating that UCHI3L1 predicts the occurrence of AKI 
stage ≥ 2 in adult critically ill patients [84]. Schmidt et al. independently showed that UCHI3L1 
predicts the occurrence of delayed graft function in adult patients who receive deceased-donor 
kidney transplants [110]. In their preclinical study, these authors reported that the transcription of 
the CHI3L1 gene is significantly upregulated in the mouse kidney after IRI with increased 
excretion of its protein in urine. These mRNA and protein levels correlated with the degree of 
kidney injury and were at earliest measured on the first day after IRI, when SCr values had 
already peaked. Recently, the same group also studied a cohort of hospitalized patients who had 
AKI, and found that UCHI3L1 was associated with the composite outcome of AKI progression 
and in-hospital death [156]. 
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We must speculate on the source of CHI3L1. Upon renal stress or damage, this protein is 
secreted by macrophages within the kidney [110], while NGAL is secreted by specific cells of the 
distal nephron [89]. Another source for the urine component of NGAL is the circulating plasma 
pool [157]. We speculate that the same is true for CHI3L1 as this protein has an apparent 
molecular weight of ±39-40 kDa [102, 103], and as within the group of patients with no AKI (in 
the 7-d prediction window) a concomitant high level of SCHI3L1 was observed more in those 
with an increased than with a normal UCHI3L1 at enrolment (Supplemental Table S8). Additionally, 
we speculate that CHI3L1 binds to the megalin receptor for tubular reabsorption. This implies 
that NGAL and CHI3L1 can each indirectly affect the urinary concentration of the other, as they 
are then competitors [157]. 
Similar to NGAL, CHI3L1 is also stored in the secondary granules of circulating neutrophils 
[158-160]. This could implicate that in the urine of patients with a urinary tract infection (UTI), 
CHI3L1 is increased too [161]. Although data on UCHI3L1 in UTI patients are missing, 
proteome profiling of human neutrophils suggests that this issue is less relevant for UCHI3L1 
[159], which agrees with the reported 12 pg NGAL and 0.16 pg CHI3L1 per leukocyte [161, 162]. 
Surprisingly, only in 2013 He et al. investigated the possibility that the CLP CHI3L1 mediates its 
biological effects through receptor binding, and identified IL-13Rα2 as its binding partner [109]. 
These biological effects include inhibition of apoptosis in renal epithelial cells [109, 110], and 
inhibition of pyroptosis and IL-1β production in macrophages [109, 111]. These innate immune 
cells play an important role in both kidney injury and repair [163]. 
Our study has important limitations. First, this is a single-center study conducted in surgical and 
medical ICUs. Although the baseline characteristics of patients, the observed outcomes, and the 
NGAL cutoff based on the Youden index suggest that the patients included are representative of 
ICUs in developed countries, these data remain to be confirmed in other centers and in different 
types of ICU. Second, only a limited number of patients reached the primary endpoint, which can 
be partly explained by selection bias, i.e. not asking (legally authorized representatives of) the 
 most critically ill patients for consent. Yet, this is a typical and hence, rather unavoidable feature 
of prospective studies like this [136]. The restricted period for observation of AKI stage ≥ 2 
certainly contributes to the low event rate as well. Therefore, we included all 21 patients (12 %) 
who developed AKISCr/UO stage ≥ 2 within 7 d after enrolment in the mixed model analysis. 
Third, following the KDIGO guidelines [11], reference SCr was defined as the lowest SCr value 
within the last 3 mo prior to enrolment. This method is prone to bias, as blood draws for SCr 
measurement tend to be performed more often when patients are in hospital or sick, thereby not 
reflecting true baseline kidney function. Fourth, we did not measure urinary [TIMP-2]•[IGFBP7], 
a two-biomarker panel found to be superior to UNGAL [136, 139, 140], because it was not 
available at the start of our study. 
VI. Conclusions 
In summary, we demonstrated that UCHI3L1 measured in critically ill patients admitted to an 
ICU, predicted the occurrence of AKI stage ≥ 2 within a 12-h or 24-h observation period. The 
results of this pilot study need confirmation in different settings and in larger patient cohorts. 
VII. Supplemental Material to Methods 
SAMPLE COLLECTION AND HANDLING 
Blood (serum) 
Approximately 6 ml of blood was obtained via an indwelling arterial line at each study-specific 
sampling moment. Blood was collected in clot activator collection tubes (Venosafe 6 ml, ref. VF-
106SAS, Terumo Europe, Leuven, BE) for serum. After clotting at 4°C (in weekends: storage up 
to ±40 h (Supplemental Table S3A) at 4°C based on our stability results (Additional Table A3)), 
serum samples were centrifuged (Heraeus Labofuge 400 R, swinging bucket rotor with round 
bucket, Thermo Fisher Scientific, Waltham, MA) at 4°C and 1992 x g for 15 min. The 
supernatant was divided into 4 aliquots: 1 for CHI3L1, 1 for Cr, and 2 as backup. These 
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eppendorf tubes containing the supernatant were immediately stored at -80°C. No preservatives 
were added. Samples were thawed at room temperature immediately prior to analysis and 
vortexed before pipetting. 
Urine 
Approximately 5-10 ml of urine was obtained via an indwelling bladder catheter at each study-
specific sampling moment. Urine was collected directly from the catheter (never from the 
collection bag) via the needle-free port-system in a standard (non-coated) transport container that 
can also be used as centrifuge tube for sediment recovery (Urine Monovette 10 ml, ref. 10.252, 
Sarstedt, Nümbrecht, DE). Urine was immediately (in weekends: storage up to ±40 h 
(Supplemental Table S3A) at 4°C based on our stability results (Additional Table A3)) centrifuged 
(Heraeus Labofuge 400 R, swinging bucket rotor with round bucket, Thermo Fisher Scientific, 
Waltham, MA) at 4°C and 1029 x g for 10 min. The supernatant was divided into 5 aliquots: 1 for 
CHI3L1, 1 for NGAL, 1 for Cr, and 2 as backup. These eppendorf tubes containing the 
supernatant were immediately stored at -80°C. No preservatives were added. Samples were 
thawed at room temperature immediately prior to analysis and vortexed before pipetting. 
Eppendorf tubes that still contained visible sediment were very shortly (< 15 seconds) 
centrifuged (Heraeus Biofuge Fresco, Thermo Fisher Scientific, Waltham, MA) at 4°C and 7697 x 
g before pipetting. 
BIOMARKER MEASUREMENTS 
Creatinine 
Cr concentrations were measured in the 24-h laboratory of Ghent University Hospital with a 
kinetic rate-blanked Jaffé assay (commercial reagents, Roche Diagnostics, Basel, CH) on a Cobas 
c502. 
 All samples were analysed within 6 mo after collection (median: 3 mo; interquartile range (IQR): 
2-4 mo) complying with the reported stability: when stored without preservatives at -22°C 
respectively -25°C, Cr was stable for 15 y in urine [164], and for 25 y in serum [165]. 
Chitinase 3-like protein 1 
The concentration of CHI3L1 was determined in-house by De Loor J, Demeyere K, and Van Nuffel 
K with an ELISA (Human Chitinase 3-like 1 Quantikine ELISA Kit, ref. DC3L10, R&D Systems, 
Minneapolis, MN). The standard procedure that was followed when measuring CHI3L1 by 
ELISA is as follows. All samples and reagents were brought to room temperature. Samples and 
standards requiring dilution were accordingly prepared using calibrator diluents (1/200 or 1/500 
dilution for serum; 1/5 or 1/10 dilution for urine) (Supplemental Table S3B). To each well pre-
coated with a rat monoclonal antibody against recombinant human CHI3L1 we added 100 μl of 
assay diluents followed by 50 μl of the appropriate sample or standard. This mixture was allowed 
to react for 2 h at room temperature. Each well was then aspirated and washed 4 times before 
adding 200 μl of a horseradish peroxidase-conjugated goat polyclonal antibody against 
recombinant human CHI3L1. After another incubation time of 2 h at room temperature, each 
well was again aspirated and washed 4 times. We then added 200 μl of substrate solution per well, 
which consisted of 100 μl of hydrogen peroxide and 100 μl of tetramethylbenzidine. This mixture 
was incubated in the dark for 30 min. Finally, 50 μl of stop solution was added per well after 
which the optical density (OD) of each well was measured with a microplate reader (Multiskan 
MS microplate reader, Thermo Fisher Scientific, Waltham, MA) set at 450 nm. The correction 
wavelength was set at 550 nm. The serum and urinary CHI3L1 concentrations were calculated 
with a microplate analysis program (DeltaSoft JV, Biomettalics, Princeton Junction, NJ). The 4-
parameter logistic (4PL) model was chosen for curve fitting, as described by the manufacturer. 
All samples were analysed within 13 mo after collection (median: 7 mo; IQR: 3-10 mo). When 
stored without preservatives (personal communication with Johansen JS) at -80°C, SCHI3L1 is stable 
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for 8 y [166]. Additionally, we showed that UCHI3L1 may even be measured after a second 
thawing step within at least 30 mo after the first freezing (Additional Table A4). 
Neutrophil gelatinase-associated lipocalin 
The concentration of UNGAL was measured in the clinical chemistry laboratory of Ghent 
University Hospital with a PETIA (NGAL Test, ref. ST001-3CA, BioPorto, Hellerup, DK) on a 
Modular P. The standard procedure that was followed when measuring UNGAL by PETIA is as 
follows. All samples and reagents were brought to room temperature. After calibrating and 
running the controls 150 μl of sample was provided in a specific sample cup, as described by the 
manufacturer. To read over the measuring principle of this PETIA, we refer to other literature 
[167]. 
All NGAL analyses were performed in batch in November 2014. Storage at -80°C for 2 y without 
preservatives has been shown not to affect UNGAL [168]. 
Urine output calculation 
For UO calculations we accepted a margin of 10 % under the 1-h block. Therefore, all urine 
volume measurements over a period less than 0.9 h (54 min) were first counted up with the 
following measurement. Then, we redistributed all blocks ≥ 1.8 h and < 2.7 h into 2 blocks, and 
all blocks ≥ 2.7 h and ≤ 3 h into 3 blocks, generating blocks of ≥ 0.9 h and < 1.8 h. Blocks > 3 h 
were considered as unreliable for redistribution and UO calculation. 
Statistical analysis 
The primary analysis was based on comparison of the AUC-ROCs of UCHI3L1 with those of 
UNGAL for predicting the defined endpoints, which was performed in MedCalc 15.2.1 
(MedCalc Software, Oostende, BE). The method by DeLong et al. was selected for calculation of 
the standard error of both the AUC-ROC and the difference between 2 AUC-ROCs [169]. For 
the AUC-ROC, a binomial exact 95 % CI was calculated. This program also lists the Youden 
index [170], defined as the maximum of [sensitivity plus specificity minus 1], with its associated 
 criterion for each AUC-ROC. We also calculated Spearman’s coefficients of rank correlation with 
this program. 
In SPSS 22 (IBM, Armonk, NY) we performed: 
(a) Mixed model analysis with log10(UCHI3L1) as outcome variable, diagnosis of the 1st episode 
of AKI stage ≥ 2 based on the KDIGO criteria (AKISCr/UO) within 24 h after sampling as 
predictor variable, and patient as random factor. 
(b) Unpaired comparison of a variable between 2 independent samples. Categorical variables 
were analysed with Fisher’s exact or the chi-square test, and continuous variables with the 
nonparametric Mann-Whitney U test. The SPSS ‘Descriptives’ menu uses Method 6 from the 
article by Hyndman and Fan for calculation of the IQR [171]. Additionally, we calculated the 95 
% CI for a proportion using the Wilson procedure without a correction for continuity [145, 146]. 
(c) Paired comparison of a continuous variable between 2 related samples (Additional Tables A3 
and A4) using the Wilcoxon matched-pair signed-rank test. 
(d) Paired comparison of a continuous variable between > 2 related samples (Additional Table A3) 
using the related- samples Friedman’s two-way analysis of variance by ranks. 
Box and whisker plots were generated in GraphPad Prism 5 (GraphPad Software, San Diego, 
CA), which also uses Method 6 for calculation of the 1st and 3rd quartile [171]. The method by 
Tukey was selected for drawing of the whiskers [172]. 
For all analyses, 2-sided P values < 0.05 were considered significant. 
We will now describe how the urinary biomarkers were introduced into the statistical models. 
Review and adjustment of CHI3L1 concentrations before input in statistical programs 
Remark: CHI3L1 concentrations are expressed in pg/ml in these raw data. 
Step 1: Evaluation of the standard curve of the ELISA 
Only when the coefficient of determination (R2) is greater than or equal to (≥) 0.995, there is a 
good fit of the 7 standard points in the 4PL model. Additionally, we evaluated whether the 
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assured dynamic range of the standard curve was in fact as dynamic as guaranteed (Supplemental 
Table S3C). 
Step 2: Re-analysis of samples with a concentration (not adjusted for dilution) outside the 
validated dynamic range of the curve 
The details of this standard procedure are outlined in Supplemental Table S3D. 
Step 3: Adjustment of CHI3L1 concentrations of optimally diluted samples with ODsample < 
OD62.5 
Supplemental Table S3E in detail outlines the standard procedure that was followed in this case. 
Note that, based on the acceptable recovery limits (70-130 %), the back-calculated 
Concentration(Conc)62.5 ranges from 43.8-81.3 pg/ml. 
Adjustment of UNGAL concentrations before input in statistical programs 
In the ‘performance data and application note for Roche Modular P’ can be read that the limit of 
quantification (LOQ) of the NGAL Test was determined to be 25 ng/ml on this analyser model. 
As the limit of detection (LOD) was not tested on this model we were advised (personal 
communication with BioPorto) to use the LOQ that was estimated on the Roche Hitachi 917, which 
was 12 ng/ml. The measured UNGAL concentrations were adjusted based on these reported 
limits (Supplemental Table S3F).  
 SUPPLEMENTAL TABLES TO METHODS 
Table S1 | STrengthening the Reporting of OBservational studies in Epidemiology 
statement – checklist of items that should be included in the reports of cohort studies 
[143] 
 Item 
No. 
STROBE recommendation Fulfilled 
Title and abstract 
 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
Yes 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Yes 
Introduction 
Background / 
rationale 
2 Explain the scientific background and rationale for the investigation being 
reported 
Yes 
Objectives 3 State specific objectives, including any pre-specified hypotheses Yes 
Methods 
Study design 4 Present key elements of study design early in the paper Yes 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Yes 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Yes 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Yes 
Data sources / 
measurement 
8a For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
if there is more than one group 
Yes 
Bias 9 Describe any efforts to address potential sources of bias Yes 
Study size 10 Explain how the study size was arrived at Yes 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Yes 
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to control for 
confounding 
Yes 
(b) Describe any methods used to examine subgroups and interactions Yes 
(c) Explain how missing data were addressed NA 
(d) If applicable, explain how loss to follow-up was addressed NA 
(e) Describe any sensitivity analyses NA 
Results 
Participants 13a (a) Report numbers of individuals at each stage of study – e.g., numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
Yes 
(b) Give reasons for non-participation at each stage Yes 
(c) Consider use of a flow diagram Yes 
Descriptive 
data 
14a (a) Give characteristics of study participants (e.g., demographic, clinical, 
social) and information on exposures and potential confounders 
Yes 
(b) Indicate number of participants with missing data for each variable of 
interest 
NA 
(c) Summarize follow-up time (e.g., average and total amount) Yes 
Outcome data 15a Report numbers of outcome events or summary measures over time Yes 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (e.g., 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Yes 
(b) Report category boundaries when continuous variables were categorized NA 
(c) If relevant, consider translating estimates of relative risk into absolute NA 
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 Item 
No. 
STROBE recommendation Fulfilled 
risk for a meaningful time period 
Other analyses 17 Report other analyses done - e.g., analyses of subgroups and interactions, 
and sensitivity analyses 
Yes 
Discussion 
Key results 18 Summarize key results with reference to study objectives Yes 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Yes 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Yes 
Generalizability 21 Discuss the generalizability (external validity) of the study results Yes 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based 
Yes 
aGive information separately for exposed and unexposed groups 
Abbreviations: NA not applicable, No. number, STROBE STrengthening the Reporting of OBservational studies in 
Epidemiology 
 
Table S2 | Kidney Disease | Improving Global Outcomes definition and classification of 
acute kidney injury [11] 
KDIGO AKI definition SCr increase to ≥ 1.5 times baseline, which is known or presumed to have 
occurred within the prior 7 d 
SCr increase by ≥ 0.3 mg/dl within 48 h 
UO < 0.5 ml/kg/h for ≥ 6 consecutive h 
 
KDIGO AKI stagea SCr UO 
1 Increase to ≥ 1.5 times baseline < 0.5 ml/kg/h for ≥ 6 consecutive 
h 
Increase by ≥ 0.3 mg/dl  
2 Increase to ≥ 2 times baseline < 0.5 ml/kg/h for ≥ 12 
consecutive h 
3 Increase to ≥ 3 times baseline < 0.3 ml/kg/h for ≥ 24 
consecutive h 
Increase to ≥ 4 mg/dl Anuria for ≥ 12 consecutive h 
Initiation of RRT  
aFor staging purposes, patients should be staged according to the criterion or criteria that give(s) them the highest 
stage 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global Outcomes, RRT renal 
replacement therapy, SCr serum creatinine, UO urine output 
  
 Table S3A | Two representative work schemes for sample centrifugation in weekends 
Work scheme 1 
Sat, 10 am Mon, 8 am 
Sample from Time stored at 4°C (h) 
before centrifugation 
Sample from Time stored at 4°C (h) 
before centrifugation 
Fri, 6 pm 16 Sat, 6 pm 38 
Sat, 6 am 4 Sun, 6 am 26 
  Sun, 6 pm 14 
  Mon, 6 am 2 
Work scheme 2 
Sun, 10 am Mon, 8 am 
Sample from Time stored at 4°C (h) 
before centrifugation 
Sample from Time stored at 4°C (h) 
before centrifugation 
Fri, 6 pm 40 Sun, 6 pm 14 
Sat, 6 am 28 Mon, 6 am 2 
Sat, 6 pm 16   
Sun, 6 am 4   
Based on our stability results (Additional Table A3), the responsible study coordinator had to come once a 
weekend: on Sat or Sun. 
 
Table S3B | Dilution of serum and urine samples for initial measurement of CHI3L1 by 
enzyme-linked immunosorbent assay 
Serum CRP (mg/l) Estimated dilution for 
serum sample 
SCr (mg/dl) Estimated dilution for 
urine sample 
< 10 1/200 No increase to ≥ 1.5 times 
baseline, which is known 
or presumed to have 
occurred within the prior 7 
d and no increase by ≥ 0.3 
mg/dl within 48 h 
1/5 
≥ 10 1/500 Increase to ≥ 1.5 times 
baseline, which is known 
or presumed to have 
occurred within the prior 7 
d or increase by ≥ 0.3 
mg/dl within 48 h 
1/10 
The dilution of a serum sample for the initial measurement of CHI3L1 by ELISA was chosen based on a patient’s 
serum CRP, while the dilution of a urine sample for the initial measurement was chosen based on a patient’s SCr. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CRP C-reactive protein, ELISA enzyme-linked immunosorbent 
assay, SCr serum creatinine 
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Table S3C | Evaluation of the assured dynamic range of the CHI3L1 enzyme-linked 
immunosorbent assay standard curve 
Expected standard 
concentration (pg/ml) 
Back-calculated 
standard concentration 
(pg/ml) 
Recovery (%) Acceptable recovery 
(%) 
4000 X (X/4000)*100 70-130 
2000 X (X/2000)*100 70-130 
1000 X (X/1000)*100 70-130 
500 X (X/500)*100 70-130 
250 X (X/250)*100 70-130 
125 X (X/125)*100 70-130 
62.5 X (X/62.5)*100 70-130 
If a standard point has an unacceptable recovery while the adjacent standard points have acceptable recoveries, 
this point is removed from the standard curve. The effect on the novel standard curve is then reviewed. 
The symbol * represents the multiplication sign, while the symbol / represents the division sign. 
Abbreviations: CHI3L1 chitinase 3-like protein 1 
 
Table S3D | Re-analysis of samples with a concentration (not adjusted for dilution) 
outside the validated dynamic range of the CHI3L1 enzyme-linked immunosorbent assay 
standard curve 
Situation 1 | narrowed validated dynamic range 
ODsample 
> ODvalidated highest 
ODsample 
> OD4000 
Re-analyse and dilute more 
ODsample 
< OD4000 
Re-analyse and dilute equally 
ODsample 
< ODvalidated lowest 
ODsample 
> OD62.5 
Re-analyse and dilute equally 
ODsample 
< OD62.5 
Re-analyse and dilute less 
Situation 2 | validated dynamic range of [62.5-4000] 
ODsample 
> OD4000 
Option 1 Re-analyse and dilute more 
Option 2 Do not re-analyse and report as 
[back-calculated Conc4000] 
multiplied with [dilution factor of 
sample]a 
Implication: most likely 
underestimation 
ODsample 
< OD62.5 
Option 1 If less dilution is possible: re-
analyse and dilute less 
Option 2 If less dilution is possible: do not 
re-analyse and report as missing 
valuea 
Option 3 If less dilution is not possible 
(sample already optimal diluted): see 
Supplemental Table S3E 
aAll samples collected at enrolment were re-analysed if needed, as CHI3L1 at enrolment is the primary dependent 
variable of the study. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, Conc concentration, OD optical density 
  
 Table S3E | Adjustment of CHI3L1 concentrations of optimally diluted samples with 
optical densitysample < optical density62.5 
Concsample 
< LOD23.9 
Concsample 
< back-calculated 
Conc62.5 
0-23.8 
< 23.9 
< 43.8-81.3 
Concsample 
< LOD23.9 
< back-calculated 
Conc62.5 
Median between 0 
and 23.9 
Concsample 
= LOD23.9 
Concsample 
< back-calculated 
Conc62.5 
23.9 
= 23.9 
< 43.8-81.3 
Concsample 
= LOD23.9 
< back-calculated 
Conc62.5 
23.9 
LOD23.9 
< Concsample 
< LOQ64.6 
Concsample 
< back-calculated 
Conc62.5 
23.9 
< 24-64.4 
< 43.8-64.5 
< 64.6 
LOD23.9 
< Concsample 
< back-calculated 
Conc62.5 
< LOQ64.6 
Median between 
23.9 and 64.6 
Concsample 
≥ back-calculated 
Conc62.5 
23.9 
< 43.8-64.5 
≤ 43.8-64.5 
< 64.6 
LOD23.9 
< back-calculated 
Conc62.5 
≤ Concsample 
< LOQ64.6 
Median between 
23.9 and 64.6 
(even if Concsample 
falls within standard 
curve range) 
Concsample 
≥ LOQ64.6 
Concsample 
< back-calculated 
Conc62.5 
64.6 
≤ 64.6-81.2 
< 64.7-81.3 
LOQ64.6 
≤ Concsample 
< back-calculated 
Conc62.5 
Median between 
23.9 and 64.6 
(even if Concsample 
equals or exceeds 
LOQ64.6) 
Concsample 
≥ back-calculated 
Conc62.5 
64.6 
≤ 64.6-81.3 
≤ 64.6-Xa 
LOQ64.6 
≤ back-calculated 
Conc62.5 
≤ Concsample 
Measured Conc 
Note that the CHI3L1 concentrations are not yet corrected for dilution. 
aX represents a concentration > 64.6 pg/ml. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, Conc concentration, LOD limit of detection, LOQ limit of 
quantification, OD optical density 
 
Table S3F | Adjustment of UNGAL concentrations before input in statistical programs 
Measured UNGAL Reported UNGAL (ng/ml) 
< LOD12 0.1 
= LOD12 12.0 
> LOD12 and < LOQ25 Median (LOD12, LOQ25) = 18.5 
≥ LOQ25 Measured UNGAL 
Abbreviations: LOD limit of detection, LOQ limit of quantification, UNGAL urinary neutrophil gelatinase-
associated lipocalin 
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Table S4 | Definition of suspected bacterial infection, arterial hypotension, organ 
dysfunction, and shock 
Medication Antibiotic drug ‘Yes’ or ‘No’  
  When responding ‘Yes’ Suspected bacterial 
infection 
   
 
Arterial hypotension Vasopressor support for 
at least 1 h 
‘Yes’ or ‘No’  
MAP < 70 mmHg ‘Yes’ or ‘No’  
Organ dysfunction SCr > 2.0 mg/dl ‘Yes’ or ‘No’  
Serum bilirubin (total) > 
2.0 mg/dl 
‘Yes’ or ‘No’  
Platelet count < 
100,000/μl 
‘Yes’ or ‘No’  
  When responding ‘Yes’ 
to at least one criterion 
Suspected bacterial 
infection leading to 
arterial hypotension or 
organ dysfunction 
   
 
Shock defined as non-
responsive arterial 
hypotension 
Vasopressor support for 
at least 1 h 
‘Yes’ or ‘No’  
MAP < 65 mmHg ‘Yes’ or ‘No’  
  When responding ‘Yes’ 
to both criteria 
Suspected bacterial 
infection leading to 
shock 
Abbreviations: MAP mean arterial pressure, SCr serum creatinine 
  
 VIII. Supplemental Material to Results 
SUPPLEMENTAL TABLES TO RESULTS 
Table S5 | Sharpened clinical phenotype analysis with areas under receiver-operating 
characteristics curves of the urinary biomarkers measured at enrolment 
  AKISCr/UO stage ≥ 2a AKISCr stage ≥ 2b 
Biomarker 
measurement 
Time 
window 
AUC-
ROC 
95 % CI Number of 
positives/total 
N 
AUC-
ROC 
95 % CI Number of 
positives/total 
N 
Enrolment 
UCHI3L1 
12 h 0.882 0.817-
0.930 
2/142 0.879 0.817-
0.926 
2/155 
24 h 0.631 0.541-
0.715 
4/126 0.879 0.815-
0.927 
2/147 
Enrolment 
UNGAL 
12 h 0.850 0.780-
0.904 
2/142 0.856 0.791-
0.907 
2/155 
24 h 0.654 0.564-
0.736 
4/126 0.852 0.784-
0.905 
2/147 
Patients with AKI stage 1 at enrolment were excluded, as were patients that maximally reached AKI stage 1 within 
the respective time window. 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum creatinine, UCHI3L1 
urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated lipocalin, UO urine output 
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Table S6 | Spearman’s coefficients of rank correlation for the urinary biomarkers 
measured at enrolment 
  Spearman’s 
coefficient of rank 
correlation 
95 % CI Number of 
patients 
  0.615 0.515-0.698 181 
AKI definition 
used to define 
subgroup 
Subgroup Spearman’s 
coefficient of rank 
correlation 
95 % CI Number of 
patients 
AKISCr/UOa Stage 0 at enrolment 0.600 0.489-0.691 158 
Stage 1 at enrolment 0.532 0.153-0.774 23 
Stage 0 or 1 within 
12 h after enrolment 
0.601 0.497-0.688 175 
Stage 2 or 3 within 
12 h after enrolment 
0.543 [-0.480]-0.940 6 
Stage 0 or 1 within 
24 h after enrolment 
0.590 0.483-0.680 172 
Stage 2 or 3 within 
24 h after enrolment 
0.800 0.290-0.956 9 
AKISCrb Stage 0 at enrolment 0.595 0.484-0.686 160 
Stage 1 at enrolment 0.575 0.191-0.807 21 
Stage 0 or 1 within 
12 h after enrolment 
0.596 0.492-0.683 177 
Stage 2 or 3 within 
12 h after enrolment 
0.800 [-0.697]-0.996 4 
Stage 0 or 1 within 
24 h after enrolment 
0.589 0.483-0.678 176 
Stage 2 or 3 within 
24 h after enrolment 
0.900 0.086-0.993 5 
Stage 0 represents no AKI. 
The urinary biomarkers are UCHI3L1 and UNGAL. 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
Abbreviations: AKI acute kidney injury, CI confidence interval, KDIGO Kidney Disease | Improving Global 
Outcomes, SCr serum creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil 
gelatinase-associated lipocalin, UO urine output 
 
Table S7 | Youden indexes with associated criterion values of the urinary biomarkers 
  AKISCr/UO stage ≥ 2a AKISCr stage ≥ 2b 
Biomarker 
measurement 
Time 
window 
J Sens 
(%) 
Spec 
(%) 
Criterion 
value 
(ng/ml) 
J Sens 
(%) 
Spec 
(%) 
Criterion 
value 
(ng/ml) 
Enrolment 
UCHI3L1 
12 h 0.651 83.3 81.7 > 7.6 0.814 100.0 81.4 > 7.6 
24 h 0.486 66.7 82.0 > 7.6 0.818 100.0 81.8 > 7.6 
Enrolment 
UNGAL 
12 h 0.467 66.7 80.0 > 139.0 0.802 100.0 80.2 > 139.0 
24 h 0.440 66.7 77.3 > 111.0 0.807 100.0 80.7 > 139.0 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
Abbreviations: AKI acute kidney injury, J Youden index defined as the maximum of [sensitivity plus specificity 
minus 1], KDIGO Kidney Disease | Improving Global Outcomes, SCr serum creatinine, Sens sensitivity, Spec 
specificity, UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated lipocalin, 
UO urine output 
  
 Table S8 | Proportion of patients with a high systemic concentration of CHI3L1 at 
enrolment in patients who did not develop acute kidney injury and either presented with 
or without an increased urinary concentration of this biomarker at enrolment 
Group N (%) Subgroup of a 
or b 
N (%) Subgroup of c, 
d, e or f 
N (%) 
(a) 
No AKISCr/UO 
within 7 d after 
enrolmenta 
95 (100 %) (c) 
UCHI3L1 > 7.6 
ng/mlb 
15 (16 %) (g) 
SCHI3L1 > 
2000 ng/ml 
6 (40 %) 
  (d) 
UCHI3L1 
normal 
80 (84 %) (h) 
SCHI3L1 > 
2000 ng/ml 
2 (3 %) 
(b) 
No AKISCr 
within 7 d after 
enrolmentc 
120 (100 %) (e) 
UCHI3L1 > 7.6 
ng/mld 
18 (15 %) (i) 
SCHI3L1 > 
2000 ng/ml 
6 (33 %) 
  (f) 
UCHI3L1 
normal 
102 (85 %) (j) 
SCHI3L1 > 
2000 ng/ml 
5 (5 %) 
aBased on the KDIGO criteria for AKI 
bCriterion value of UCHI3L1 associated with the Youden index for predicting AKISCr/UO stage ≥ 2 within 12 h 
after enrolment 
cBased on the KDIGO SCr criteria for AKI 
dCriterion value of UCHI3L1 associated with the Youden index for predicting AKISCr stage ≥ 2 within 24 h after 
enrolment 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 
serum chitinase 3-like protein 1, SCr serum creatinine, UCHI3L1 urinary chitinase 3-like protein 1, UO urine 
output 
 
IX. Additional Analyses and Results 
METHODS 
Subgroup analyses 
We evaluated the biomarkers’ diagnostic performances for predicting the primary endpoint as 
well as the 24-h AKISCr secondary endpoint in subgroups of patients. The selected variables used 
for grouping were: age, baseline estimated GFR (eGFR) calculated with the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formula, reason for ICU admission, patient’s 
location prior to ICU admission, Sepsis-related Organ Failure Assessment (SOFA) score at d1, 
and presence of suspected bacterial infection, either leading to arterial hypotension or organ 
dysfunction, or leading to shock (Supplemental Table S4), at d1. 
Additionally, we used the same grouping variables in both patients who did not develop 
AKISCr/UO within 7 d after enrolment and those who did not develop AKISCr within 7 d after 
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enrolment. The distribution of UCHI3L1 and UNGAL at enrolment in selected subgroups of 7-
d no-AKISCr/UO patients was plotted against the distribution in all 12-h no-AKISCr/UO patients and 
in all those maximally reaching AKISCr/UO stages 1, 2, or 3 within 12 h after enrolment. Likewise, 
the distribution of these biomarkers at enrolment in selected subgroups of 7-d no-AKISCr patients 
was plotted against the distribution in all 24-h no-AKISCr patients and in all those maximally 
reaching AKISCr stages 1, 2, or 3 within 24 h after enrolment. 
Additional area under the receiver-operating characteristics curve analyses 
Additional endpoints of the study were: AKISCr/UO stage ≥ 1 within 12 h and 24 h after 
enrolment; AKISCr stage ≥ 1 within 12 h and 24 h after enrolment. As these endpoints include 
AKI stage 1, we additionally excluded the patients with AKI stage 1 at enrolment from the 
analysis cohort (n = 181). The number of patients in the resulting sub-cohorts was 158 
(AKISCr/UO) and 160 (AKISCr). 
Validation of the analytical stability of CHI3L1 
Short-term stability of CHI3L1 in serum and urine before centrifugation 
Høgdall et al. found no change in the CHI3L1 concentration when serum samples were left on 
the clot at 4°C for 24 h before centrifugation, however, after 72 h SCHI3L1 was significantly 
increased [173]. We further tested the stability of CHI3L1 in serum (n = 2) and also in urine (n = 
4) of ICU patients when stored at 4°C for 6 h (urine), 24 h, and 48 h before centrifugation by 
comparing these concentrations with those of the immediately centrifuged samples and 
calculating the mean coefficient of variation (CV).  
 Combined long-term and freeze-thaw stability of CHI3L1 in urine 
SCHI3L1 is stable for 8 y when stored at -80°C without preservatives (personal communication with 
Johansen JS). Høgdall et al. additionally showed that repetitive freezing and thawing of serum 
samples up to 8 times does not influence the concentration of SCHI3L1 [173]. 
For our study the most relevant stability feature concerning UCHI3L1 was whether UCHI3L1 
measured in an aliquot that was thawed for the first time stayed stable after refreezing followed 
by thawing for the second time. Indeed, this was the protocol when UCHI3L1 fell outside the 
range of the standard curve at the first measurement. To evaluate this combined stability we 
compared those concentrations measured after the second thawing with those measured after the 
first thawing and calculated the mean CV. Total freezing times (i.e., time between first freezing 
and second thawing), specifically for this stability evaluation, ranged from 6-30 mo (n = 2 for 6 
mo, 12 mo, 18 mo, 24 mo and 30 mo). 
Partial in-house validation of the CHI3L1 enzyme-linked immunosorbent assay 
Within-run precision or intra-assay variability 
Of the 101 ELISA runs performed for CHI3L1 measurement (with ELISA kits from 6 different 
lots), 31 runs had replicate analyses of at least 1 sample or standard. These replicate samples were 
divided into 3 (serum) or 2 (urine) groups, i.e. low, intermediate (serum), and high, covering the 
analytical range of the standard curve (0.06-4.00 ng/ml). Note that for urine there was no 
intermediate group as there were no replicates available of urine samples with a UCHI3L1 
concentration > 1.0 ng/ml and ≤ 2.5 ng/ml. Replicate analyses of the 0.25, 0.50 and 1.00 ng/ml 
standards were consistently performed as these constitute the middle 3 points of the standard 
curve. The intra-assay between-lot CV was calculated as the weighted mean of the mean intra-
assay within-lot CVs.  
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Between-run precision or inter-assay variability 
Upon inquiry it appeared that the inter-assay CVs reported by the manufacturer were generated 
using 40 different assays that were divided between 4 technicians. Each of them performed one 
ELISA per day. The 40 assays consisted of 2 different matched sets of reagents, just like 2 
different kit lots (Additional Table A1), so lot-to-lot variation was taken into account. Therefore, 
this part of the validation process was not repeated in-house. Three samples (type not specified) 
with a known CHI3L1 concentration (±0.50, ±1.00, and ±2.00 ng/ml) were analysed. The 
reported mean inter-assay between-lot CV was 5.3 % for the ±0.50 ng/ml sample, 5.8 % for the 
±1.00 ng/ml sample, and 6.9 % for the ±2.00 ng/ml sample. The mean of these 3 CVs is 6.0 %. 
Calculation of the limit of detection and limit of quantification 
The minimal detectable dose or LOD was determined by adding 2.6 [174] standard deviations 
(SD) to the mean OD value of 10 replicates of the zero standard (i.e., calibrator diluents) and 
calculating the corresponding concentration (DeltaSoft JV, Biomettalics, Princeton Junction, NJ). 
Likewise, the minimal quantifiable dose or LOQ was determined by adding 10 [175] SDs to the 
mean OD value of 10 replicates of the zero standard and calculating the corresponding 
concentration. 
Linearity check for urine 
The linearity of the assay was assessed by the manufacturer using samples from apparently 
healthy volunteers. Because our study population consisted of critically ill patients we rechecked 
the linearity for the specimen type urine. More specifically, we wanted to investigate ‘how far 
undiluted’ we could go as urinary components linked with severe illness may possibly interfere 
with the CHI3L1 measurement by ELISA. Therefore, undiluted urine was not tested and 
designated as unsuitable. The reference for our serial dilution experiment (1/2 - 1/4 - 1/8 - 1/16) 
was the 1/2 diluted sample. The relationship between the measured (not adjusted for dilution) 
 and the expected (1/2 as reference) analyte concentration was investigated by linear regression 
analysis (GraphPad Prism 5, GraphPad Software, San Diego, CA). 
RESULTS 
Biomarkers’ diagnostic performances in subgroups 
Diagnostic performance at enrolment for prediction of AKISCr/UO stage ≥ 2 within the next 12 h, 
could be calculated in 9 of the 12 subgroups (Additional Figure A1). Likewise, diagnostic 
performance at enrolment for prediction of AKISCr stage ≥ 2 within the next 24 h, could be 
calculated in 8 of the 12 subgroups (Additional Figure A2). As for UCHI3L1, this biomarker 
showed decreased diagnostic performance – defined as an AUC-ROC < the lowest border of the 
95 % CI in the analysis cohort – for predicting the primary endpoint in patients either with a 
medical reason for ICU admission, or referred from either an emergency room, or operating 
room, or other hospital at ICU admission, or with a SOFA score < 12 at d1 [176]. Its 
performance for predicting the 24-h AKISCr secondary endpoint was decreased in patients either 
≥ 65 y old, or with a SOFA score ≥ 12 at d1. As for UNGAL, this biomarker showed decreased 
diagnostic performance for predicting the primary endpoint in patients either ≥ 65 y old, or with 
a medical reason for ICU admission, or referred from the floor at ICU admission. In the latter 2 
subgroups UNGAL could not predict the primary endpoint. Its performance for predicting the 
24-h AKISCr secondary endpoint was decreased in patients ≥ 65 y old. 
We found that patients referred from the floor at ICU admission who did not develop AKISCr/UO 
within 7 d after enrolment, had higher urinary biomarker concentrations at enrolment than all 
patients who did not develop AKISCr/UO within 12 h after enrolment (P = 0.002 for UCHI3L1; P 
= 0.001 for UNGAL) (Additional Figure A3). Similarly, 7-d no-AKISCr patients who were referred 
from the floor at ICU admission showed higher enrolment concentrations of both urinary 
biomarkers than all 24-h no-AKISCr patients (P = 0.001 for both biomarkers) (Additional Figure 
A4).  
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Additional diagnostic performances 
The AUC-ROCs for predicting AKISCr/UO stage ≥ 1 within 12 h and 24 h in patients with no 
AKISCr/UO at enrolment were markedly decreased for both UCHI3L1 and UNGAL (Additional 
Table A2). Likewise, the AUC-ROCs for predicting AKISCr stage ≥ 1 within 12 h and 24 h in 
patients with no AKISCr at enrolment were markedly decreased as well (Additional Table A2). This 
can be explained by less renal stress or damage in patients with AKI stage 1. 
Stability of CHI3L1 in serum and urine 
Storage at 4°C up to 48 h before centrifugation had no effect on the CHI3L1 concentration in 
both serum and urine (P ≥ 0.05), with a mean CV ranging from 3.8 to 3.9 % for serum and from 
5.0 to 8.5 % for urine (Additional Table A3). 
Refreezing at -80°C followed by a second thawing step had no effect on the CHI3L1 
concentration in urine (P ≥ 0.05), even when the time between initial freezing and second 
thawing was 30 mo, with a mean CV ranging from 0.7 to 18.8 % (Additional Table A4). 
Partial in-house validation of the CHI3L1 enzyme-linked immunosorbent assay 
For the human CHI3L1 standards 0.25, 0.50 and 1.00 ng/ml of the ELISA, the intra-assay 
between-lot CV was 2.9 % for the 0.25 ng/ml standard, 4.4 % for the 0.50 ng/ml standard, and 
5.0 % for the 1.00 ng/ml standard (Additional Table A5). Serum samples with a low or a high 
CHI3L1 concentration showed an excellent intra-assay between-lot CV of 2.6 % for the low and 
3.2 % for the high concentrations (Additional Table A6). For urine samples with a low CHI3L1 
concentration an intra-assay between-lot CV of 4.1 % was calculated (Additional Table A7). A 
mean intra-assay within-lot CV of 6.7 % was obtained for serum samples with an intermediate 
CHI3L1 concentration. Likewise, a mean intra-assay within-lot CV of 1.9 % was obtained for 
urine samples with a high CHI3L1 concentration. 
The LOD was determined as 0.02 ng/ml, the LOQ as 0.06 ng/ml. 
 For all three serial dilution experiments, each being performed with another urine sample, the 95 
% CI of the slope of the linear regression equation included 1, indicating 100 % recovery 
(Additional Table A8). The corresponding R2 was systematically ≥ 0.99. 
CONCLUSIONS REGARDING THE VALIDATION OF THE ANALYTICAL STABILITY OF CHI3L1 
AND THE PARTIAL IN-HOUSE VALIDATION OF THE CHI3L1 ENZYME-LINKED 
IMMUNOSORBENT ASSAY 
As an important first step, we showed that serum and urine may be stored for at least 48 h at 4°C 
before centrifugation without affecting the CHI3L1 stability, in analogy with the reported data 
for UNGAL [177]. Based on these results the study personnel could flexibly plan the handling of 
the samples, especially in weekends (Supplemental Table S3A). When subsequently stored at -80°C, 
UCHI3L1 may even be measured after a second thawing step within at least 30 mo after the first 
freezing, in analogy with the reported data for SCHI3L1 [166, 173]. This information was 
required for our laboratory agenda, and is also relevant for biobanking purposes. Additionally, we 
can guarantee that our reported CHI3L1 concentrations are accurate and reproducible. 
ADDITIONAL TABLES 
Table A1 | Experimental setup for evaluation of between-run precision or inter-assay 
variability of the CHI3L1 enzyme-linked immunosorbent assay by the manufacturer 
Technician 1 Technician 2 Technician 3 Technician 4 
Reagent set 
1 
Reagent set 
2 
Reagent set 
1 
Reagent set 
2 
Reagent set 
1 
Reagent set 
2 
Reagent set 
1 
Reagent set 
2 
Day 1 Day 6 Day 1 Day 6 Day 1 Day 6 Day 1 Day 6 
Day 2 Day 7 Day 2 Day 7 Day 2 Day 7 Day 2 Day 7 
Day 3 Day 8 Day 3 Day 8 Day 3 Day 8 Day 3 Day 8 
Day 4 Day 9 Day 4 Day 9 Day 4 Day 9 Day 4 Day 9 
Day 5 Day 10 Day 5 Day 10 Day 5 Day 10 Day 5 Day 10 
Within-lot 
CV by tech 
1 
Within-lot 
CV by tech 
1 
Within-lot 
CV by tech 
2 
Within-lot 
CV by tech 
2 
Within-lot 
CV by tech 
3 
Within-lot 
CV by tech 
3 
Within-lot 
CV by tech 
4 
Within-lot 
CV by tech 
4 
Between-lot CV by tech 1 Between-lot CV by tech 2 Between-lot CV by tech 3 Between-lot CV by tech 4 
Reported by manufacturer: mean of between-lot CVs 
Day X of technician 1 is not necessarily the same as day X of technicians 2-4. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CV coefficient of variation 
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Table A2 | Areas under receiver-operating characteristics curves of the urinary 
biomarkers measured at enrolment for prediction of additional endpoints 
  AKISCr/UO stage ≥ 1a AKISCr stage ≥ 1b 
Biomarker 
measurement 
Time 
window 
AUC-
ROC 
95 % CI Number 
of 
positives 
(%) 
AUC-
ROC 
95 % CI Number 
of 
positives 
(%) 
Enrolment 
UCHI3L1 
12 h 0.614 0.534-
0.691 
18 (11.4) 0.647 0.568-
0.721 
7 (4.4) 
24 h 0.554 0.473-
0.633 
36 (22.8) 0.603 0.523-
0.680 
15 (9.4) 
Enrolment 
UNGAL 
12 h 0.553 0.472-
0.632 
18 (11.4) 0.503 0.423-
0.583 
7 (4.4) 
24 h 0.542 0.461-
0.621 
36 (22.8) 0.504 0.424-
0.584 
15 (9.4) 
Patients with AKI stage 1 at enrolment were excluded. 
aBased on the KDIGO criteria for AKI 
bBased on the KDIGO SCr criteria for AKI 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, KDIGO Kidney Disease | Improving Global Outcomes, SCr serum creatinine, UCHI3L1 
urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated lipocalin, UO urine output 
 
Table A3 | Short-term stability of CHI3L1 in serum and urine before centrifugation 
Time 
between 
sampling and 
centrifugation 
(h) 
Conc at X 
ha 
(ng/ml) 
Conc at 0 
hb 
(ng/ml) 
Mean SD CV 
(%) 
Mean CV 
(%) 
P valuec 
Serum 
24 1035.3 1060.2 1047.72 17.62 1.7 3.8 0.180 
1396.5 1514.9 1455.70 83.75 5.8 
48 978.3 1060.2 1019.23 57.91 5.7 3.9 0.655 
1559.7 1514.9 1537.32 31.68 2.1 
Urine 
6 1050.3 1035.8 1043.03 10.30 1.0 6.3 0.655 
577.4 679.2 628.29 71.99 11.5 
24 3.6 3.6 3.59 0.06 1.6 8.5 0.593 
12.5 15.7 14.13 2.27 16.0 
1096.1 1035.8 1065.93 42.68 4.0 
571.1 679.2 625.17 76.40 12.2 
48 3.9 3.6 3.77 0.20 5.2 5.0 0.715 
14.1 15.7 14.89 1.19 8.0 
1039.2 1035.8 1037.46 2.42 0.2 
619.0 679.2 649.08 42.59 6.6 
aConcentration of sample that was stored for X h at 4°C before centrifugation 
bConcentration of sample that was centrifuged immediately after collection 
cThe P values are the significance levels between samples that were immediately centrifuged and those stored for 6 
h, 24 h or 48 h at 4°C before centrifugation 
Abbreviations: CHI3L1 chitinase 3-like protein 1 
  
 Table A4 | Combined long-term and freeze-thaw stability of CHI3L1 in urine 
Time 
between 
first 
freezing 
and 
second 
thawing 
(mo) 
Conc 2a 
(ng/ml) 
Conc 1b 
(ng/ml) 
Mean SD CV (% 
minus 6.0 
%)c 
Mean CV 
(%) 
P valued 
6 2.3 3.0 2.65 0.48 12.3 18.8 0.655 
0.7 0.4 0.54 0.17 25.3 
12 4.2 3.8 4.03 0.30 1.3 0.7 0.180 
8.6 8.1 8.35 0.37 0.0e 
18 4.3 3.7 3.97 0.43 4.8 3.6 0.655 
9.5 10.7 10.12 0.85 2.4 
24 2.0 1.9 1.95 0.10 0.0e 11.9 0.655 
0.6 0.9 0.72 0.21 23.7 
30 14.0 11.9 12.94 1.46 5.3 2.6 0.180 
6.3 5.9 6.09 0.32 0.0e 
aConcentration of sample measured after first thawing of an aliquot; the samples in this stability study were 
initially analysed after a period ranging from 1-9 mo. 
bConcentration of sample measured after second thawing of an aliquot 
cMean inter-assay CV reported by the manufacturer = 6.0 % (Additional Table A1) 
dThe P values are the significance levels between samples that were thawed for the first time and those thawed for 
the second time 
eCV of (Conc 2, Conc 1) ≤ mean inter-assay CV of 6.0 % 
Abbreviations: CHI3L1 chitinase 3-like protein 1, Conc concentration, CV coefficient of variation, SD standard 
deviation 
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Table A5 | Within-run precision or intra-assay variability of the CHI3L1 enzyme-linked 
immunosorbent assay for standard points 
Analyte 
concentration 
(ng/ml) 
Standards 
(n) 
Repetitions 
(n) 
Mean SD CV (%) Between-lot 
CV with 
range of 
mean 
within-lot 
CV (%) 
Standard 0.3 4 2 0.25a 0.00 0.9 2.9 (2.6-3.9) 
0.25a 0.01 3.2 
0.23a 0.01 3.7 
0.25b 0.01 3.9 
Standard 0.5 11 2 0.49a 0.02 5.1 4.4 (3.5-4.6) 
0.46a 0.03 6.9 
0.52a 0.01 2.6 
0.53a 0.02 4.2 
0.51b 0.02 3.5 
0.49c 0.02 3.9 
0.46a 0.03 6.9 
0.49a 0.01 2.6 
0.48d 0.02 4.2 
0.49d 0.02 4.9 
0.49a 0.02 4.2 
Standard 1.0 18 2 1.01a 0.02 2.4 5.0 (2.4-5.8) 
2 0.95b 0.07 7.5 
2 1.02b 0.00 0.3 
2 0.97b 0.02 1.9 
2 0.97b 0.03 2.7 
2 0.94b 0.04 4.2 
2 0.97c 0.04 3.8 
2 0.95c 0.03 3.1 
2 0.94c 0.03 3.5 
2 0.98b 0.03 2.8 
2 0.96b 0.10 10.3 
2 0.97b 0.02 2.5 
4 1.10c 0.10 9.2 
2 0.95c 0.07 7.4 
2 0.94c 0.07 7.7 
2 0.93b 0.11 12.3 
2 1.05b 0.05 4.7 
2 0.98b 0.04 3.6 
Letters in superscript indicate different lots within each group. In the 3 different groups, letter X does not 
necessarily represent the same lot. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CV coefficient of variation, SD standard deviation 
  
 Table A6 | Within-run precision or intra-assay variability of the CHI3L1 enzyme-linked 
immunosorbent assay for serum samples 
Analyte 
concentration 
(ng/ml) 
Serum 
samples (n) 
Repetitions 
(n) 
Mean SD CV (%) Between-lot 
CV with 
range of 
mean 
within-lot 
CV (%) 
Low 5 2 0.45a 0.02 3.9 2.6 (2.1-2.8) 
0.86a 0.01 1.2 
0.73a 0.01 1.2 
0.69b 0.01 2.1 
0.95a 0.05 4.8 
Intermediate 
> 1.0 
2 2 
4 
1.21a 0.02 1.8 (6.7) 
2.22a 0.26 11.6 
High > 2.5 3 2 3.01a 0.05 1.7 3.2 (1.7-3.9) 
3.08b 0.1 3.1 
3.24b 0.15 4.6 
Highlighted results represent the mean, SD and CV of the OD value (out of dynamic range of the curve). 
Letters in superscript indicate different lots within each group. In the 3 different groups, letter X does not 
necessarily represent the same lot. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CV coefficient of variation, OD optical density, SD standard 
deviation 
 
Table A7 | Within-run precision or intra-assay variability of the CHI3L1 enzyme-linked 
immunosorbent assay for urine samples 
Analyte 
concentration 
(ng/ml) 
Urine 
samples (n) 
Repetitions 
(n) 
Mean SD CV (%) Between-lot 
CV with 
range of 
mean 
within-lot 
CV (%) 
Low 9 2 0.21a 0.00 0.3 4.1 (1.6-9.3) 
0.07a 0.00 2.8 
0.17a 0.00 1.7 
0.18a 0.00 0.8 
0.20a 0.01 3.7 
0.20b 0.03 14.8 
0.09c 0.00 1.6 
0.94a 0.07 7.0 
0.70b 0.03 3.9 
High > 2.5 2 2 2.52a 0.06 2.3 (1.9) 
2.74a 0.04 1.4 
Highlighted results represent the mean, SD and CV of the OD value (out of dynamic range of the curve). 
Letters in superscript indicate different lots within each group. In the 2 different groups, letter X does not 
necessarily represent the same lot. 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CV coefficient of variation, OD optical density, SD standard 
deviation 
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Table A8 | Assessment of the enzyme-linked immunosorbent assay linearity for CHI3L1 
Urine sample Dilution Expected 
concentration 
Measured 
concentration 
Slope (95 % 
CI) 
R2 
1 1/2 0.953 0.953 0.98 (0.75-1.21) 0.99 
1/4 0.476 0.545 
1/8 0.238 0.271 
1/16 0.119 0.136 
2 1/2 2.248 2.248 0.94 (0.72-1.15) 0.99 
1/4 1.124 1.312 
1/8 0.562 0.720 
1/16 0.281 0.387 
3 1/2 2.569 2.569 0.97 (0.93-1.01) 1.00 
1/4 1.284 1.345 
1/8 0.642 0.719 
1/16 0.321 0.381 
Abbreviations: CHI3L1 chitinase 3-like protein 1, CI confidence interval, OD optical density, R2 coefficient of 
determination 
 
  
 ADDITIONAL FIGURES 
Figure A1 | Areas under receiver-operating characteristics curves of (A) UCHI3L1 and 
(B) UNGAL at enrolment for predicting AKI stage ≥ 2 based on the KDIGO criteria 
(AKISCr/UO) within 12 h in different subgroups of patients 
The dotted vertical lines delineate the AUC-ROC with 95 % CI in the analysis cohort. The total 
number of patients in each of the 9 subgroups (top-down) was 71, 134, 73, 108, 43, 138, 35, 146, 
and 122. The definition of infection ++ is outlined in Supplemental Table S4. 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating 
characteristics curve, CI confidence interval, eGFR estimated glomerular filtration rate, ER 
emergency room, KDIGO Kidney Disease | Improving Global Outcomes, M medical, OH 
other hospital, OR operating room, S surgical, SCr serum creatinine, SOFA Sepsis-related Organ 
Failure Assessment, UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil 
gelatinase-associated lipocalin, UO urine output  
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Figure A2 | Areas under receiver-operating characteristics curves of (A) UCHI3L1 and 
(B) UNGAL at enrolment for predicting AKI stage ≥ 2 based on the KDIGO SCr criteria 
(AKISCr) within 24 h in different subgroups of patients 
The dotted vertical lines delineate the AUC-ROC with 95 % CI in the analysis cohort. The total 
number of patients in each of the 8 subgroups (top-down) was 71, 110, 134, 73, 43, 35, 146, and 
122. The definition of infection ++ is outlined in Supplemental Table S4. 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating 
characteristics curve, CI confidence interval, eGFR estimated glomerular filtration rate, KDIGO 
Kidney Disease | Improving Global Outcomes, S surgical, SCr serum creatinine, SOFA Sepsis-
related Organ Failure Assessment, UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary 
neutrophil gelatinase-associated lipocalin  
0.5 0.6 0.7 0.8 0.9 1.0
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< 12
 12tSOFA d1: 
Referral: floor
Reason: S
 90teGFR: 
< 65
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 Figure A3 | Distribution of (A) UCHI3L1 and (B) UNGAL at enrolment in selected 
subgroups of patients who did not develop AKI based on the KDIGO criteria (no-
AKISCr/UO) within 7 d after enrolment, compared to the distribution in all 12-h no-
AKISCr/UO patients, and in all those maximally reaching AKISCr/UO stages 1, 2, or 3 within 12 
h after enrolment 
The total number of patients in each group (left-right) was 33, 16, 39, 56, 16, 79, 8, 56, 140, 35, 4, 
and 2. The definition of infection ++ is outlined in Supplemental Table S4. 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating 
characteristics curve, CI confidence interval, eGFR estimated glomerular filtration rate, ER 
emergency room, KDIGO Kidney Disease | Improving Global Outcomes, OH other hospital, 
OR operating room, SCr serum creatinine, SOFA Sepsis-related Organ Failure Assessment, 
UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated 
lipocalin, UO urine output  
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Figure A4 | Distribution of (A) UCHI3L1 and (B) UNGAL at enrolment in selected 
subgroups of patients who did not develop AKI based on the KDIGO SCr criteria (no-
AKISCr) within 7 d after enrolment, compared to the distribution in all 24-h no-AKISCr 
patients, and in all those maximally reaching AKISCr stages 1, 2, or 3 within 24 h after 
enrolment 
The total number of patients in each group (left-right) was 49, 28, 45, 75, 22, 98, 15, 76, 145, 31, 
2, and 3. The definition of infection ++ is outlined in Supplemental Table S4. 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating 
characteristics curve, CI confidence interval, eGFR estimated glomerular filtration rate, ER 
emergency room, KDIGO Kidney Disease | Improving Global Outcomes, OH other hospital, 
OR operating room, SCr serum creatinine, SOFA Sepsis-related Organ Failure Assessment, 
UCHI3L1 urinary chitinase 3-like protein 1, UNGAL urinary neutrophil gelatinase-associated 
lipocalin  
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 The following figures were added to this dissertation and are not found in the published paper. 
Figure A5 | Distribution of UCHI3L1 measured 
at enrolment in patients who either developed or 
did not develop AKI stage ≥ 2 based on the 
KDIGO criteria (AKISCr/UO) within 12 h after 
enrolment (primary endpoint) 
Abbreviations: AKI acute kidney injury, KDIGO 
Kidney Disease | Improving Global Outcomes, SCr 
serum creatinine, UCHI3L1 urinary chitinase 3-like 
protein 1, UO urine output 
 
 
 
 
 
 
 
 
 
Figure A6 | Revised probability of AKI stage ≥ 2 based on the KDIGO criteria 
(AKISCr/UO) within 12 h after enrolment (primary endpoint) 
This figure shows the revised (post-test) probability of the primary endpoint (y-axis) as a function 
of prior (pre-test) probability (x-axis) of the primary endpoint for positive and negative 
biomarker results of both enrolment UCHI3L1 and enrolment UNGAL, based on the likelihood 
ratios (data not shown) associated with the criterion values (shown in Table S7) of these 
biomarkers. 
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I. Abstract 
ackground: A common and serious complication of cardiac 
surgery prompting early detection and intervention is cardiac 
surgery-associated AKI (CSA-AKI). UCHI3L1 was found to 
predict AKI associated with critical illness in adults. Our aims were therefore to evaluate whether 
UCHI3L1 can also be used to predict AKI associated with elective cardiac surgery in adults, and 
to compare this predictive ability with that of UNGAL, more frequently assessed early SCr 
measurements, and various two-biomarker panels. 
Methods: This was a single-centre prospective cohort study at the 8-bed cardiac surgery ICU of 
Ghent University Hospital. AKI was diagnosed and classified according to the KDIGO 
definitions for the diagnosis and staging of AKI, which are based on SCr and UO. Of the 211 
enrolled elective cardiac surgery patients, we included 203 patients who had no AKI pre-
operatively and at time of post-operative ICU admission (t1) in the primary endpoint analysis 
(i.e., AKI stage ≥ 1 within 48 h after t1), while 210 patients without AKI stage ≥ 2 pre-
operatively and at t1 were included in the secondary endpoint analysis (i.e., AKI stage ≥ 2 within 
12 h after t1). Systemic and/or urine concentrations of Cr, CHI3L1 and NGAL were measured 
more frequently than SCr in routine early post-operative ICU practice. UO was monitored hourly 
in the ICU. 
Results: Within 48 h after t1, 46.8 % of the patients had developed AKI (70.5 % stage 1, 20.0 % 
stage 2 and 9.5 % stage 3). In the early post-operative period, only SCr was a good predictor of 
AKI within 48 h after t1 (primary endpoint). SCHI3L1 combined with either UCHI3L1 or 
UNGAL was a good predictor of AKI stage ≥ 2 within 12 h after t1 (secondary endpoint). 
However, SCr and its absolute difference from pre-operative to early measures after surgery 
outperformed these combinations. 
Conclusions: We found that more frequent assessment of the functional biomarker SCr in the 
early post-operative ICU period (first 4 h) after elective cardiac surgery in adult patients had good 
B 
 to excellent predictive value for CSA-AKI, indicating that routine SCr assessment must become 
more frequent in order to detect AKI more early. This performance was in contrast with the 
inadequate predictive value of the urinary renal stress or damage biomarkers UCHI3L1 and 
UNGAL. 
II. Background 
CSA-AKI is a common and serious complication of cardiac surgery [178]. Depending on its 
severity and differences in both baseline characteristics and type of cardiac surgical procedure, the 
range of incidence of CSA-AKI is between 3.1 and 50.0 % when applying KDIGO-like criteria 
[179-183]. CSA-AKI treated with RRT presents post-operatively in 2.0-6.0 % of cardiac surgery 
patients [179, 184, 185], of which 1 out of 2 die in hospital [179]. Importantly, also when the 
injury is mild, CSA-AKI is independently associated with significant effects on early (i.e., hospital 
or 30-d) mortality [186, 187]. 
Risk for CSA-AKI is increased by the presence of established pre-operative (e.g., increased SCr) 
and peri-operative (e.g., low cardiac output) factors that increase susceptibility to AKI [188, 189]. 
Moreover, potentially important modifiable intra-operative susceptibilities are the type of cardiac 
surgical technique and, if cardiopulmonary bypass (CPB) (synonym: extracorporeal circulation 
(ECC)) is used, the characteristics of the perfusion technique [190]. Early CSA-AKI occurs 
within 7 d after the cardiac surgical procedure and is directly related to it [17]. CSA-AKI more 
than 1 w but within 30 d after the cardiac surgical procedure is mainly related to another 
exposure that presents as a complication of the cardiac surgical procedure (e.g., sepsis) [17]. 
Only recently the term ‘acute kidney stress’ (AKS) was proposed to describe the pre-injury phase 
that leads to AKI [80]. Biomarkers, or “measurable and quantifiable biological parameters” [81], 
that respond to AKS open new horizons in regard to the prediction and early detection of 
emerging AKI. These biomarkers serve as surrogate measurements, estimating renal cell 
perfusion, function or metabolism [80]. As regulator of the iron metabolism, NGAL measured in 
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blood or urine represents a way to monitor initial damage [191], which was confirmed in more 
than 7000 paediatric and adult patients who underwent cardiac surgery [135, 138, 192]. Recently, 
our group demonstrated the role of UCHI3L1 as predictor of AKI in an adult general ICU 
cohort, with a performance similar to that of UNGAL [193]. 
Higher systemic concentrations of CHI3L1 have been independently associated with the 
presence of coronary artery disease, seeming a quantitative indicator of disease progression as 
well [194]. Additionally, it was shown that in patients with type 1 and type 2 diabetes mellitus 
higher systemic concentrations of CHI3L1 were associated with progressing vascular damage in 
the kidneys, as assessed by the level of albuminuria [194]. It seems plausible that low-grade 
inflammation and endothelial dysfunction progressing to micro- and macrovascular 
complications account for higher systemic concentrations of CHI3L1. Besides a marker of 
chronic inflammation, systemic CHI3L1 is a marker of acute inflammation as well [96]. Cardiac 
surgery and the use of CPB have a critical role in inducing the systemic inflammatory response 
syndrome leading to CSA-AKI. Consequently, SCHI3L1 can be proposed as a potential AKI risk 
factor. 
The objectives of this study were: (a) to evaluate whether UCHI3L1 can be used to predict 
occurrence of AKI in adult patients who underwent elective cardiac surgery, (b) to compare this 
predictive ability with that of UNGAL, a well-known biomarker of tubular damage, and that of 
more frequently assessed early measurements of SCr, a routine biomarker of kidney dysfunction, 
(c) to evaluate whether combining either two urinary renal stress or damage biomarkers, or a 
systemic kidney dysfunction biomarker and a urinary renal stress or damage biomarker can 
improve the predictive ability for CSA-AKI, (d) to evaluate whether combining SCHI3L1 with 
either a systemic kidney dysfunction biomarker or a urinary renal stress or damage biomarker can 
improve the predictive ability for CSA-AKI.  
 III. Methods (see also section VII. “Supplemental Material”) 
This research is reported according to the STROBE Statement (Supplemental Table S1) [143]. 
DEFINING AKI 
AKI was diagnosed and classified according to the KDIGO definitions for the diagnosis and 
staging of AKI, which are based on SCr and UO (Supplemental Figure S1) [11]. 
STUDY PATIENTS 
In this single-centre cohort study, we prospectively enrolled patients who were admitted to the 8-
bed cardiac surgery ICU of Ghent University Hospital from May 2012 till February 2014. The 
inclusion and exclusion criteria of the study are incorporated in the flow diagram in Figure 1. 
PRIMARY ENDPOINT 
The primary endpoint of the current study was the development of AKI stage ≥ 1 within 48 h 
after ICU admission (t1). Reference SCr, representing baseline SCr, was defined as the lowest 
SCr value within the last 3 mo prior to enrolment (lowest of history SCr value(s) and pre-
operative SCr). In our cohort 30.0 % of the patients had only the pre-operative SCr value 
available. In 49.3 % the lowest history SCr was lower than or equal to the pre-operative SCr, 
while in 20.7 % the pre-operative SCr was lower than the lowest history SCr. The details for 
calculation of UO are outlined by our group [21]. Note that UO was registered hourly in the ICU 
only. 
SECONDARY ENDPOINT 
The secondary endpoint was AKI stage ≥ 2 within 12 h after t1. 
ETHICS APPROVAL AND CONSENT TO PARTICIPATE 
The Ethical Committee of Ghent University Hospital approved this study (Belgian Registration 
Number of the study: B670201213147). All patients or their legally authorized representatives 
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provided written informed consent. We respected the Declaration of Helsinki and the Good 
Clinical Practice Guidelines. 
PROSPECTIVE SAMPLE AND DATA COLLECTION 
The first collection of blood and urine was after the induction of anaesthesia and before the start 
of surgery (time 0 (t0) on the day of surgery (dsurgery)). The rest of the specimens (n = 7) were 
collected post-operatively, starting at ICU admission (t1) and then at 2 h (t2), 4 h (t3), 6 h, 12 h, 
24 h and 48 h after ICU admission. If the patient was discharged to the Midcare unit before 24 h 
or 48 h, those samples were collected there. Whenever possible, the routine collection times were 
followed (i.e., at 4 pm on the first post-operative day (d1post-op) and at 6 am on the second post-
operative day (d2post-op)). The sample collection times for a fictional patient who underwent 
surgery in the morning are outlined on the timeline in Supplemental Figure S2A, while those for a 
fictional patient who underwent surgery in the afternoon are outlined on the timeline in 
Supplemental Figure S2B. 
These paired blood and urine samples were collected by standard methods and centrifuged by 
standard protocols, as described in Chapter 3 [193]. Serum and urine supernatants were stored at -
80°C and thawed at room temperature immediately prior to analysis. Clinical data needed to 
complete the individual clinical research files (Supplemental Table S2) were extracted from the 
hospital records by study coordinators. Samples were anonymized as were clinical data. All 
technicians were blinded to clinical data. 
BIOMARKER ANALYSIS AND SINGLE-BIOMARKER DIAGNOSTIC TEST POSSIBILITIES 
The CHI3L1 analysis was performed in-house. We measured the concentration of CHI3L1 by a 
sandwich ELISA technique (DC3L10, R&D Systems, Minneapolis, MN, USA). Analyses 
performed externally were Cr and UNGAL. The Cobas c502 measured the concentration of Cr 
by a kinetic rate-blanked Jaffé assay (commercial reagents, Roche Diagnostics, Basel, 
Switzerland), whereas the Modular P measured the concentration of UNGAL by a PETIA 
 technique (ST001-3CA, BioPorto, Hellerup, Denmark). All details were described in Chapter 3 
[193], except for the standard sample dilution scheme used in the CHI3L1 ELISA, which is 
presented in Supplemental Table S3. For blood samples that were collected at routine collection 
times, a SCr concentration was already available in the hospital records. Based on the temporal 
relationship of the predictive value of UNGAL for CSA-AKI [135], we measured this biomarker 
at t1 and t3 only. 
Besides UCHI3L1 and UNGAL, we also evaluated UCHI3L1 and UNGAL corrected for urine 
dilution by using the ratio to UCr as diagnostic test. Besides SCr, we also evaluated ΔSCrtx-t0 as 
diagnostic test, representing the absolute change in SCr between SCrtx and SCrt0. The most recent 
SCr value recorded prior to surgery was considered as SCrt0. 
DEFINING ACUTE TUBULAR DAMAGE AND SUBCLINICAL AKI 
Following the recommendations of de Geus et al., acute tubular damage was defined as a CSA-
NGAL score of 2 or greater, i.e. either as UNGALt1 or UNGALt3 ≥ 150 ng/ml or as ΔUNGALt3-
t1 > 100 ng/ml with UNGALt3 ≥ 125 ng/ml [195]. Subclinical AKI was defined when there was 
acute tubular damage (according to the ‘de Geus criteria’) and absence of AKI according to the 
KDIGO definition. 
DEFINING GOOD AND EXCELLENT BIOMARKERS 
An AUC-ROC of 0.750 or greater was considered to represent a good biomarker, whereas an 
AUC-ROC of 0.900 or greater was considered to represent an excellent biomarker [196]. 
STATISTICAL ANALYSIS 
The principal statistical analysis was based on comparison of the AUC-ROCs of UCHI3L1 with 
those of UNGAL, more frequently assessed early measurements of SCr, and various two-
biomarker panels for predicting both defined endpoints. It was performed in MedCalc 15.2.1 
(MedCalc Software, Oostende, Belgium). The unpaired comparison of a variable between two 
independent samples was done in SPSS 22 (IBM, Armonk, NY, USA). Categorical variables were 
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analysed with Fisher’s exact or the Chi-square test, and continuous variables with the 
nonparametric Mann-Whitney U test. Additionally, we calculated the 95 % CI for a proportion 
using the Wilson procedure without a correction for continuity [145, 146]. For all analyses, two-
sided P values < 0.05 were considered statistically significant. All details and a description of how 
the biomarkers were introduced into the statistical programs are provided in Chapter 3 [193]. 
IV. Results (see also section VII. “Supplemental Material”) 
INCIDENCE OF THE PRIMARY ENDPOINT, CHARACTERISTICS OF THE PATIENTS AND 
PROCEDURES, AND SHORT-TERM PATIENT OUTCOMES 
The flow of patients during the study is illustrated in Figure 1. The initial enrolment cohort 
consisted of 211 patients. In the primary endpoint analysis, 8 patients who already had AKI stage 
≥ 1 at t0 (n = 3) or t1 were excluded, resulting in a total number of 203 patients for analysis. 
Within 48 h after t1, 95 patients (46.8 %) had developed AKI: 67 (70.5 %) were classified as stage 
1, 19 (20.0 %) as stage 2 and 9 (9.5 %) as stage 3. Three patients received RRT starting on d2post-op. 
Duration of RRT was 3 d in 2 patients and 14 d in 1 patient. The flow of patients over different 
diagnostic windows for AKI is illustrated in Figure 1. The limited extent to which the UO 
criterion identified AKI patients is illustrated in Supplemental Figure S3. Median time to AKI 
diagnosis was 12.2 h (IQR: 7.2-18.4 h). Subclinical AKI, which was missed by KDIGO, occurred 
in 5.1 % of the patients (Figure 2).  
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Figure 1 | Flow diagram of patient enrolment and primary endpoint analysis 
aPlanned ≥ 4 h in advance 
bKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO [11] 
cKDOQI definitions for the diagnosis and staging of CKD [144] 
d≤ 3 mo before 
Abbreviations: AKI acute kidney injury, CKD chronic kidney disease, ICU intensive care unit, 
KDIGO Kidney Disease | Improving Global Outcomes, KDOQI Kidney Disease Outcomes 
Quality Initiative, No. number, SCr serum creatinine, UO urine output 
 
Figure 2 | 
Combining 
functional and 
damage 
biomarkers 
simultaneously 
to delineate the 
spectrum of 
acute kidney 
injury 
Patients of the 
primary analysis 
cohort (n = 203) 
who had no 
UNGALt1 or 
UNGALt3 
concentration 
available were 
excluded. Missing 
UNGALt1 
occurred in 5 
patients, and 
missing 
UNGALt3 in 1 patient, resulting in a total of 197 patients. Following the recommendations of de 
Geus et al., acute tubular damage was defined as a CSA-NGAL score of 2 or greater, i.e. either as 
UNGALt1 or UNGALt3 ≥ 150 ng/ml or as ΔUNGALt3-t1 > 100 ng/ml with UNGALt3 ≥ 125 
ng/ml. Subclinical AKI was defined when there was acute tubular damage (according to the ‘de 
Geus criteria’) and absence of AKI according to the KDIGO definition. In this way 84.6 % of 
AKI in our specific cohort (i.e., 77/[77+14]) was classified as AKI without acute tubular damage. 
Further, we found that when there was acute tubular damage, 41.7 % of these patients had no 
AKI according to the KDIGO definition (i.e., subclinical AKI). 
Abbreviations: AKI acute kidney injury, CSA cardiac surgery-associated, KDIGO Kidney 
Disease | Improving Global Outcomes, t1 time of intensive care unit admission, t3 4 h after 
intensive care unit admission, UNGAL urinary neutrophil gelatinase-associated lipocalin 
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 Table 1 summarizes the characteristics of the patients and procedures at baseline. Compared 
with patients without AKI, patients who developed AKI within 48 h after t1 were older; had a 
higher body mass index (BMI); a lower eGFR; a higher prevalence of diabetes mellitus (DM) 
type 2; a higher predicted operative mortality, which was estimated by the simple additive 
European system for cardiac operative risk evaluation (EuroSCORE); more combined surgical 
procedures; and a higher prevalence of diuretic treatment at home. 
Table 1 | Characteristics of the patients and procedures at baseline as well as short-term 
patient outcomes 
 Total AKI stage ≥ 1 
within 48 ha 
No AKI within 48 
ha 
P value 
Number of patients 203 (100 %) 
[98.1-100 %] 
95 (46.8 %) 
[40.1-53.7 %] 
108 (53.2 %) 
[46.3-59.9 %] 
NA 
Characteristics 
Male sex 133 (65.5 %) 
[58.7-71.7 %] 
65 (68.4 %) 
[58.5-76.9 %] 
68 (63.0 %) 
[53.6-71.5 %] 
0.461 
White race 202 (99.5 %) 
[97.3-99.9 %] 
95 (100 %) 
[96.1-100 %] 
107 (99.1 %) 
[94.9-99.8 %] 
1.000 
Age (y)b 70.0 (61.0-76.0) 74.0 (65.0-80.0) 67.0 (58.0-75.0) < 0.001 
BMI 27 (24-29) 27 (25-31) 26 (23-29) 0.004 
Medical history 
Reference renal function 
SCr (mg/dl) 0.90 (0.75-1.05) 0.99 (0.81-1.16) 0.82 (0.70-0.95) < 0.001 
eGFRCKD-EPI 
(ml/min/1.73 m2) 
82 (64-94) 73 (54-85) 87 (77-97) < 0.001 
DM    0.025 
Type 1 2 (1.0 %) 
[0.3-3.5 %] 
2 (2.1 %) 
[0.6-7.4 %] 
0 (0.0 %) 
[0.0-3.4 %] 
 
Type 2 46 (22.7 %) 
[17.4-28.9 %] 
28 (29.5 %) 
[21.2-39.3 %] 
18 (16.7 %) 
[10.8-24.8 %] 
 
No DM 155 (76.4 %) 
[70.1-81.7 %] 
65 (68.4 %) 
[58.5-76.9 %] 
90 (83.3 %) 
[75.2-89.2 %] 
 
Heart failure    0.252 
NYHA class I 145 (71.4 %) 
[64.9-77.2 %] 
64 (67.4 %) 
[57.4-76.0 %] 
81 (75.0 %) 
[66.1-82.2 %] 
 
NYHA class II 36 (17.7 %) 
[13.1-23.6 %] 
17 (17.9 %) 
[11.5-26.8 %] 
19 (17.6 %) 
[11.6-25.8 %] 
 
NYHA class III 20 (9.9 %) 
[6.5-14.7 %] 
12 (12.6 %) 
[7.4-20.8 %] 
8 (7.4 %) 
[3.8-13.9 %] 
 
NYHA class IV 2 (1.0 %) 
[0.3-3.5 %] 
2 (2.1 %) 
[0.6-7.4 %] 
0 (0.0 %) 
[0.0-3.4 %] 
 
Clinical examination 
Blood pressure (mmHg) 
Systolic 134 (122-149) 132 (122-150) 134 (120-149) 0.704 
Diastolic 72 (64-78) 72 (63-78) 71 (66-78) 0.619 
Mean 93 (85-101) 92 (84-102) 93 (86-100) 0.734 
Heart rhythm    0.074 
Atrial fibrillation 16 (7.9 %) 
[4.9-12.4 %] 
11 (11.6 %) 
[6.6-19.6 %] 
5 (4.6 %) 
[2.0-10.4 %] 
 
Normal sinus 187 (92.1 %) 84 (88.4 %) 103 (95.4 %)  
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 Total AKI stage ≥ 1 
within 48 ha 
No AKI within 48 
ha 
P value 
rhythm [87.6-95.1 %] [80.4-93.4 %] [89.6-98.0 %] 
Heart rate in normal 
sinus rhythm (bpm) 
N = 187 
69 (61-79) 70 (62-81) 69 (60-76) 0.143 
Distribution of 
ejection fraction 
   0.531 
≤ 20 % 5 (2.5 %) 
[1.1-5.6 %] 
4 (4.2 %) 
[1.6-10.3 %] 
1 (0.9 %) 
[0.2-5.1 %] 
 
21-30 % 3 (1.5 %) 
[0.5-4.3 %] 
2 (2.1 %) 
[0.6-7.4 %] 
1 (0.9 %) 
[0.2-5.1 %] 
 
31-50 % 33 (16.3 %) 
[11.8-22.0 %] 
16 (16.8 %) 
[10.6-25.6 %] 
17 (15.7 %) 
[10.1-23.8 %] 
 
> 50 % 119 (58.6 %) 
[51.7-65.2 %] 
55 (57.9 %) 
[47.8-67.3 %] 
64 (59.3 %) 
[49.8-68.1 %] 
 
Index surgical procedure 
EuroSCORE 5 (3-8) 6 (4-9) 5 (2-7) 0.004 
Type of cardiac 
surgical procedure 
   0.005 
Isolated CABG 93 (45.8 %) 
[39.1-52.7 %] 
34 (35.8 %) 
[26.9-45.8 %] 
59 (54.6 %) 
[45.2-63.7 %] 
 
Isolated valve repair 
or replacement 
55 (27.1 %) 
[21.4-33.6 %] 
28 (29.5 %) 
[21.2-39.3 %] 
27 (25.0 %) 
[17.8-33.9 %] 
 
CABG and valve 
repair or 
replacement 
34 (16.7 %) 
[12.2-22.5 %] 
25 (26.3 %) 
[18.5-36.0 %] 
9 (8.3 %) 
[4.4-15.1 %] 
 
Aortic root 12 (5.9 %) 
[3.4-10.0 %] 
5 (5.3 %) 
[2.3-11.7 %] 
7 (6.5 %) 
[3.2-12.8 %] 
 
Other 9 (4.4 %) 
[2.3-8.2 %] 
3 (3.2 %) 
[1.1-8.9 %] 
6 (5.6 %) 
[2.6-11.6 %] 
 
ECC    0.516 
Yes 179 (88.2 %) 
[83.0-91.9 %] 
82 (86.3 %) 
[78.0-91.8 %] 
97 (89.8 %) 
[82.7-94.2 %] 
 
No 24 (11.8 %) 
[8.1-17.0 %] 
13 (13.7 %) 
[8.2-22.0 %] 
11 (10.2 %) 
[5.8-17.3 %] 
 
Duration of ECC 
(min) 
N = 179 
91.5 (70.8-123.3) 92.0 (70.3-131.3) 91.5 (70.3-117.8) 0.527 
Priming volume of 
ECC pump (ml) 
N = 179 
1300 (1200-1500) 1300 (1200-1500) 1300 (1150-1400) 0.246 
Duration of aortic 
clamp during ECC 
(min) 
N = 179 
56.0 (42.8-82.0) 62.0 (45.0-88.0) 55.0 (40.5-74.5) 0.174 
Duration of 
ischemia during 
ECC (min) 
N = 179 
54.0 (39.0-78.0) 61.0 (43.0-81.0) 52.0 (37.8-70.5) 0.164 
Duration of surgery 
(h) 
4.6 (3.9-5.2) 4.7 (3.9-5.3) 4.5 (3.9-5.1) 0.196 
IABP peri-
operatively 
7 (3.4 %) 
[1.7-6.9 %] 
2 (2.1 %) 
[0.6-7.4 %] 
5 (4.6 %) 
[2.0-10.4 %] 
0.452 
Medication 
Statins 127 (62.6 %) 
[55.7-68.9 %] 
63 (66.3 %) 
[56.3-75.0 %] 
64 (59.3 %) 
[49.8-68.1 %] 
0.313 
ACE inhibitors 56 (27.6 %) 
[21.9-34.1 %] 
28 (29.5 %) 
[21.2-39.3 %] 
28 (25.9 %) 
[18.6-34.9 %] 
0.638 
ARBs 7 (3.4 %) 6 (6.3 %) 1 (0.9 %) 0.052 
  Total AKI stage ≥ 1 
within 48 ha 
No AKI within 48 
ha 
P value 
[1.7-6.9 %] [2.9-13.1 %] [0.2-5.1 %] 
Diuretics 51 (25.1 %) 
[19.7-31.5 %] 
36 (37.9 %) 
[28.8-47.9 %] 
15 (13.9 %) 
[8.6-21.7 %] 
< 0.001 
NSAIDs 4 (2.0 %) 
[0.8-5.0 %] 
1 (1.1 %) 
[0.2-5.7 %] 
3 (2.8 %) 
[0.9-7.9 %] 
0.624 
Corticosteroids 13 (6.4 %) 
[3.8-10.6 %] 
8 (8.4 %) 
[4.3-15.7 %] 
5 (4.6 %) 
[2.0-10.4 %] 
0.390 
Tacrolimus 0 (0.0 %) 
[0.0-1.9 %] 
0 (0.0 %) 
[0.0-3.9 %] 
0 (0.0 %) 
[0.0-3.4 %] 
NA 
Cyclosporine 2 (1.0 %) 
[0.3-3.5 %] 
2 (2.1 %) 
[0.6-7.4 %] 
0 (0.0 %) 
[0.0-3.4 %] 
0.218 
Aminoglycosides 3 (1.5 %) 
[0.5-4.3 %] 
1 (1.1 %) 
[0.2-5.7 %] 
2 (1.9 %) 
[0.5-6.5 %] 
1.000 
Corticosteroids 
intra-operatively 
0 (0.0 %) 
[0.0-1.9 %] 
0 (0.0 %) 
[0.0-3.9 %] 
0 (0.0 %) 
[0.0-3.4 %] 
NA 
Iodinated contrast d 
72 h before surgery 
37 (18.2 %) 
[13.5-24.1 %] 
14 (14.7 %) 
[9.0-23.2 %] 
23 (21.3 %) 
[14.6-29.9 %] 
0.275 
Outcomes 
RRT in ICU 3 (1.5 %) 
[0.5-4.3 %] 
3 (3.2 %) 
[1.1-8.9 %] 
0 (0.0 %) 
[0.0-3.4 %] 
0.101 
ICU LOS (d) 1 (1-3) 2 (1-3) 1 (1-2) < 0.001 
Hospital LOS (d) 12 (9-16) 13 (10-20) 10 (9-13) < 0.001 
Data represent number (proportion) [95 % CI of proportion] for categorical variables and median (IQR) for 
continuous variables. 
aKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
bDetermined at the day of surgery 
Abbreviations: ACE angiotensin-converting enzyme, AKI acute kidney injury, ARB angiotensin-II receptor 
blocker, BMI body mass index, bpm beats per minute, CABG coronary artery bypass grafting, CI confidence 
interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, DM diabetes mellitus, ECC 
extracorporeal circulation, eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac 
Operative Risk Evaluation, h hour, IABP intra-aortic balloon pump, ICU intensive care unit, IQR interquartile 
range, KDIGO Kidney Disease | Improving Global Outcomes, LOS length of stay, min minute, no. number, 
NSAID nonsteroidal anti-inflammatory drug, NYHA New York Heart Association, RRT renal replacement 
therapy, SCr serum creatinine, UO urine output 
 
Peri-operative characteristics of the patients and procedures are provided in Supplemental Table S4. 
In comparison with patients without AKI, patients who developed AKI within 48 h after t1 had 
a higher SOFA score; a higher white blood cell count; a higher serum C-reactive protein 
concentration; a more positive fluid balance; a higher number of plasma units that were 
transfused; and a higher prevalence of vasopressor, milrinone and diuretic treatment. 
AKI patients had a longer ICU and hospital LOS (Table 1).  
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INCIDENCE OF THE SECONDARY ENDPOINT 
In the secondary endpoint analysis, 1 patient who already had AKI stage ≥ 2 at t0 was excluded, 
resulting in a total number of 210 patients for analysis. Within 12 h after t1, 5 patients (2.4 %) 
had developed AKI stage ≥ 2: all 5 (100 %) were classified as stage 2. The flow of patients over 
different diagnostic windows for AKI stage ≥ 2 is illustrated in Supplemental Figure S4. 
BIOMARKER PERFORMANCES FOR PREDICTION OF THE PRIMARY ENDPOINT 
In the early post-operative period, only the functional biomarker SCr was a good predictor of 
AKI within 48 h after t1, showing the highest AUC-ROC at t3 (0.792; 95 % CI: 0.728-0.847) 
(Figure 3). The information in Figure 3 is summarized in numerical format in Supplemental Tables 
S5B-D, including also the performances of the urinary renal stress or damage biomarkers 
corrected for urine dilution by using the ratio to UCr. Table S5A reports the performances of the 
biomarkers measured at t0. 
BIOMARKER PERFORMANCES FOR PREDICTION OF THE SECONDARY ENDPOINT 
In the early post-operative period, SCHI3L1 combined with a urinary renal stress or damage 
biomarker, either UCHI3L1 or UNGAL, was a good predictor of AKI stage ≥ 2 within 12 h 
after t1, showing the highest AUC-ROC at t2 when combined with UCHI3L1 (0.773; 95 % CI: 
0.708-0.829) and at t3 when combined with UNGAL (0.774; 95 % CI: 0.710-0.830). However, 
the functional biomarkers SCr and ΔSCrtx-t0 outperformed these combinations with good to 
excellent performances, showing the highest AUC-ROC at t3 (0.857 for SCr; 95 % CI: 0.801-
0.902; 0.938 for ΔSCrtx-t0; 95 % CI: 0.860-1.000) (Figure 3). The information in Figure 3 is 
summarized in numerical format in Supplemental Tables S5B-D, including also the performances of 
the urinary renal stress or damage biomarkers corrected for urine dilution by using the ratio to 
UCr. Table S5A reports the performances of the biomarkers measured at t0.
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V. Discussion 
Additions to the published paper are marked in italic font. 
We found that in adult patients who underwent elective cardiac surgery, UCHI3L1 had 
inadequate predictive value for CSA-AKI. This was also true for the well-known tubular damage 
biomarker UNGAL. In contrast, more frequent assessment of the functional biomarker SCr in 
the early post-operative ICU period (first 4 h) had good to excellent predictive value for CSA-
AKI. 
Similar to others, our ICU routinely measures SCr at t1 and either around t4 (morning patient) or 
t5 (afternoon patient) in the early post-operative period. However, with ±50 % of AKI diagnosed 
before t5, of which ±50 % before t4, our study highlights the importance of more frequent SCr 
assessment in the first 4 h. This aids in early AKI diagnosis and could also reveal some cases of 
rapid reversal of AKI (i.e., “complete reversal of AKI by KDIGO criteria within 48 h of AKI 
onset” [47]). These findings are in accordance with those of a small retrospective study (n = 29) 
by Maciel et al. [197]. 
Novel findings of our study are the good to excellent performances of ΔSCrt1-t0, ΔSCrt2-t0 and 
ΔSCrt3-t0 for the prediction of AKI stage ≥ 2 within 12 h after t1. In accordance with these 
results, measurement of very early post-operative SCr changes, either absolute [187] or relative 
[198, 199], in adult [187, 198] and paediatric [199] cardiac surgery patients has been reported to 
provide prognostic utility for a subsequent diagnosis of AKI. However, each of these three 
studies was restricted by some of the following limitations: AKI was not defined according to 
KDIGO, including oliguric criteria; more severe AKI was not included as endpoint; SCr was less 
frequently assessed in the early post-operative period; and AUC-ROC analysis was not reported. 
The simultaneous utilization of functional and damage biomarkers, as in the CSA-NGAL score 
[195], permits to delineate the spectrum of AKI [133]. In this way 84.6 % of AKI in our specific 
cohort (i.e., 77/[77+14]) was classified as AKI without acute tubular damage, which can explain 
the inadequate performance of the urinary renal stress or damage biomarkers UCHI3L1 and 
 UNGAL for prediction of AKI stage ≥ 2 within 12 h after t1. Further, we found that when there was 
acute tubular damage, 41.7 % of these patients had no AKI according to the KDIGO definition (i.e., subclinical 
AKI). 
The capacity of the kidneys to increase baseline GFR under physiological or pathological kidney 
stress is described by the renal functional reserve of the glomerular function (RFR-G) 
(Supplemental Figure S5) [200]. In congestive heart failure, CKD and AKI, utilization of the RFR-G 
allows to replace (in part) the lost function, maintaining a normal whole-organ baseline GFR until 
±50 % of the nephrons are non-functional. The presence of both a normal RFR-G and a normal 
functioning nephron mass guarantees a low renal frailty or susceptibility [201]. Compared with 
the general ICU cohort of our previous AKI biomarker study [193], the patients in this study 
were older (median 70.0 vs. 60.0 y), more often diabetic (23.6 vs. 7.2 %), had a higher BMI 
(median 27 vs. 24) and a lower baseline eGFR (median 82 vs. 102 ml/min/1.73 m2), prompting 
the hypothesis that the patients in this study had a lower RFR-G or a lower functioning nephron 
mass. We further hypothesize that this lower RFR-G or lower functioning nephron mass decreased the incidence of 
subclinical AKI in this population by increasing the incidence of AKI with acute tubular damage. 
Our study is not the first to report inadequate diagnostic ability of UNGAL for moderate to 
severe CSA-AKI [192]. In their multicentre high-risk cohort with 21 % emergent surgeries, 
Parikh et al. reported an AUC-ROC of 0.67 (standard error: 0.04) for the prediction of AKI 
defined by receipt of RRT or doubling of SCr [168]. Interestingly, Koyner et al. found an AUC-
ROC of 0.88 (95 % CI: 0.73-0.99) for the prediction of AKI AKIN stage 3 in a cohort 
comparable to ours [202], indicating the importance of the severity of AKI in the diagnostic 
ability of UNGAL. 
Our study has several limitations. First, it is limited in being a single-centre study in elective 
cardiac surgery patients. However, baseline characteristics and the incidence of AKI suggest that 
our population is representative of cardiac surgery ICUs in developed countries. Second, our 
study is further limited by the relatively low incidence of AKI stage ≥ 2 within 12 h after t1 
Chapter 4 
Page | 133  
(secondary endpoint). Both the fact that we included only elective surgeries and the implemented 
narrow diagnostic window contribute to this constraint. As such, these biomarker data need to be 
further validated in larger multicentre prospective studies. Third, we did not measure the panel of 
G1 cell-cycle arrest biomarkers [TIMP-2]•[IGFBP7] [136], because it was not available at the start 
of our study. 
VI. Conclusions 
In summary, we demonstrated that more frequent assessment of the functional biomarker SCr in 
the early post-operative ICU period (first 4 h) after elective cardiac surgery in adult patients had 
good to excellent predictive value for CSA-AKI, indicating that routine SCr assessment must 
become more frequent in order to detect AKI more early. We found that AKI was 
predominantly without acute tubular damage in this cohort, which may explain the inadequate 
predictive value for CSA-AKI of the urinary renal stress or damage biomarkers UCHI3L1 and 
UNGAL. Further, we found that when there was acute tubular damage, more than 40 % of these patients had 
no AKI according to the KDIGO definition (i.e., subclinical AKI). These results need to be further 
validated in larger multicentre prospective studies.  
 VII. Supplemental Material 
SUPPLEMENTAL TABLES 
Table S1 | STROBE statement – checklist of items that should be included in the reports 
of cohort studies [143] 
 Item 
No. 
STROBE recommendation Fulfilled 
Title and abstract 
 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
Yes 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Yes 
Introduction 
Background / 
rationale 
2 Explain the scientific background and rationale for the investigation being 
reported 
Yes 
Objectives 3 State specific objectives, including any pre-specified hypotheses Yes 
Methods 
Study design 4 Present key elements of study design early in the paper Yes 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Yes 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Yes 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Yes 
Data sources / 
measurement 
8a For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
if there is more than one group 
Yes 
Bias 9 Describe any efforts to address potential sources of bias Yes 
Study size 10 Explain how the study size was arrived at Yes 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Yes 
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to control for 
confounding 
Yes 
(b) Describe any methods used to examine subgroups and interactions Yes 
(c) Explain how missing data were addressed Yes 
(d) If applicable, explain how loss to follow-up was addressed Yes 
(e) Describe any sensitivity analyses NA 
Results 
Participants 13a (a) Report numbers of individuals at each stage of study – e.g., numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
Yes 
(b) Give reasons for non-participation at each stage Yes 
(c) Consider use of a flow diagram Yes 
Descriptive 
data 
14a (a) Give characteristics of study participants (e.g., demographic, clinical, 
social) and information on exposures and potential confounders 
Yes 
(b) Indicate number of participants with missing data for each variable of 
interest 
Yes 
(c) Summarize follow-up time (e.g., average and total amount) Yes 
Outcome data 15a Report numbers of outcome events or summary measures over time Yes 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (e.g., 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Yes 
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 Item 
No. 
STROBE recommendation Fulfilled 
(b) Report category boundaries when continuous variables were categorized NA 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
NA 
Other analyses 17 Report other analyses done - e.g., analyses of subgroups and interactions, 
and sensitivity analyses 
Yes 
Discussion 
Key results 18 Summarize key results with reference to study objectives Yes 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Yes 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Yes 
Generalizability 21 Discuss the generalizability (external validity) of the study results Yes 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based 
Yes 
aGive information separately for exposed and unexposed groups 
Abbreviations: NA not applicable, No. number, STROBE STrengthening the Reporting of OBservational studies in 
Epidemiology 
 
Table S2 | Data collected in the clinical research file 
I. Patient information 
A. Study identification A / □□□ 
B. Date of birth □□ / □□ / □□□□ 
C. Sex □ Male or □ Female 
D. Race □ Caucasian or □ Black 
E. Smoking status □ Current smoker or □ Ex-smoker or □ Non-smoker 
• Smoking history: cumulative number of pack-
yearsa 
▬ Textbox 
F. Alcohol use □ Yes or □ No 
• Quantity of alcohol intake ▬ Textbox 
G. Weight (kg) ▬ Textbox 
H. Length (cm) ▬ Textbox 
I. BMI ▬ Textbox 
II. Medical data 
A. Medical history 
1. NYHA class □ I or □ II or □ III or □ IV 
2. DM □ Type 1 or □ Type 2 or □ No DM 
• Therapy for DM □ Insulin therapy or □ Therapy per os 
3. Other comorbidities ▬ Textbox 
4. Pre-operative medication list ▬ Textbox 
B. Admission diagnosis 
1. Date of hospital admission □□ / □□ / □□□□ 
• Diagnosis at hospital admission ▬ Textbox 
2. Date of ICU admission □□ / □□ / □□□□ 
• Diagnosis at ICU admission ▬ Textbox 
C. Baseline registrations 
1. Blood pressure (mmHg; highest)  
i. Systolic / Diastolic ▬ Textbox 
ii. Mean ▬ Textbox 
2. Heart rhythm □ Atrial fibrillation or □ Normal sinus rhythm 
3. Heart rate in normal sinus rhythm (bpm) ▬ Textbox 
4. Ejection fraction (%)  
i. Pre-operative ▬ Textbox 
 ii. Post-operative ▬ Textbox 
5. Fractional shortening (%)  
i. Pre-operative ▬ Textbox 
ii. Post-operative ▬ Textbox 
6. Reference SCr ▬ Textbox 
7. Reference eGFRCKD-EPI ▬ Textbox 
8. Medication  
i. Statins □ Yes or □ No 
ii. ACE inhibitors □ Yes or □ No 
iii. ARBs □ Yes or □ No 
iv. Diuretics □ Yes or □ No 
v. NSAIDs □ Yes or □ No 
vi. Corticosteroids □ Yes or □ No 
vii. Tacrolimus □ Yes or □ No 
viii. Cyclosporine □ Yes or □ No 
ix. Aminoglycosides □ Yes or □ No 
x. Iodinated contrast pre-operatively □ Yes or □ No 
• Date □□ / □□ / □□□□ 
xi. Corticosteroids intra-operatively □ Yes or □ No 
D. Index surgical procedure 
1. EuroSCORE ▬ Textbox 
2. Type of cardiac surgical procedure ▬ Textbox 
3. Duration of surgery (h) ▬ Textbox 
4. IABP peri-operatively □ Yes or □ No 
5. ECC data  
i. Mean blood pressure on pump ▬ Textbox 
ii. Diuretics on pump □ Yes or □ No 
iii. Diuresis on pump (ml) ▬ Textbox 
iv. Priming volume of pump (ml) ▬ Textbox 
v. Haematocrit (%)  
• Before pump ▬ Textbox 
• After pump ▬ Textbox 
vi. SCr (mg/dl)  
• Before pump ▬ Textbox 
• After pump ▬ Textbox 
vii. Duration of ECC (min) ▬ Textbox 
viii. Duration of aortic clamp (min) ▬ Textbox 
ix. Duration of ischemia (min) ▬ Textbox 
E. Study follow-up (to be filled in for dsurgery, d1post-op and d2post-op) 
1. RRT □ Yes or □ No 
• Date □□ / □□ / □□□□ 
2. SOFA score ▬ Textbox 
3. WBC count (103/μl) ▬ Textbox 
4. Serum CRP (mg/l) ▬ Textbox 
5. Fluid balance ▬ Textbox 
• Total fluid IN (ml) ▬ Textbox 
• Total fluid OUT (ml) ▬ Textbox 
6. Transfusions  
i. Whole blood □ Yes or □ No 
• Number of units transfused ▬ Textbox 
ii. Plasma □ Yes or □ No 
• Number of units transfused ▬ Textbox 
iii. Platelets □ Yes or □ No 
• Number of units transfused ▬ Textbox 
7. Medication  
i. Milrinone (PDE3 inhibitor) □ Yes or □ No 
ii. Vasopressor(s) □ Yes or □ No 
• Generic name(s) ▬ Textbox 
iii. Antibiotic(s) □ Yes or □ No 
• Generic name(s) ▬ Textbox 
iv. Statins □ Yes or □ No 
Chapter 4 
Page | 137  
v. ACE inhibitors □ Yes or □ No 
vi. ARBs □ Yes or □ No 
vii. Diuretics □ Yes or □ No 
viii. Tacrolimus □ Yes or □ No 
ix. Cyclosporine □ Yes or □ No 
x. Iodinated contrast post-operatively □ Yes or □ No 
aA pack-year is defined as twenty cigarettes smoked every day for one year 
Abbreviations: ACE angiotensin-converting enzyme, ARB angiotensin-II receptor blocker, BMI body mass 
index, bpm beats per minute, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, CRP C-reactive 
protein, DM diabetes mellitus, ECC extracorporeal circulation, eGFR estimated glomerular filtration rate, 
EuroSCORE European System for Cardiac Operative Risk Evaluation, IABP intra-aortic balloon pump, ICU 
intensive care unit, min minute, NSAID non-steroidal anti-inflammatory drug, NYHA New York Heart 
Association, PDE3 phosphodiesterase 3, post-op post-operatively, RRT renal replacement therapy, SCr serum 
creatinine, SOFA Sepsis-related Organ Failure Assessment, WBC white blood cell 
 
Table S3 | Dilution of serum and urine samples for the initial measurement of CHI3L1 
by enzyme-linked immunosorbent assay 
Time point of the study Estimated dilution for serum sample Estimated dilution for urine sample 
t0 1/100 1/2 
t1 1/100 1/2 
t2 1/200 1/4 
t3 1/200 1/4 
t4 1/200 1/4 
t5 1/500 1/4 
t6 1/500 1/4 
t7 1/500 1/4 
Abbreviations: CHI3L1 chitinase 3-like protein 1 
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 Table S5A | Biomarker performances at t0 for prediction of acute kidney injury 
 AKI stage ≥ 2 within 12 h after t1a AKI stage ≥ 1 within 48 h after t1a 
 AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
[SCHI3L1]•[UCHI3L1] 0.595 0.524 0.663 0.599 0.526 0.668 
[SCr]•[SCHI3L1] 0.580 0.510 0.648 0.705 0.637 0.768 
[SCr]•[UCHI3L1] 0.669 0.599 0.733 0.582 0.510 0.652 
SCHI3L1 0.508 0.438 0.578 0.660 0.590 0.725 
UCHI3L1/UCr 0.530 0.459 0.601 0.518 0.445 0.589 
UCHI3L1 0.578 0.507 0.647 0.532 0.459 0.603 
SCr 0.696 0.629 0.758 0.709 0.641 0.771 
aKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 serum chitinase 3-like 
protein 1, SCr serum creatinine, t0 time after the induction of anaesthesia and before the start of surgery, t1 time 
of intensive care unit admission, UCHI3L1 urinary chitinase 3-like protein 1, UCr urinary creatinine, UO urine 
output 
 
Table S5B | Biomarker performances at t1 for prediction of acute kidney injury 
 AKI stage ≥ 2 within 12 h after t1a AKI stage ≥ 1 within 48 h after t1a 
 AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
ΔSCr 0.833 0.776 0.881 0.504 0.433 0.575 
[SCHI3L1]•[UNGAL] 0.659 0.590 0.724 0.646 0.575 0.713 
[SCHI3L1]•[UCHI3L1] 0.633 0.562 0.699 0.621 0.549 0.690 
[UCHI3L1]•[UNGAL] 0.615 0.544 0.682 0.570 0.497 0.640 
[SCr]•[SCHI3L1] 0.611 0.541 0.678 0.725 0.658 0.786 
[SCr]•[UNGAL] 0.718 0.651 0.779 0.661 0.590 0.726 
[SCr]•[UCHI3L1] 0.665 0.596 0.730 0.598 0.526 0.667 
SCHI3L1 0.505 0.435 0.575 0.671 0.601 0.735 
UNGAL/UCr 0.648 0.578 0.713 0.599 0.528 0.668 
UNGAL 0.650 0.581 0.716 0.583 0.511 0.653 
UCHI3L1/UCr 0.631 0.561 0.698 0.557 0.484 0.628 
UCHI3L1 0.621 0.550 0.688 0.556 0.484 0.627 
SCr 0.780 0.718 0.834 0.735 0.669 0.794 
aKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, ΔSCr represents ΔSCrt1-t0, which is the absolute change in SCr between SCrt1 and SCrt0, 
KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 serum chitinase 3-like protein 1, SCr serum 
creatinine, t0 time after the induction of anaesthesia and before the start of surgery, t1 time of intensive care unit 
admission, UCHI3L1 urinary chitinase 3-like protein 1, UCr urinary creatinine, UNGAL urinary neutrophil 
gelatinase-associated lipocalin, UO urine output 
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Table S5C | Biomarker performances at t2 for prediction of acute kidney injury 
 AKI stage ≥ 2 within 12 h after t1a AKI stage ≥ 1 within 48 h after t1a 
 AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
ΔSCr 0.915 0.840 0.991 0.556 0.471 0.641 
[SCHI3L1]•[UCHI3L1] 0.773 0.708 0.829 0.643 0.571 0.711 
[SCr]•[SCHI3L1] 0.725 0.658 0.786 0.695 0.625 0.760 
[SCr]•[UCHI3L1] 0.746 0.680 0.805 0.651 0.579 0.718 
SCHI3L1 0.628 0.557 0.695 0.649 0.577 0.716 
UCHI3L1/UCr 0.662 0.593 0.726 0.574 0.502 0.644 
UCHI3L1 0.686 0.617 0.748 0.575 0.503 0.645 
SCr 0.821 0.760 0.871 0.761 0.694 0.819 
aKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, ΔSCr represents ΔSCrt2-t0, which is the absolute change in SCr between SCrt2 and SCrt0, 
KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 serum chitinase 3-like protein 1, SCr serum 
creatinine, t0 time after the induction of anaesthesia and before the start of surgery, t1 time of intensive care unit 
admission, t2 2 hours after intensive care unit admission, UCHI3L1 urinary chitinase 3-like protein 1, UCr urinary 
creatinine, UO urine output 
 
Table S5D | Biomarker performances at t3 for prediction of acute kidney injury 
 AKI stage ≥ 2 within 12 h after t1a AKI stage ≥ 1 within 48 h after t1a 
 AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
AUC-ROC Lower 
limit of 95 
% CI 
Upper 
limit of 95 
% CI 
ΔSCr 0.938 0.860 1.000 0.643 0.562 0.724 
[SCHI3L1]•[UNGAL] 0.774 0.710 0.830 0.665 0.594 0.731 
[SCHI3L1]•[UCHI3L1] 0.758 0.692 0.816 0.684 0.613 0.749 
[UCHI3L1]•[UNGAL] 0.678 0.610 0.741 0.633 0.563 0.700 
[SCr]•[SCHI3L1] 0.814 0.754 0.866 0.723 0.654 0.785 
[SCr]•[UNGAL] 0.728 0.660 0.788 0.673 0.602 0.738 
[SCr]•[UCHI3L1] 0.754 0.688 0.812 0.725 0.656 0.786 
SCHI3L1 0.720 0.653 0.781 0.664 0.593 0.730 
UNGAL/UCr 0.649 0.579 0.713 0.600 0.529 0.669 
UNGAL 0.656 0.587 0.720 0.612 0.541 0.679 
UCHI3L1/UCr 0.653 0.584 0.718 0.617 0.546 0.685 
UCHI3L1 0.678 0.610 0.741 0.649 0.578 0.715 
SCr 0.857 0.801 0.902 0.792 0.728 0.847 
aKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, ΔSCr represents ΔSCrt3-t0, which is the absolute change in SCr between SCrt3 and SCrt0, 
KDIGO Kidney Disease | Improving Global Outcomes, SCHI3L1 serum chitinase 3-like protein 1, SCr serum 
creatinine, t0 time after the induction of anaesthesia and before the start of surgery, t1 time of intensive care unit 
admission, t3 4 hours after intensive care unit admission, UCHI3L1 urinary chitinase 3-like protein 1, UCr urinary 
creatinine, UNGAL urinary neutrophil gelatinase-associated lipocalin, UO urine output 
  
 SUPPLEMENTAL FIGURES 
Figure S1 | KDIGO definition and classification of acute kidney injury [11] 
aFor staging purposes, patients should be staged according to the criterion or criteria that give(s) 
them the highest stage. 
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global 
Outcomes, RRT renal replacement therapy, SCr serum creatinine, UO urine output 
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Figure S4 | Flow of patients over different diagnostic windows for AKI stage ≥ 2 
aPlanned ≥ 4 h in advance 
bKDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO 
cKDOQI definitions for the diagnosis and staging of CKD 
d≤ 3 mo before 
Abbreviations: AKI acute kidney injury, CKD chronic kidney disease, ICU intensive care unit, 
KDIGO Kidney Disease | Improving Global Outcomes, KDOQI Kidney Disease Outcomes 
Quality Initiative, No. number, SCr serum creatinine, UO urine output 
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he scientific aim of this dissertation was to provide clinical validation of 
the biomarker UCHI3L1 as early diagnostic or ‘predictive’ tool for 
emerging AKI in specific adult ICU settings. 
I. Main results of this dissertation 
In this dissertation we evaluated various biomarkers for early diagnosis or prediction of AKI in 
two different adult ICU settings. Our adult general ICU setting comprised patients who either 
underwent non-cardiac surgery or had a non-surgical reason for critical illness, and who had a 
respiratory SOFA score ≥ 2 or a cardiovascular SOFA score ≥ 1. In this cohort the UCHI3L1 
concentration at ICU admission could predict occurrence of AKI stage ≥ 2 within the next 12 h 
with an AUC-ROC of 0.792 (95 % CI: 0.726-0.849). This performance was similar to that of 
UNGAL (P = 0.587), which had an AUC-ROC of 0.748 (95 % CI: 0.678-0.810). In our adult 
elective cardiac surgery ICU setting early post-operative measurements (i.e., within 4 h after ICU 
admission) of both UCHI3L1 and UNGAL could less satisfactorily predict occurrence of AKI 
stage ≥ 2 within 12 h after ICU admission. The highest AUC-ROC value for UCHI3L1 was 
0.686 (95 % CI: 0.617-0.748) and for UNGAL 0.656 (95 % CI: 0.587-0.720). However, by using 
the CSA-NGAL score, we found that AKI was predominantly without acute tubular damage in 
this cohort, making us conclude that renal stress or damage biomarkers were not the most suited 
biomarkers to measure in these patients. On the other hand, also in this cohort renal stress or 
damage biomarkers were valuable tools as without UNGAL we would not have been able to 
identify the patients with subclinical AKI. As alternative, we demonstrated that more frequent 
assessment of the functional biomarker SCr in the early post-operative ICU period (first 4 h) was 
the best performing diagnostic tool in these patients. These key findings indicate that SCr 
assessment should be performed more frequently than in current routine clinical practice in order 
to detect CSA-AKI more early.  
T 
 II. A unifying hypothesis explaining the findings in adult cardiac surgery patients 
In our adult elective cardiac surgery ICU setting, specific patient characteristics prompted the 
hypothesis that these patients had a lower RFR-G or a lower functioning nephron mass than the 
patients in our adult general ICU setting. When the exposure (i.e., the cardiac surgical procedure) 
caused hypoperfusion with ischemia, it also elicited acute tubular damage as defined by the CSA-
NGAL score. We hypothesize that there was a lower risk of subclinical AKI, i.e. diagnostic rise in 
renal stress or damage biomarkers (e.g., UNGAL) without diagnostic rise in functional 
biomarkers (e.g., SCr) (Figure 1, upper left graph). Further, we hypothesize that in most AKI 
patients with acute tubular damage, the diagnostic rise in functional biomarkers occurred before 
the diagnostic rise in renal stress or damage biomarkers due to early failure (i.e., before the 
development of ischemia) in maintaining a normal whole-organ baseline GFR (Figure 1, upper 
right graph, clinical scenario a-b). Patients with a higher RFR-G or a higher functioning 
nephron mass may in a timely matter benefit more from measuring renal stress or damage 
biomarkers, as these biomarkers can then diagnose subclinical AKI (Figure 1, upper left graph) 
or predict occurrence of AKI (Figure 1, upper right graph, clinical scenario c-d). The lower 
graphs in Figure 1 also show the correlation between functional biomarkers, renal stress or 
damage biomarkers, and RFR-G and functioning nephron mass in patients where the exposure 
caused hypoperfusion without ischemia. Note that in a patient with a normal RFR-G and a 
normal functioning nephron mass there is a lower probability of reaching the diagnostic 
threshold of the functional biomarker (Figure 1, lower left graph), whereas in a patient with a 
subnormal RFR-G or a subnormal functioning nephron mass there is a higher probability of 
reaching the diagnostic threshold of the functional biomarker (Figure 1, lower right graph). 
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Figure 1 | Correlation between functional biomarkers (e.g., serum creatinine), renal 
stress or damage biomarkers (e.g., urinary neutrophil gelatinase-associated lipocalin), 
and renal functional reserve of the glomerular function and functioning nephron mass 
The 4 quadrants represent ‘no AKI and no acute tubular damage’ (lower left quadrant), ‘AKI 
without acute tubular damage’ (lower right quadrant), ‘subclinical AKI’ (upper left quadrant) and ‘AKI 
with acute tubular damage’ (upper right quadrant). 
The letters indicate reaching of a diagnostic threshold. Note that 2 different clinical scenarios are 
possible in the upper right graph. 
Upper graphs: The exposure (i.e., the cardiac surgical procedure) causes hypoperfusion with 
ischemia (indicated by the black colour of the kidneys) 
Lower graphs: The exposure (i.e., the cardiac surgical procedure) causes hypoperfusion without 
ischemia (indicated by the white colour of the kidneys) 
Left graphs: The patient has a normal RFR-G and a normal functioning nephron mass 
(indicated by the large kidneys) 
Right graphs: The patient has a subnormal RFR-G or a subnormal functioning nephron mass 
(indicated by the small kidneys) 
Abbreviations: AKI acute kidney injury, RFR-G renal functional reserve of the glomerular 
function 
c
d
a
ba
a
 III. The long and uncertain path to biomarker utility for AKI diagnosis 
A biomarker will not be widely used in the clinic unless all four steps in Table 1 have been 
successfully completed [203]. The decision that a biomarker is ‘reasonable and necessary’ (Table 
1) indirectly influences coverage by private insurance carriers [204]. 
Table 1 | Roadmap to biomarker utility in the United States (based on [204]) 
Step 1 | Biomarker identification 
   File patent application on 
invention 
Step 2 | Biomarker application 
   Describe preferred 
embodiments of 
invention 
Granting of patent by USPTO No granting of patent by USPTO 
 No use of biomarker for patient care 
 
Step 3 | Analytical and clinical validation 
 Document, through use 
of specific laboratory 
investigations, that 
analytical performance 
characteristics of IVD 
method are suitable and 
reliable 
Apply manufacturing 
controls that are adequate 
to ensure consistent 
manufacturing of finished 
IVD product 
Document, by conducting 
clinical trials, that clinical 
performance 
characteristics of IVD 
product are suitable and 
reliable 
FDA approval: ‘safe and 
effective’ 
No FDA approval  
 No use of biomarker for 
patient care 
 
   
Step 4 | Cost-benefit analysis 
   Conduct RCT 
CMS-
approval: 
'reasonable 
and 
necessary' 
No CMS-
approval 
  
Routine 
use of 
biomarker 
for patient 
care 
Use of 
biomarker 
for patient 
care 
  
Abbreviations: CMS Center for Medicare and Medicaid Services, FDA Food and Drug Administration, IVD In 
Vitro Diagnostic, RCT Randomized Controlled Trial, USPTO United States Patent and Trademark Office 
 
On the roadmap to biomarker utility for AKI diagnosis major hurdles are to be foreseen [205], 
which are briefly discussed in the following paragraphs.  
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KDIGO AS THE ‘BRONZE STANDARD’ 
It is of critical importance to understand that we do not have a true ‘gold standard’ for diagnosis 
of AKI when validating old (e.g., SCr) and novel biomarkers (e.g., UCHI3L1). Kidney biopsy 
information would seem a logical tool that may serve as such, however, it is important to realize 
that nearly all pathologists recognize that overt renal pathology is limited, only making a diagnosis 
of AKI in clinical context (i.e., basically intact renal morphology, compatible with AKI) [206]. 
Morphology complemented by immunostaining may enable the identification of an injury pattern 
that is apparently limited, or obscured by reparative processes [206]. Unlike a ‘gold standard’, a 
‘bronze standard’ can distort the apparent diagnostic performance of a novel biomarker [207], as 
illustrated in Table 2. This is related to the fact that renal stress or damage may not always be 
reflected by a decline in GFR (these are the false negatives using KDIGO (n = 6, Table 2), 
assuming that the novel biomarker is in fact 100 % sensitive and specific for AKI), and vice 
versa, that a decline in GFR may not always reflect renal stress or damage (these are the false 
positives using KDIGO (n = 8, Table 2), assuming that the novel biomarker is in fact 100 % 
sensitive and specific for AKI). Based on these calculations, it is indicated to use a ‘bronze 
standard’ that minimizes false positive misclassifications of disease status, particularly in clinical 
settings with relatively low expected incidence of true AKI. An appropriate AKI definition may 
be KDIGO stage ≥ 2 [207]. This AKI endpoint is less prone to prerenal azotaemia and 
fluctuations in baseline (or ‘reference’) SCr. Consistent with this suggestion, the multinational 
cross-sectional AKI-EPI study (n = 1,802) reported that KDIGO stages 2 (OR: 2.945; 95 % CI: 
1.382-6.276; P = 0.005) and 3 (OR: 6.884; 95 % CI: 3.876-12.228; P < 0.001), but not KDIGO 
stage 1 (OR: 1.679; 95 % CI: 0.890-3.169; P = 0.109), were still associated with increased in-
hospital mortality in adult ICU patients when adjusted for other variables that may explain 
mortality [36].  
 Table 2 | The effect of a ‘bronze standard’ on the sensitivity and specificity of a novel 
biomarker that is in fact 100 % sensitive and specific for AKI (based on [207]) 
 True AKI 
 AKI No AKI Total 
AKI according to KDIGO 14 8 22 
No AKI according to KDIGO 6 72 78 
Total 20 80 100 
 Sensitivity = 70 % Specificity = 90 %  
  
 AKI according to KDIGO 
 AKI No AKI Total 
Novel biomarker positive 14 6 20 
Novel biomarker negative 8 72 80 
Total 22 78 100 
 Apparent sensitivity = 64 % Apparent specificity = 92 %  
Abbreviations: AKI acute kidney injury, KDIGO Kidney Disease | Improving Global Outcomes 
 
SUPPORT OF NOVEL BIOMARKERS TO KDIGO 
Thanks to de Geus et al., from 2016 onwards acute tubular damage can be staged for severity 
according to defined UNGAL or plasma NGAL criteria in the cardiac surgery patient [195]. 
Additionally, novel biomarkers may also support KDIGO staging of AKI, correlating severity 
stages of renal stress or damage to severity stages of decreased renal function (Figure 2) [133]. In 
2013 ADQI concluded that there were insufficient renal stress or damage biomarker data to 
support KDIGO classification and thus also KDIGO definition of AKI (Figure 2). Today, we 
can state that NGAL already provides additional information to current functional biomarkers in 
cardiac surgery patients. Indeed, in the absence of diagnostic increases in SCr, NGAL detected 
patients with likely subclinical AKI who had an increased risk of adverse outcomes [208]. The 
reliability on cardiac troponin biomarkers to diagnose acute myocardial infarction in the absence 
of ST-elevation on electrocardiography in patients with unstable angina gives hope that one day 
clinicians will – in the appropriate clinical context – rely on renal stress or damage biomarkers to 
diagnose AKI in the absence of a positive KDIGO criterion [121]. 
NOVEL BIOMARKER THRESHOLD 
It is of critical importance to recognize that the threshold for identifying biomarker elevation of a 
novel renal stress or damage biomarker may be different in each clinical setting, particularly in the 
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context of sepsis. Considering UNGAL in patients without AKI, higher ‘baseline’ concentrations 
were reported for those with sepsis (median 138 ng/ml; 95 % CI: 39-324) than for those without 
sepsis (median 12 ng/ml; 95 % CI: 5-33) [209, 210]. Likewise, thresholds for identifying 
biomarker elevations are likely to be different in patients with CKD (i.e., generally higher) [133, 
211], making biomarker thresholds not only setting-dependent, but also population-dependent. 
Coming back to specifically septic patients, in analogy with UNGAL [157], a part of the urine 
component of CHI3L1 will likely originate from the circulating plasma pool. Indeed, a non-AKI-
specific increase in UCHI3L1 will likely occur when the transport maximum of CHI3L1 is 
reached, expressed as the maximum transporting capacity of the megalin receptor also used by 
NGAL [157]. In patients with systemic inflammatory response syndrome (SIRS), plasma 
CHI3L1 was associated with disease severity: the concentration increased gradually when moving 
from SIRS without infection through sepsis, severe sepsis, and septic shock [212]. Assessed by 
AUC-ROC analysis plasma CHI3L1 did not discriminate between SIRS only and sepsis, 
suggesting that CHI3L1 is a marker of severity of inflammation rather than bacterial load. We 
speculate that in patients with severe sepsis or septic shock but without AKI as defined by 
KDIGO, increased UCHI3L1 may perhaps reflect ‘subclinical’ AKI and not only increased 
filtered CHI3L1 from the circulating plasma pool. Compared to NGAL which is increased in 
urine upon UTI (the rate of catheter-associated UTI in the ICU is approximately 2.50 per 1,000 
catheter-days [213]), CHI3L1 may have the benefit of being less prone to this interference. 
Indeed, while bacterial infection leads to induction and secretion of NGAL by superficial 
epithelial cells facing the lumen of the bladder [214], and infiltrating neutrophils secrete NGAL in 
urine as well [214], neutrophil-derived CHI3L1 will probably contribute far less to UCHI3L1 in 
UTI patients. This hypothesis is based on the fact that the secondary granules in one neutrophil 
contain 0.16 pg CHI3L1 compared to 12 pg NGAL [161, 162]. Nevertheless, whether bacterial 
infection also leads to induction and secretion of CHI3L1 by the urothelium of the bladder needs 
to be investigated. 
 Figure 2 | Proposed novel criteria by the international and interdisciplinary organization 
Acute Dialysis Quality Initiative for diagnosis and staging of acute kidney injury using 
functional and renal stress or damage biomarkers (based on [133]) 
Abbreviations: KDIGO Kidney Disease | Improving Global Outcomes 
 
AETIOLOGY OF AKI 
Specific renal biomarkers are linked to specific segments in the nephron as are the site-specific 
actions of nephrotoxicants (Table 3). Consequently, monitoring of kidney injury molecule-1 
(Kim-1, a proximal tubule-specific urinary biomarker) in a patient treated with amphotericin B, 
which elicits distal tubule-specific toxicity, is not the best option (Table 3). The unique 
anatomical fingerprint of a renal biomarker thus determines its utility for AKI diagnosis in 
nephrotoxic AKI [83]. In line with this, it is likely that the utility for AKI diagnosis of novel renal 
stress or damage biomarkers will be aetiology-dependent in non-nephrotoxic AKI as well. 
Additionally, novel renal stress or damage biomarkers also have unique (patho)physiological 
fingerprints, on which we expounded in sections III.B.2.ii. “Kidney iron transport: role of neutrophil 
gelatinase-associated lipocalin” and III.B.3.iii. “Inflammation signalling cascades: role of chitinase 3-like 
protein 1” of Chapter 1. 
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 NOVEL BIOMARKER CONCENTRATION-TIME-COURSE 
It is of critical importance to realize that the concentration-time-course of a novel biomarker 
after stress or damage to the kidneys is unique. This is illustrated in Figure 3, where a decline in 
urinary alkaline phosphatase concentrations with time suggests that this pre-formed brush border 
enzyme is excreted in diminishing amounts after renal stress or damage [215], whereas a rise in 
UNGAL concentrations with time is consistent with induction of the this protein after renal 
stress or damage [215]. This highlights the likely ‘window of opportunity’ during which a 
particular biomarker could be used for triaging. The first early intervention study to test the 
concept that a renal stress or damage biomarker can triage patients at high risk of AKI to early 
treatment was the EARLYARF trial [216]. In this study the intervention was triggered by a 
positive reading of the biomarker panel [γ-glutamyltranspeptidase]•[alkaline phosphatase]. 
Unfortunately, the clinical test performance of this biomarker panel for prediction of emerging 
AKI was inadequate. The authors had to conclude that imperfect triaging into the intervention 
arm limited their conclusions regarding the efficacy of early intervention with erythropoietin-β 
versus placebo 
Figure 3 | Concentration-time-course of urinary biomarkers from putative renal insult 
(based on [216]; created with GraphPad) 
Urinary AP concentration in Units/l; urinary NGAL concentration in ng/ml; urinary Cr 
concentration in mmol/l 
Values shown are the mean. There are ±50 measures at each time point for the AKI group. 
Abbreviations: AKI acute kidney injury, AP alkaline phosphatase, Cr creatinine, h hour, NGAL 
neutrophil gelatinase-associated lipocalin 
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LAB-BASED AUTO-ANALYSER AND BED-SIDE/POINT-OF-CARE BENCH-TOP/TABLE-TOP 
ANALYSER FORMATS 
Expansion of the diagnostic criteria for AKI mandates early reporting of laboratory test results 
(e.g., novel biomarker concentration), implying the availability of rapid assay methods. Moreover, 
these assay methods must be available in non-labour-intensive formats (e.g., lab-based auto-
analyser or bed-side/point-of-care bench-top/table-top analyser formats). Comparison of 
measured biomarker concentrations across these formats is important. 
In contrast to the traditional centralization of diagnostic analysis in the hospital laboratory, i.e. 
central laboratory (CL) testing, there has been a recent trend towards a more decentralized 
diagnostic analysis, i.e. point-of-care testing (POCT)), which occurs directly at patients’ beds – as 
indicated by “bed-side” –and purports to reduce the turnaround time for test results to reach the 
clinician by eliminating some of the pre-analytical (e.g., sample transport) and post-analytical (e.g., 
forwarding of test results) steps [217]. In their systematic narrative review Quinn et al. identified 
4 distinct categories of barriers to the clinical adoption of POCT devices [218], which are listed in 
Table 4. 
  
 Table 4 | Barriers to hospital-based clinical adoption of point-of-care testing (based on 
[218]) 
Barrier 1 | Economic issues 
The cost per test of POCT is higher than that of traditional CL testing 
The cost-effectiveness of a POCT system is difficult to gauge and cost comparison studies against 
traditional CL testing methods are complex 
The initial costs of implementing a POCT system can be high 
The allocation of budgets for POCT is not appropriate 
Reimbursement is a major hurdle to POCT implementation 
Barrier 2 | Quality assurance and regulatory issues 
Device operation by untrained or non-competent staff 
Product qualification 
Complex regulatory requirements for accreditation 
Barrier 3 | Device performance and data management issues 
Reduced analytical performance in comparison to centralized laboratory testing 
Connectivity and data management problems 
Poor usability of devices 
Barrier 4 | Staff and operational issues 
Reduced levels of staff satisfaction and increased friction between staff groups 
Alterations to clinical care pathways 
Resistance of the CL to pass control of testing to others 
Inappropriate use of POCT 
Management structure and clinical governance 
Reluctance to change health service practice 
The most significant barriers identified are indicated with a lightning bolt. 
Abbreviations: CL central laboratory, POCT point-of-care testing 
 
NOVEL BIOMARKER COST-EFFECTIVENESS 
Last but not least, the cost-effectiveness ratio of validated novel biomarkers must be investigated 
in order to convince policymakers to redistribute financial resources towards use of these 
markers in the clinic. At present, it is still uncertain whether early diagnosis of AKI by a novel 
more expensive biomarker is cost-effective. Using a decision analysis model for a base case (i.e., a 
67-year-old male in the United Kingdom undergoing CABG surgery without a history of CKD 
admitted to the ICU immediately after the procedure), Shaw et al. calculated a cost-effectiveness 
ratio of £358 per quality-adjusted life-year for the NGAL strategy (i.e., the use of UNGAL in 
addition to current clinical practice for the diagnosis of AKI) compared with £396 per quality-
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adjusted life-year for the standard approach (i.e., monitoring of SCr, blood urea nitrogen and 
UO) [219]. A quality-adjusted life-year takes into account longevity and quality-of-life [220]. The 
number of quality-adjusted life-years is estimated by multiplying the years of survival by quality-
of-life measured on a scale from zero (equivalent to death) to 1 (perfect health) [220]. Recently, 
Meersch et al. showed that the use of an AKI care bundle (i.e., intervention therapy) vs. a 
standard care bundle (i.e., control therapy) targeted at a cohort of adult cardiac surgery patients at 
high risk for AKI could reduce the occurrence and severity of AKI [26]. The risk for AKI was 
determined by the low 0.3 cutoff of the NephroCheck® test. This threshold has a very high 
negative predictive value (i.e., 97 %) meaning that patients testing positive are at much higher risk 
for AKI than those testing negative. Göcze et al. used the same 0.3 cutoff for risk stratification in 
adult ICU patients after major elective non-cardiac surgery and could demonstrate a reduced 
occurrence and severity of AKI in the intervention group (AKI care bundle) compared to the 
control group (standard care bundle) in a subgroup (i.e., NephroCheck® test result ≤ 2.0) 
analysis [27]. These authors did not calculate the cost-effectiveness ratio for this intervention, but 
given the fact that Chertow et al. found that even SCr increases by ≥ 0.3 mg/dl in hospitalized 
adults are associated with a 4.1-fold increase (95 % CI: 3.1-5.5) in the odds of in-hospital death 
and US$4,886 in excess hospital costs [221], the cost-effectiveness ratio of the use of an AKI care 
bundle in adult cardiac surgery patients at high risk for AKI (as identified by the NephroCheck® 
test) may indeed be lower than that of the use of a standard care bundle. 
POSITIONING OF UCHI3L1, UNGAL AND URINARY [TIMP-2]•[IGFBP7] TOWARDS THESE 
HURDLES 
A cautious estimate on how far the biomarkers UCHI3L1, UNGAL and urinary [TIMP-
2]•[IGFBP7] have come today on the roadmap to biomarker utility for AKI diagnosis is provided 
in Table 5. None of these three biomarkers could evade the use of KDIGO as the ‘bronze 
standard’ test in the evaluation of their diagnostic test performance for AKI. 
 Table 5 | Positioning of UCHI3L1, UNGAL and urinary [TIMP-2]•[IGFBP7] towards 
hurdles on the roadmap to biomarker utility for AKI diagnosis 
Hurdle UCHI3L1 UNGAL Urinary [TIMP-
2]•[IGFBP7] 
Support to KDIGO x Preliminary: CSA-NGAL score [195] 
Preliminary: RCTs with 
risk stratification based on 
0.3 cutoff [26, 27] 
  Adult cardiac surgery Adult cardiac surgery 
Adult major elective non-
cardiac surgery 
Threshold Preliminary: Chapter 3 
[193] 
CSA-NGAL score [195] Opal study [140] 
  Stage 1 cutoff 
Considered to have high 
NPV 
Stage 2 cutoff 
Considered to have high 
PPV 
0.3 cutoff 
NPV (%) = 97 (95 % CI: 
96-99) 
2.0 cutoff 
PPV (%) = 49 (95 % CI: 
41-58) 
 Adult non-cardiac surgery 
or non-surgical reason for 
critical illness (need for 
multicentre study) 
Adult cardiac surgery Adult non-cardiac surgery 
or non-surgical reason for 
critical illness 
Aetiology of AKI Background: major source of biomarker in AKI 
 Intrarenal macrophages 
upon activation in the 
renal milieu [110] 
Cells of distal tubule 
origin [89] 
TIMP-2: cells of distal 
tubule origin [222] 
IGFBP7: cells of proximal 
tubule origin [222] 
 Preliminary: Chapter 3 
[193] 
Sapphire study [136] 
Inferior to [TIMP-
2]•[IGFBP7] 
Sapphire study [136] 
Superior to UNGAL 
AUC-ROC = 0.80 (95 % 
CI: 0.74-0.84) 
 Adult non-cardiac surgery 
or non-surgical reason for 
critical illness 
Presumed: poor 
specificity in sepsis as two 
“marker-sensitive” 
conditions overlap in one 
patient [212] 
Adult non-cardiac surgery 
or non-surgical reason for 
critical illness 
Poor specificity in sepsis 
as two “marker-sensitive” 
conditions overlap in one 
patient [223] 
Adult non-cardiac surgery 
or non-surgical reason for 
critical illness 
Sapphire and Topaz sub-
analysis: test performance 
is not affected by non-
renal organ dysfunction 
[224] 
  TRIBE-AKI consortium 
AUC-ROC = 0.67 (SE: 
0.04) [168] 
 
 Need for evaluation in 
adult cardiac surgery 
cohort with evidence of 
acute tubular damage 
according to CSA-NGAL 
score (cf. Chapter 4, 
[225]) 
Adult cardiac surgery Need for multicentre 
study in adult cardiac 
surgery 
Concentration-time-
course x 
Within 6 h after insult 
[135] x 
  Adult cardiac surgery  
Analyser format x Lab-based auto-analyser format (BioPorto, 
NGAL® test) 
Bed-side/point-of-care 
bench-top/table-top 
analyser format (Astute 
Medical, NephroCheck® 
test) 
 ELISA (e.g., R&D 
Systems, Quantikine® 
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ELISA Human Chitinase 
3-like 1 Immunoassay) 
Cost-effectiveness Cost per test 
 € 6-10 (RUO) € 30-50 (IVD) € 30-50 (IVD) 
 x x Preliminary: RCTs with risk stratification based on 
0.3 cutoff [26, 27] 
Abbreviations: AKI acute kidney injury, AUC-ROC area under the receiver-operating characteristics curve, CI 
confidence interval, CSA cardiac surgery-associated, IGFBP7 insulin-like growth factor-binding protein 7, IVD In 
Vitro Diagnostic, NPV negative predictive value, PPV positive predictive value, RUO Research Use Only, TAL 
thick ascending limb of loop of Henle, TIMP-2 tissue inhibitor of metalloproteinases-2, UCHI3L1 urinary 
chitinase 3-like protein 1, UNGAL urinary neutrophil-gelatinase associated lipocalin 
 
IV. Neutrophil gelatinase-associated lipocalin for canine AKI diagnosis 
Zhou et al. randomized purpose-bred research beagle dogs to either daily intramuscular injection 
with saline for 9 d or daily intramuscular injection with gentamicin for 9 d [226]. AUC-ROC 
curves of different biomarkers at d3, d6 or d9 were plotted for the outcome ‘histopathological 
changes of kidneys’ (i.e., tubular cell necrosis or tubular cell hyaline droplet formation) at d3, d6 
or d9 (no lesions were observed in control dogs). This analysis (including all time points) revealed 
that UNGAL/UCr was superior to SCr for the detection of acute tubular damage (AUC-ROC of 
1.000 (95 % CI: 0.903-1.000) for UNGAL/UCr versus 0.872 (95 % CI: 0.718-0.959) for SCr; P = 
0.029). 
In another study biomarker concentrations after acute haemorrhage (via femoral artery catheter) 
and colloid-mediated reperfusion in anaesthetized Greyhound dogs were measured [227]. 
Histology confirmed that the model successfully induced acute tubular damage. Increases in 
UNGAL and UNGAL/UCr from baseline were observed as early as 3 h following the inciting 
cause (P < 0.050). An increase in SCr (IRIS grade 2) was evident immediately following 
hypotension, suggesting that this resulted from a pre-renal functional change. Despite the 
observation that AKI was not purely pre-renal, SCr did not increase further during reperfusion. 
This may be explained by volume resuscitation leading to dilution, and so blunting of SCr 
increase. 
 The novel biomarker UNGAL has also been investigated in dogs with naturally occurring AKI. 
The first study to investigate UNGAL prospectively enrolled 39 dogs that were to undergo 
surgery [228]. Dogs with azotaemia or relevant renal historical/clinical/imaging signs before 
surgery were excluded. Pre-operative SCr was considered as the baseline. The endpoint was AKI 
defined as an acute increase in SCr of ≥ 0.3 mg/dl from baseline within 48 h. Biomarkers were 
measured before surgery and at 12 h, 24 h, 48 h and 72 h after surgery. AKI occurred in 30.8 % 
of the canine patients. Compared with the no AKI group, UNGAL increased at 12 h post-
surgery in dogs with AKI (P = 0.022), while SCr was only increased at 24 h post-surgery (P = 
0.040). Another cohort study prospectively enrolled 30 dogs with heatstroke [229]. SCr was 
measured at presentation, 4 h post presentation and then every 12 h until discharge or death. 
AKI occurred in 63.3 % of the canine patients (IRIS guidelines implemented after fluid 
resuscitation; UO was not measured). Compared with the no AKI group, UNGAL/UCr was 
increased at presentation in dogs with AKI (P = 0.006). Although measured GFR (Cr clearance) 
after fluid resuscitation (4 h post presentation) was < 1 ml/min/kg in 69.2 % of dogs (normal 
GFR in dog is > 2 ml/min/kg), 50 % of dogs were non- or only mildly azotaemic at that time, 
emphasizing the insensitivity of SCr. 
Overall, the results from these 4 studies illustrate the limitations of SCr and the potential of the 
acute tubular damage biomarker UNGAL in dogs, and so underline the urgent need for this and 
other novel renal stress or damage biomarkers, thus corroborating the findings in human 
patients. 
In the context of sepsis, it is presumed that UNGAL has a poor specificity for AKI in septic 
dogs as two “marker-sensitive” conditions overlap in these patients. Both serum NGAL and 
UNGAL/UCr at admission were higher in dogs presented with no AKI and sepsis requiring 
emergency laparotomy (n= 15) than in dogs presented with no AKI and intervertebral disk 
disease requiring emergency surgical intervention (n = 10) [230]. An alternative explanation is 
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that similar to humans, sepsis is associated with renal stress or damage and subclinical AKI, 
leading to increased NGAL. In dogs with negative urine culture (n = 33), the severity of pyuria 
correlated with the concentration of UNGAL [231], suggesting that in dogs with UTI [232], 
UNGAL is influenced not only by bacteriuria (induction and secretion of NGAL by superficial 
epithelial cells facing the lumen of the bladder [214]), but also by pyuria. 
In addition to the use of NGAL as a biomarker for AKI in dogs, Bland et al. demonstrated 
kidney injury molecule-1 (KIM-1) expression in the feline kidney and identified its shedding into 
urine of cats at risk for AKI [233]. Performance data are lacking to date, but based on these 
preliminary findings, further investigation of KIM-1 as a biomarker of AKI in cats appears 
warranted.  
At present, there are to the best of our knowledge no published data on the use of UCHI3L1 and 
urinary [TIMP-2]•[IGFBP7] as biomarkers for AKI in companion animals. 
V. Biomarkers for AKI management 
Although this dissertation focused on diagnostic AKI biomarkers, it should be emphasized that 
the context of use of biomarkers is much broader (cf. preferred embodiments of an invention as 
stated in Chapter 2) (Figure 4). Also, it should be noted that causal and sensitizing AKI risk 
factors, or exposures and susceptibilities, form the pillars of AKI risk assessment (Figure 4) [11]. 
Our invention (filed as international patent application WO2012/136548) has other preferred 
embodiments than ‘a method wherein the correlation step comprises assigning a diagnosis of the 
occurrence or non-occurrence of AKI to the subject based on the assay result’. Another 
preferred embodiment is ‘a method wherein the correlation step comprises assessing whether or 
not renal function is improving or worsening in a subject who has suffered from AKI based on 
the assay result’. In accordance with this, Schmidt et al. independently showed that UCHI3L1 
predicts the occurrence of delayed graft function in adult patients who receive deceased-donor 
kidney transplants [110]. Recently, the same group also studied a cohort of hospitalized patients 
 with AKI and found that UCHI3L1 was associated with the composite outcome of AKI 
progression and in-hospital death [156]. 
Recently, Montgomery et al. used unilateral renal IRI as a robust model for acute to chronic 
kidney injury in mice [234, 235]. Based on their findings, the authors proposed a model of 
CHI3L1-mediated macrophage-myofibroblast crosstalk during kidney fibrosis (Figure 5) [234], 
suggesting that translational investigation of CHI3L1 as an outcome AKI biomarker (i.e., 
progression to AKD or CKD) in humans is warranted. 
Figure 4 | The gear wheels ‘AKI risk factors’ and ‘AKI biomarkers’ set into motion a 
good AKI management (based on [121]) 
Only when both these gear wheels work well, the ‘AKI management’ gear wheel will turn around 
smoothly. AKI management comprises exposure containment, preventive intervention or 
therapy, supportive intervention or therapy, and follow-up. 
Abbreviations: AKI acute kidney injury, CKD chronic kidney disease, RRT renal replacement 
therapy 
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Which patients are developing 
AKI, what is their prognosis, 
which AKI patients need 
personalized therapy? 
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To early detect AKI, often referred 
to as 'predict' 
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To make a prognosis, i.e. will a 
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patient,…? 
Predictive AKI biomarkers 
To identify AKI patients likely to 
respond well to a specific therapy, 
i.e. which patient will benefit the 
most from RRT, specific 
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therapies,…? 
AKI risk factors 
Which individuals will have either a 
low, a moderate or a high risk of 
developing AKI when hospitalized? 
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Always necessary to cause AKI 
Sometimes sufficient to cause AKI 
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 VI. Future prospects 
RANDOMISED CONTROLLED TRIAL 
The question that should be asked by any clinician is: “in what respect does the result of the 
biomarker test changes the management and treatment of my patient?”. As mentioned, Meersch 
et al. showed that the use of an AKI care bundle (i.e., intervention therapy) vs. a standard care 
bundle (i.e., control therapy) targeted at a cohort of adult cardiac surgery patients at high risk for 
AKI (as identified by the NephroCheck® test) could reduce the occurrence and severity of AKI. 
A first future prospect is to test whether clinical outcomes (most likely intermediate endpoints 
such as AKI stage, but ideally hard endpoints such as new requirement for RRT, mortality or 
new-onset CKD [236]) are improved in patients that do versus do not undergo renal stress or 
damage biomarker testing with subsequent clinical decision making on the basis of these 
biomarker results. An example of a randomised controlled trial of a diagnostic test is the 
RATPAC trial [237], which aimed to evaluate the clinical effectiveness of using a point-of-care 
cardiac marker panel in patients presenting to the emergency department with suspected but not 
proven acute myocardial infarction. Participants were allocated to receive either diagnostic 
assessment using the point-of-care cardiac marker panel or conventional diagnostic assessment 
without the panel. All tests and treatments other than the panel were provided at the discretion of 
the clinician. The primary outcome was the proportion of patients successfully discharged home, 
defined as patients with a discharge decision having been made at 4 h after initial presentation 
and without any major adverse event during the following 3 mo. The authors concluded that the 
POCT increased the proportion of patients successfully discharged home. Importantly, when 
comparing this proportion between the 6 participating hospitals, the clinical effectiveness of 
using the point-of-care cardiac marker panel varied markedly [238]. This indicates that simple 
provision of rapid biomarker results will be ineffective unless it is accompanied by treatment 
decision. 
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SINGLE BIOMARKER VERSUS BIOMARKER PANEL 
A second future prospect is to test whether combining novel renal stress or damage biomarkers 
to be used either concurrently in a biomarker panel in analogy with the NephroCheck® test 
[TIMP-2]•[IGFBP7], or one by one as confirmatory evidence, would improve the clinical 
performance characteristics of both single biomarkers. 
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cute kidney injury (AKI) is an abrupt loss of kidney function. Over 
the years this syndrome has had many names, like ischuria renalis 
(1802), war nephritis (1914), crush syndrome (1939) and acute renal 
failure (ARF) (1951). Only with the birth of the ‘Risk, Injury, Failure, Loss, and End-stage renal 
disease’ (RISK) system in 2004, AKI had its first consensus definition. RISK defined acute 
changes in kidney function using serum creatinine (SCr) and urine output (UO) as criterion. 
Revised systems for the diagnosis and staging of AKI followed, with in 2007 the Acute Kidney 
Injury Network (AKIN) system, and in 2012 the Kidney Disease | Improving Global Outcomes 
(KDIGO) system. 
As logical approach to AKI the FIRST CHAPTER starts by describing kidney function. 
Subsequently, the AKI syndrome is expounded with in-depth exploration of the current 
consensus definition of AKI (including its limitations), the high incidence of AKI and the poor 
outcomes of AKI. Finally, the latest understanding of the pathophysiology of AKI as logical 
approach to novel biomarkers for AKI is summarized. Based on this knowledge, experts 
proposed to name the pre-phase that leads to AKI ‘acute kidney stress’, which is debatably 
described as a condition of either renal stress or initial renal damage. Ideally, urinary biomarkers 
can localize renal stress or damage to a specific nephron site. As regulator of kidney iron 
transport, urinary neutrophil gelatinase-associated lipocalin (UNGAL) is a clinically validated 
biomarker for the early diagnosis or ‘prediction’ of emerging AKI in different intensive care unit 
(ICU) settings. This biomarker herewith showed a good clinical test performance in numerous 
studies. 
The SECOND CHAPTER states the scientific aim of the two clinical studies that were conducted, 
which was to provide clinical validation of the novel candidate biomarker urinary chitinase 3-like 
protein 1 (UCHI3L1) as early diagnostic or ‘predictive’ tool for emerging AKI in specific adult 
ICU settings. This regulatory protein of signalling in kidney tubular epithelial cells’ and 
A 
 macrophages’ inflammation signalling cascades, was discovered in 2012 at the Faculty of 
Veterinary Medicine of Ghent University by urinary proteomics in a novel mouse model for 
sepsis-induced AKI. 
The THIRD CHAPTER describes a single-center (Ghent University Hospital) prospective cohort 
study in the adult surgical and medical – or ‘general’ – ICU setting, which aimed to provide 
clinical validation of the biomarker UCHI3L1 in patients who either underwent non-cardiac 
surgery or had a non-surgical reason for critical illness. AKI was diagnosed and staged according 
to the KDIGO system, which is based on SCr and UO. One-hundred eighty-one patients who 
had either a respiratory Sepsis-related Organ Failure Assessment (SOFA) score ≥ 2 or a 
cardiovascular SOFA score ≥ 1, and did not yet have AKI stage ≥ 2 at time of enrolment, were 
included. Twenty-one patients (12 %) developed AKI stage ≥ 2 within 7 days (d) after 
enrolment, of which 6 (3 %) within the first 12 hours (h). The concentration of UCHI3L1 at 
enrolment predicted the occurrence of AKI stage ≥ 2 within the next 12 h, in which the 
probability that UCHI3L1 correctly ranked a randomly chosen case / non-case pair with respect 
to their measured concentrations, was high. This test performance and that of the biomarker 
UNGAL measured at enrolment were of equal value. In-depth study of the biomarker UCHI3L1 
further showed that increasing UCHI3L1 concentrations were associated with an increasing 
severity of AKI. This study allowed to conclude that in the adult ‘general’ ICU setting UCHI3L1 
is a clinically validated biomarker for the early diagnosis or prediction of AKI stage ≥ 2 occurring 
within 12 h after its measurement. The biomarker UCHI3L1 herewith showed a good clinical test 
performance. 
The FOURTH CHAPTER describes a single-centre (Ghent University Hospital) prospective cohort 
study in the adult elective cardiac surgery ICU setting, which aimed to provide clinical validation 
of the biomarker UCHI3L1 in patients who underwent elective cardiac surgery. AKI was 
diagnosed and classified according to the KDIGO system, which is based on SCr and UO. Acute 
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tubular damage was diagnosed according to the UNGAL score developed for use in adult cardiac 
surgery patients. The biomarkers UCHI3L1, UNGAL and SCr were measured more frequently 
than SCr in routine early post-operative ICU practice. Of the 211 enrolled elective cardiac surgery 
patients, 203 patients who had no AKI pre-operatively and at time of post-operative ICU 
admission (t1) were included in the analysis of the primary endpoint (i.e., AKI stage ≥ 1 within 
48 h after t1), while 210 patients without AKI stage ≥ 2 pre-operatively and at t1 were included 
in the analysis of the secondary endpoint (i.e., AKI stage ≥ 2 within 12 h after t1). Within 48 h 
after t1, 95 patients (46.8 %) had developed AKI, of which 67 (70.5 %) had stage 1, 19 (20.0 %) 
stage 2 and 9 (9.5 %) stage 3. AKI was classified predominantly as AKI without acute tubular 
damage (84.6 %). During the first 4 h postoperatively, only SCr predicted the occurrence of AKI 
within 48 h after t1, in which the probability that SCr correctly ranked a randomly chosen case / 
non-case pair with respect to their measured concentrations, was high. In the same period, both 
UCHI3L1 and UNGAL predicted the occurrence of AKI stage ≥ 2 within 12 h after t1. 
However, the probability herewith that either UCHI3L1 or UNGAL correctly ranked a randomly 
chosen case / non-case pair with respect to their measured concentrations, was low. Moreover, 
this test performance was inferior to both that of SCr and that of the absolute change in SCr 
from the pre-operative measurement to early post-operative measurements. This study allowed to 
conclude that in the adult elective cardiac surgery ICU setting UCHI3L1 is a clinically validated 
biomarker for the early diagnosis or prediction of AKI stage ≥ 2 occurring within 12 h after its 
measurement. The biomarker UCHI3L1 herewith showed, however, an inadequate clinical test 
performance. This marked difference with the first clinical validation study could be explained by 
the finding that AKI was classified predominantly as AKI without acute tubular damage. 
In the final FIFTH CHAPTER the results of both clinical studies are discussed and major hurdles 
on the roadmap to biomarker utility for AKI diagnosis as well as future prospects are defined. 
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cute nierinsufficiëntie (ANI) staat voor een plots functieverlies van 
de nier. Dit syndroom kende door de jaren heen verschillende 
benamingen, zoals renale ischurie (1802), oorlogs-nefritis (1914), 
crush syndroom (1939) en acuut nierfalen (ANF) (1951). De eerste consensus definitie van ANI 
kwam er pas in 2004 met het ‘Risk, Injury, Failure, Loss, and End-stage renal disease’ (RISK) 
systeem. RISK definieerde acute veranderingen in de nierfunctie gebruik makend van serum 
creatinine (SCr) en urine debiet (UD) als maatstaf. Aangepaste systemen voor de diagnose en 
stagering van ANI volgden, met in 2007 het ‘Acute Kidney Injury Network’ (AKIN) systeem, en 
in 2012 het ‘Kidney Disease | Improving Global Outcomes’ (KDIGO) systeem. 
Als logische aanloop naar ANI start het EERSTE HOOFDSTUK met het beschrijven van de 
nierfunctie. Vervolgens wordt het ANI syndroom toegelicht met uitdieping van de huidige 
consensus definitie van ANI (inclusief limitaties), de hoge incidentie van ANI en de slechte 
uitkomsten van ANI. Tenslotte worden de laatste inzichten in de pathofysiologie van ANI 
samengevat als logische aanloop naar nieuwe biomerkers voor ANI. Op basis van deze kennis 
stelden experten voor om de pre-fase die leidt tot ANI te benoemen als ‘acute nier-stress’. Dit is 
een conditie die dubbelzinnig omschreven wordt als hetzij renale stress, hetzij renale schade. 
Urinaire biomerkers kunnen idealiter renale stress of schade specifiek lokaliseren in het nefron. 
Als regulator van het ijzertransport in de nier is urinair ‘neutrophil gelatinase-associated’ 
lipocaline (UNGAL) een klinisch gevalideerde biomerker voor de vroege diagnose of ‘predictie’ 
van opkomende ANI in verschillende intensieve zorg afdeling (IZA) omgevingen. Deze 
biomerker liet hierbij een goede klinische testprestatie zien in talrijke studies. 
Het TWEEDE HOOFDSTUK geeft het wetenschappelijke doel van de twee uitgevoerde klinische 
studies aan, namelijk het klinisch valideren van de nieuwe kandidaat biomerker urinair ‘chitinase 
3-like’ proteïne 1 (UCHI3L1) als vroeg diagnostische of ‘voorspellende’ test voor opkomende 
ANI in specifieke adulte IZA omgevingen. Dit regulator-eiwit van inflammatoire signalisatie in 
A 
 tubulaire cellen van de nier en macrofagen werd in 2012 aan de faculteit Diergeneeskunde van de 
Universiteit van Gent ontdekt via urinair proteoom onderzoek in een nieuw muismodel voor 
sepsis-geïnduceerde ANI. 
Het DERDE HOOFDSTUK beschrijft een unicenter (Universitair Ziekenhuis Gent) prospectieve 
cohortstudie in de adulte heelkundige en medische – of ‘algemene’ – IZA omgeving. Deze eerste 
studie beoogde de klinische validatie van de biomerker UCHI3L1 in patiënten die ofwel niet-
cardiale heelkunde ondergingen, ofwel kritisch ziek waren door een andere oorzaak dan 
heelkunde. De diagnose en stagering van ANI gebeurden volgens het KDIGO systeem dat 
gebaseerd is op SCr en UD. Honderd eenentachtig patiënten die ofwel een respiratoire ‘Sepsis-
related Organ Failure Assessment’ (SOFA) score ≥ 2 hadden, ofwel een cardiovasculaire SOFA 
score ≥ 1, en nog geen ANI stadium ≥ 2 hadden bij rekrutering, werden geïncludeerd. 
Eenentwintig patiënten (12 %) ontwikkelden ANI stadium ≥ 2 binnen de 7 dagen (d) na 
rekrutering, waarvan 6 (3 %) binnen de eerste 12 uur (u). De concentratie van UCHI3L1 bij 
rekrutering voorspelde het optreden van ANI stadium ≥ 2 in de eerstvolgende 12 u, waarbij de 
kans dat UCHI3L1 een willekeurig gekozen ziek / niet-ziek paar correct rangschikte gebaseerd 
op hun gemeten concentraties, hoog was. Deze testprestatie was evenwaardig aan die van de 
biomerker UNGAL gemeten bij rekrutering. Grondige studie van de biomerker UCHI3L1 
toonde verder dat stijgende concentraties geassocieerd waren met een stijgende ernst van ANI. 
Deze studie liet toe te besluiten dat in de adulte ‘algemene’ IZA omgeving UCHI3L1 een klinisch 
gevalideerde biomerker is voor de vroege diagnose of predictie van ANI stadium ≥ 2 optredend 
binnen de 12 u na zijn meting. De biomerker UCHI3L1 liet hierbij een goede klinische 
testprestatie zien. 
Het VIERDE HOOFDSTUK beschrijft een unicenter (Universitair Ziekenhuis Gent) prospectieve 
cohortstudie in de adulte electieve hartchirurgie IZA omgeving. Deze tweede studie beoogde de 
klinische validatie van de biomerker UCHI3L1 in patiënten die electieve hartchirurgie 
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ondergingen. De diagnose en stagering van ANI gebeurden volgens het KDIGO systeem dat 
gebaseerd is op SCr en UD. De diagnose van acute tubulaire schade gebeurde volgens de 
UNGAL score ontwikkeld voor gebruik bij volwassen hartchirurgie patiënten. De biomerkers 
UCHI3L1, UNGAL en SCr werden meer frequent gemeten dan SCr in routine vroeg-
postoperatieve IZA praktijk. Van de 211 gerekruteerde electieve hartchirurgie patiënten, werden 
203 patiënten die zowel preoperatief als bij postoperatieve IZA opname (t1) geen ANI hadden, 
geïncludeerd in de analyse van het primaire eindpunt (i.e., ANI stadium ≥ 1 binnen de 48 u na 
t1), terwijl 210 patiënten die zowel preoperatief als op t1 geen ANI stadium ≥ 2 hadden, 
geïncludeerd werden in de analyse van het secundaire eindpunt (i.e., ANI stadium ≥ 2 binnen de 
12 u na t1). Binnen de 48 u na t1 hadden 95 patiënten (46.8 %) ANI ontwikkeld, waarvan er 67 
(70.5 %) stadium 1 hadden, 19 (20.0 %) stadium 2 en 9 (9.5 %) stadium 3. ANI werd 
hoofdzakelijk geklasseerd als ANI zonder acute tubulaire schade (84.6 %). Tijdens de eerste 4 uur 
postoperatief, voorspelde enkel SCr het optreden van ANI binnen de 48 u na t1, waarbij de kans 
dat SCr een willekeurig gekozen ziek / niet-ziek paar correct rangschikte gebaseerd op hun 
gemeten concentraties, hoog was. In dezelfde periode voorspelden zowel UCHI3L1 als UNGAL 
het optreden van ANI stadium ≥ 2 binnen de 12 u na t1. Hierbij was de kans dat hetzij 
UCHI3L1, hetzij UNGAL een willekeurig gekozen ziek / niet-ziek paar correct rangschikte 
gebaseerd op hun gemeten concentraties, echter laag. Daarenboven was deze testprestatie 
inferieur aan zowel die van SCr als die van de absolute verandering in SCr van de preoperatieve 
meting tot vroege postoperatieve metingen. Deze studie liet toe te besluiten dat in de adulte 
electieve hartchirurgie IZA omgeving UCHI3L1 een klinisch gevalideerde biomerker is voor de 
vroege diagnose of predictie van ANI stadium ≥ 2 optredend binnen de 12 u na zijn meting. De 
biomerker UCHI3L1 liet hierbij echter een ontoereikende klinische testprestatie zien. Dit 
opvallend verschil met de eerste klinische studie zou kunnen verklaard worden door de bevinding 
dat ANI hoofdzakelijk geklasseerd werd als ANI zonder acute tubulaire schade. 
 In het laatste VIJFDE HOOFDSTUK worden de resultaten van beide klinische studies besproken en 
worden belangrijke obstakels voor de bruikbaarheid van nieuwe biomerkers voor ANI diagnose 
alsook de vooruitzichten voor verder onderzoek toegelicht.  
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orien De Loor werd geboren op 25 september 1987 te Ninove. Na het 
beëindigen van het secundair onderwijs – richting Wetenschappen-Wiskunde 
– aan het Sint-Aloysiuscollege van Ninove, is zij in 2005 gestart met de studies 
Diergeneeskunde aan de Universiteit van Gent. Ze behaalde in 2011 het Masterdiploma van 
‘Veterinary Medicine in de diergeneeskunde – afstudeerrichting gezelschapsdieren’ met grote 
onderscheiding. 
In de herfst van datzelfde jaar werkte zij drie maanden als assistent bij de unit Histologie van de 
faculteit Diergeneeskunde, waarna ze zich in de winterperiode samen met haar promotoren 
engageerde voor het schrijven en indienen van een aspirantenmandaat-aanvraag bij het Fonds 
Wetenschappelijk Onderzoek - Vlaanderen (FWO) rond humane acute nierinsufficiëntie. Deze 
aanvraag werd in de herfst van 2012 goedgekeurd. De lente en zomer van 2012 overbrugde ze als 
doctoraatsbursaal aan de unit Biochemie van de faculteit Diergeneeskunde om dan aan de slag te 
gaan als FWO Aspirant bij diezelfde unit en de dienst Intensieve Zorg van het Universitair 
Ziekenhuis van Gent. Het uitgevoerde onderzoek spitste zich toe op de klinische validatie van 
een nieuwe kandidaat biomerker voor vroege diagnose van acute nierinsufficiëntie bij humane 
patiënten op Intensieve Zorg, in verderzetting van het (pre)klinisch onderzoek uitgevoerd door 
dr. Bert Maddens aan de unit Biochemie van de faculteit Diergeneeskunde. 
Jorien De Loor is auteur van meerdere wetenschappelijke publicaties en lichtte dit onderzoek toe 
op verschillende nationale en internationale congressen.  
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 “As soon as I saw you, I knew an adventure was going to happen.” 
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Prof. dr. Meyer, Evelyne, de voorbije 5 jaar heb je je dikwijls druk gemaakt in het feit dat data 
management veel tijd kost. Ik hoop dat je vandaag overtuigd bent dat de research papers binnen 
een realistische termijn gepubliceerd zijn geweest. Als administratief verantwoordelijke promotor 
had je een aanvullend takenpakket naast het wetenschappelijke luik, gaande van nazicht van 
voortgangsrapporten tot beheer van logistieke middelen. Ook deze taken nam je nauw ter harte, 
waarvoor dank u. 
“Think, think, think.” 
Prof. dr. Daminet, dr. De Corte, dr. de Geus, Prof. dr. Benoit, Prof. dr. De Waele, het is een eer 
dat jullie lid wilden zijn van mijn examencommissie. Het vinden van een vrij moment voor het 
lezen van mijn doctoraal proefschrift was zeker niet evident door de vele uren die jullie dagelijks 
in de (dieren)kliniek doorbrengen. Jullie kritische vragen en opmerkingen hebben dit proefschrift 
een niveau hoger getild, waarvoor dank u. 
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Stafleden Intensieve Zorg Inwendige Geneeskunde – Prof. dr. Benoit (lid van de 
examencommissie), Prof. dr. Depuydt, dr. Druwé, dr. Vermassen – de artsen-assistenten in 
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Herck (coauteur), dr. Peperstraete, dr. Vandenberghe – de artsen-assistenten in opleiding en het 
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Stafleden Hartchirurgie – Prof. dr. François (coauteur), Prof. dr. Van Belleghem, dr. Bové, dr. 
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Kristel Demeyere, dank u voor je steeds perfecte ondersteuning in het labo tijdens de vele 
ELISA’s. Op jou kon (en kan) ik altijd rekenen. 
Luc De Crop, Daisy Vermeiren, Stephanie Bracke en tot voor kort ook Charlotte Clauwaert, dank u 
voor jullie eindeloze inzet. Het kan niet genoeg gezegd worden dat jullie als studiecoördinatoren 
onmisbaar zijn op de dienst Intensieve Zorg. 
Chris Danneels, dank u voor je IT support. Zonder jou was ik waarschijnlijk nog altijd aan het 
vechten met de urinedebiet data. 
Lisa Malfait en Silvy Matthys, dank u voor jullie administratieve ondersteuning bij de UZ Gent 
contracten van de voorbije maanden. Jullie zijn top. 
Lieve Nuytinck, dank u voor het vele werk dat je geleverd hebt om dit project gefinancierd te 
krijgen en voor je blijvend optimisme. 
Prof. Croubels, Siska, dank u voor je interesse in dit onderzoek en voor je motiverende woorden 
wanneer ik die nodig had. 
Heidi Wyns, Jonas Steenbrugge, Femke Vandael, Koen Breyne, Donna Vanhauteghem, Elke Gasthuys, 
Joren De Smet, Joske Millecam, Nathan Broekaert, Sophie Fraeyman, Elke Plessers, Anneleen Watteyn, 
Mathias Devreese, Thomas De Mil, dank u voor de gezellige PhD-koekjespauze op 
donderdagnamiddag. 
Sophie Dhaese, dank u voor de welgekomen intermezzo’s over antibiotica resistentie gedurende 
de afwerkingsmaanden van mijn PhD.  
Dankwoord 
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“Any day spent with you is my favourite day. So today is my new favourite day.” 
Kim Vertraeten, Nathalie Pintelon, Nicky Van Der Vekens, Gerty Vanantwerpen, Katrien De Raes, 
Katrien Govaert, Sarah Anssens, Ineke Bockstael, jullie hielpen me om de belangrijke dingen terug te 
vinden wanneer ik ze kwijt was geraakt: mijn glimlach, mijn hoop en mijn moed. De beste 
therapie is een time out met vrienden. Dank u. 
Mama en papa, eigenlijk kan ik niet onder woorden brengen hoeveel jullie voor mij betekenen. 
Jullie gaven Nele en mij – jullie tweelingmeisjes – de warmste thuis en stonden voor ons klaar, 
altijd en overal. Dankzij jullie had ik de moed om door te zetten. Dank u. 
Nele – Peel – als onbezorgde kleuter vergat ik altijd wel iets. Gelukkig had ik toen jou aan mijn 
zijde. En gelukkig ben je altijd zo zorgzaam gebleven. Zonder jou was ik nooit zo ver gekomen. 
Dank u. 
Lore, mijn allerliefste metekindje, dank u om het zonnetje te zijn in mijn leven. 
Emma, dank u om zo flink te luisteren naar mijn verhaal vandaag. Je bent een schat. 
Meter en peter, er zijn weinig grootouders die zoveel gedaan hebben voor hun kleinkinderen als 
jullie. Niets was jullie te veel. Meter, dank u om ons ’s morgens ‘school-klaar’ te maken en om 
zoveel lekkers te koken. Peter, dank u om ons elke dag veilig naar school te brengen en om 
samen met ons te gaan fietsen, zwemmen of wandelen. Ik mis je. 
Pepe, ik herinner me ons laatste gesprek alsof het gisteren was. Je vroeg me of ik al wist of ik 
‘dokter’ ging worden voor kleine huisdieren of ‘dokter’ voor grote huisdieren. Dank u om mij 
jouw grote liefde voor dieren mee te geven. Ik mis je. 
Geoffrey, liefje, de laatste 2 jaar heb jij mijn leven zoveel mooier gemaakt. Bij jou kan ik gewoon 
mezelf zijn, elke dag opnieuw (cf. hoeveel keer heb je al niet moeten horen: “oh kijk…zo een 
schattig hondje”). Dank u voor je geduld (je bent de beste skileraar ooit), voor je rust en kalmte, 
en voor je vertrouwen. 
 “Happiness starts with a wet nose and ends with a tail.” 
Yari, mijn happy Beagle, dank u voor je eeuwig enthousiasme. Je 
was onbevreesd en ongelooflijk sterk. 
 
 
 
Aslan, mijn kleine Golden Retriever, dank u om de ster van de 
cover te zijn. Je bent mijn grote knuffelhond en trouwste vriend. 
